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ABSTRACT
Dengue has a broad spectrum of clinical symptoms, ranging from 
asymptomatic infection, undifferentiated fever and dengue fever (DF) to dengue 
hemorrhagic fever (DHF) or dengue shock syndrome (DSS). DHF and DSS are the 
most severe forms of the disease, as they involve bleeding and hypovolemic shock 
and may lead to death if they are not diagnosed early and treated correctly. Every 
year, about 36 million cases of DF, of which about 2.1 million cases are DHF/DSS 
resulting in 21,000 deaths among children and young adults, are reported. Dengue not 
only has negative effects on public health worldwide but also poses significant 
economic burden. However, no licensed vaccines or (specific) anti-viral therapies for 
prevention or treatment o f dengue are available. Thus, timely diagnosis and an 
accurate prognosis o f severe dengue in the first few days o f illness for clinical triage, 
treatment management, disease surveillance and research activities are vital and very 
helpful. We conducted three studies aiming to identify early markers of dengue, 
especially severe dengue and identify prognostic markers o f severe dengue in 
Vietnamese children with clinically suspected dengue within the first few days of the 
illness. The results firstly showed that plasma collected within the first week of the 
illness could be used for dengue diagnosis as well as differentiation between primary 
and secondary dengue virus infections. Secondly, the research showed that plasma 
concentration o f NS1 correlated with plasma viraemia and associated with DSS. NS1 
concentrations in enrolment plasma of patients within the first four days of illness 
could be used for predicting DSS in patients with DENV-1 or DENV-2 infections. 
Thirdly, in the first three days o f illness, we observed differences in clinical and 
haematological profiles between patients with DHF and those with DF or other febrile 
illnesses. Logistic models were then generated using the early clinical characteristics 
and/or haematological profiles to predict patients who will develop DHF. Our 
findings also showed that a greater virus burden leads to an augmented cascade of 
plasma concentrations o f IL-lp, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13, IFNy and 
TNFa in DHF patients compared to DF patients. This thesis shows the results and 
also points out predictive models that may be used to prognosticate o f severe dengue 
among patients with clinically suspected dengue who are admitted to hospital within 
the first few days of the illness.
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1. Introduction
Introduction
1.1. Introduction
The dengue virus (DENY) is considered to be one of the most important 
arboviruses in terms of its contributions to morbidity and mortality, and dengue has 
emerged as a major public health problem in tropical and subtropical countries around 
the world in recent decades. Dengue is caused by any one of four DENV serotypes 
(DENV-1 to -4) and is transmitted by Aedes mosquitoes. Dengue has a broad 
spectrum of clinical symptoms, ranging from asymptomatic infection, undifferentiated 
fever and dengue fever (DF) to dengue hemorrhagic fever (DHF) or dengue shock 
syndrome (DSS). DHF and DSS are the most severe forms of the disease, as they 
involve bleeding and hypovolemic shock and may lead to death if they are not 
recognized early and treated correctly [1]. Although most dengue occurs in children 
under 15 years of age, the disease also occurs in adults. Dengue not only has negative 
effects on public health worldwide but also represents a significant economic burden 
including, but not be limited to, the costs of hospital care to patients and vector 
control activities [2, 3]. There are currently no licensed vaccines or anti-viral therapies 
for the prevention or treatment o f  dengue, although a number of these are in 
development [4, 5].
Thus, in order to reduce the high rates o f morbidity and mortality caused by 
dengue, early, rapid, and accurate detection o f DENV infection and clinical 
deterioration during the acute phase are vital. These are challenging problems, but 
they have the potential to help public health efforts to limit transmission, epidemic 
spread and reduce mortality.
1.2. Dengue epidemiology
1.2.1. Dengue epidemiology in the world
Dengue is the most rapidly spreading mosquito-borne viral disease in the 
world; in the last half century, dengue incidence has increased 30-fold and expanded 
to new countries (Figure 1-1 and Figure 1-2). There are approximately 3.6 billion 
people living in at-risk areas, with 70-500 million dengue infections per year. It is 
estimated that 36 million dengue fever cases and 2.1 million severe dengue cases 
occur annually in 124 countries, resulting in approximately 21,000 deaths [6].
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Figure 1-1: Countries/areas at risk of dengue transmission, 2008.
(Taken from [1]).
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Figure 1-2: Average annual number of dengue cases reported globally and 
number of countries reporting to WHO by year, 1955 to 2007.
Taken from [1].
3
Introduction
Two remarkable aspects o f dengue epidemiology have emerged as global 
trends. Firstly, as described in a recent WHO document, dengue has rapidly spread 
into many new geographic areas and populations, and is now endemic in all WHO 
regions except the WHO European Region, More than 70% of the populations at risk 
for dengue worldwide reside in the WHO South-East Asia Region and Western 
Pacific Region, and these regions bear nearly 75% of the current global dengue 
burden. In the Region of the Americas, dengue has spread and the disease burden is 
characterized by cyclical outbreaks every 3-5 years. In the WHO African Region, 
there is evidence of dengue outbreaks which are increasing in size and frequency. The 
frequency and geographic range o f outbreaks reported from the WHO Eastern 
Mediterranean Region have also increased since the past three decades after a 
reduction in dengue transmission in the 1940s due to vector control activities [1].
Secondly, although dengue has been reported predominantly among children, 
recent reports from Southeast Asia noted a shift in the age o f dengue cases towards 
older age groups over the past three decades [7, 8]. This is important because 
numerous age-related differences in clinical manifestations have been shown among 
these older cases [9, 10]. This has led to calls for changes to clinical diagnosis, 
management and the dengue case classification [11,12].
1.2.2. Dengue epidemiology in Vietnam
Dengue has been a public health problem in Vietnam for nearly a century, 
with tens of thousands of cases reported every year. Historically, a dengue-like illness 
was first recorded in Vietnam in 1913, when epidemics occurred in the north and the 
central provinces [13]. In 1929, the south o f Vietnam experienced the first o f many 
dengue fever epidemics. The first DHF outbreak in the country was identified in 
1963 in the Mekong Delta region o f southern Vietnam [14]. Between 1963 and 1995, 
Vietnam reported 1,518,808 DHF cases and 14,133 deaths [15]. Data from the dengue 
surveillance programme in southern Vietnam showed epidemic peaks o f increasing 
magnitude occurring approximately every five years between 1975 and 1987, with a 
longer gap o f 11 years preceding a large epidemic involving 119,429 DHF cases and 
342 fatalities in 1998 [16]. Figure 1-3 illustrates important aspects o f dengue 
epidemiology in Vietnam from 1960 to 2010.
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Figure 1-3: Vietnamese dengue cases and deaths officially reported from 1960-
2010.
(Source: WHO, dengueNet [17]).
(A) Num ber o f  dengue (DF/DHF/DSS) cases and deaths in Vietnam. (B) Case- fatality 
rate and incidence rate in Vietnam. Incidence data was not available prior 2000.
In the southern 20 provinces of Vietnam from 1996 to 2008, the annual 
incidence o f hospitalized dengue cases per 100,000 population peaked at 450 in 1998, 
then rose again to 263 in 2007 following a gradual increase over the previous decade 
(Figure 1-4). During the same period, the mortality rate progressively declined from 
approximately 0.3% in 1996, and leveled off at 0.1% in 2005 [18]. Similar trends 
were observed among children and adults at three referral hospitals in Ho Chi Minh 
City (Children Hospital N o.l, No.2 and Hospital for Tropical Diseases, HCMC), with 
a rapid increase in dengue cases documented in adults. The annual dengue caseload 
steadily increased between 1996 and 2009, from around 8,000 to 12,000 cases per 
year in children and from less than 500 to more than 6,000 annual cases in adults 
(Figure 1-5). Dengue shock syndrome (DSS) accounted for 14.3% of paediatric and 
1.6% of adult dengue cases; among all DSS cases, 1.6% resulted in death [19].
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Figure 1-4: Annual incidence of hospitalized dengue cases per 100,000 
population and mortality rate among dengue cases in southern 20 provinces of 
VN. (Source: Pasteur Institute HCMC, Vietnam [18])
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Figure 1-5: Temporal trends in dengue admissions in HCMC, Vietnam, 1996 -
2009. [19]
Bars show the number o f  inpatients with clinically diagnosed dengue each year at 
each o f  the major referral hospitals in HCMC (HTD: Hospital fo r  Tropical Diseases, 
CHI: Children's Hospital No. I and CH2: Children's Hospital No. 2). Lines show 
the number o f  dengue cases in children aged 15 years or less (triangles) and in adults 
over 15 years old (circles), combined across the study sites.
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All four serotypes of DENV circulate concurrently in the south o f Vietnam, 
but a single serotype generally dominates over multiple dengue seasons. DENV-3 was 
dominant from 1997 to 1999, followed by DENV-4 from 2000 to 2002. Between 
2002 and 2006, DENV-2 was the major serotype detected in hospitalized patients, 
with DENV-1, currently the most prevalent serotype, replacing it as the predominant 
lineage in 2007 [18].
1.3. The viruses
1.3.1. Dengue virus structure
DENV belongs to the Flavivirus genus of the Flaviviridae family, which 
contains almost 70 viruses, including those causing yellow fever and several 
encephalitides (e.g., Japanese, St. Louis, West Nile, and tick-borne) [20]. DENVs 
comprise four antigenically-related serotypes (DENV-1 to DENV-4), all o f which are 
capable of causing disease. A mature dengue virion contains a single-stranded RNA 
genome surrounded by an icosahedral (20 identical equilateral triangular faces) 
nucleocapsid (core protein, C) and covered by an internal host-derived lipid bilayer 
membrane and an outer glycoprotein shell that consists of 180 copies each of an 
envelope (E) and membrane protein (M) [21, 22]. The complete virion is 
approximately 50nm in diameter [23].
The RNA genome is a single strand o f positive polarity RNA with a length of 
approximately 1 lkb. It consists o f two non-translated regions of lOObp and ~450bp at 
the 5’ end and 3’ end, respectively, and a single open reading frame. The open reading 
frame encodes for a polyprotein o f approximately 3400aa. In the polyprotein, three 
structural proteins, C, prM -  precursor membrane -  or M and E, are synthesized first. 
Seven nonstructural proteins are then translated: NS1, NS2a and NS2b, NS3, NS4a 
and NS4b, NS5 with a function o f NS3 -  trypsin-like serine protease -  responsible for 
processing o f the polyprotein between NS2A-NS2B, NS2B-NS3, NS3-NS4A, NS4B- 
NS5 and possibly some processing o f the capsid protein [24, 25]. Other junctions 
between C protein-prM, prM-E protein, E-NS1, and NS4A-NS4B are believed to be 
cleaved by host cell signalase in the lumen o f the endoplasmic reticulum (ER) [22, 26, 
27] (Figure 1-6).
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Figure 1-6: Schematic diagram of DENV genome and polyprotein processing.
A. The viral genome is a positive sense RNA o f  -11 kb in length. It is capped at the 5' 
end hut lacks a poly-(A) at its 3' end. The structural proteins (open box) are encoded 
at the 5 ' one-third o f  the genome, follow ed by the nonstructural proteins (grey box).
B. Membrane topology o f the polyprotein. The viral RNA is translated as a 
polyprotein and processed by cellular and. viral proteases (denoted by arrows). 
Source [22].
1.3.2. Protein function
The C protein is a small (9 to 12 kDa), highly positively charged protein that 
consists of -120 amino acids, -25%  of which are lysine and arginine residues. This 
character probably enables the C protein to interact with virion RNA, functioning in 
the packaging of the viral genome and formation of the nucleocapsid core [28].
There are two forms of the M protein -  prM, which is contained in immature 
intracellular virions, and M protein, which is contained in mature extracellular virions. 
The cleavage of the prM precursor (18 to 19 kDa) during viral maturation results in 
the formation of the 7 to 9 kDa M structural protein containing 75 amino acids. The
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prM protein may function as a chaperone for the fold and assembly o f the E protein 
[29,30].
The E protein (54 -  60 kDa, -500  amino acids) is the major protein 
component o f the virion surface. It is involved in a number o f biological activities, 
including receptor binding [31], hemagglutination of erythrocytes [32], and mediation 
of membrane fusion in acidic pH endosomes [21]. The E protein also induces 
neutralizing antibodies in the protective immune response [33-35]
The NS1 protein (42 to 50 kDa, -350 amino acids) can be detected on the 
outer membranes o f infected cells (dimer form), as well as in the extracellular milieu 
(hexamer form) [36, 37], and may play a role in viral replication [38]. The NS1 
protein has been identified as a soluble complement-fixing antigen that can elicit 
antibodies and serve as a target for the immune response. Levels of secreted NS1 in 
plasma positively correlate with viral titers [39]. This makes it useful for diagnostic 
purposes, acting as a surrogate marker of viraemia [40] and early NS1 concentrations 
have been suggested to be useful as prognostic markers for DHF/DSS [39, 41].
The roles of the NS3 and NS5 proteins in viral replication are better 
understood. The NS3 protein (67 to 70 kDa, -600 amino acids) plays helicase and 
protease functions that mediate post-translational cleavage of the DENV polyprotein; 
it also interacts with NS2B [42-45]. The NS5 protein (104 to 106 kDa, -900 amino 
acids) is an RNA-dependent RNA polymerase that may also take part in the capping 
of viral RNA [46, 47]. The functions of the other small nonstructural proteins are not 
well understood. The NS2 consists of two proteins, NS2A (18-22 kDa, 218 amino 
acids) and NS2B (13-15 kDa, 130 amino acids); NS2A contains several possible 
transmembrane domains and participates in the processing of the C-terminal of NS1
[48], while NS2B is required for NS3 to function correctly [45]. NS4A (16.0-16.4 
kDa, 150 amino acids) is critical to the rearrangement of intracellular membranes
[49], while the function o f NS4B (27- 28 kDa, 248-249 amino acids) has not yet been 
determined.
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1.4. Transmission of dengue virus
DENVs are transmitted to humans through the bites of infected female Aedes 
mosquitoes. Mosquitoes generally acquire the virus while feeding on the blood o f an 
infected person. After the incubation of the virus for 8-10 days, an infected mosquito 
is capable o f transmitting the virus to other humans during probing and blood feeding.
Non-vector-bome transmission o f dengue is also known to occur. Vertical 
transmission involves transplacental transmission from near-term pregnant women 
infected with DENV to the foetus [50]. Transfusion-related transmission [51], 
transplantation-related transmission (renal transplantation [52], bone marrow 
transplantation [53]) and needle-stick-mediated transmission have been shown to 
occur [54, 55] but are not common, as the infected blood or organs must be derived 
from a DENV-infected donor who is in the viraemic stage.
1.5. The vectors
Two major species o f mosquitoes of the genus Aedes, A. aegypti and A. 
albopictus, are known to act as vectors in the transmission o f DENV. Among these, 
A. aegypti is the principal vector for humans and is found in tropical and subtropical 
areas [56]. A. albopictus is not an urban vector of dengue, except in countries 
where A. aegypti is absent (parts o f China, the Seychelles, Japan and Hawaii) [57]. In 
Asia, A. aegypti is regarded as the primary vector of DENV [58]. The eggs o f A. 
aegypti are laid on the damp walls of clean water containers and can resist desiccation 
for several weeks or months. The lifespan o f A. aegypti is 15 days on average, though 
it can live up for up to 174 days [59]. A. aegypti prefers to rest indoors and to feed on 
humans during the day; females often feed on several persons during the course of 
taking a single blood meal and, if infective, can transmit dengue virus to multiple 
persons in a short time, even if they only probe without taking blood [60].
After biting an infected human, dengue viruses enter and replicate firstly in 
cells o f the mosquito’s midgut. From there, the viruses gain access to different insect 
tissues. Viruses in the saliva o f the infected mosquitoes are transmitted to humans 
during ingestion of blood meals. An infected female mosquito can transmit the virus 
for the rest o f its life. Some evidences suggest the infected mosquito takes a longer
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period of time to take a blood meal, thus enhancing the efficiency of transmission 
[61]. Moreover, transovarial transmission (via eggs), documented by Joshi and 
Gunther et al. [62, 63], allows the propagation o f virus to the offspring during inter­
epidemic periods without the participation o f human or other vertebrate hosts, 
although there are still some doubts as to the overall significance o f vertical 
transmission in dengue epidemiology.
1.6. Clinical management
Dengue has a wide clinical spectrum, including both severe and non-severe 
clinical manifestations. Most dengue patients recover without requiring 
hospitalization, while some infections may necessitate hospital care. The main 
principles o f management of the disease are early detection o f severe disease, careful 
supportive management, and adequate nursing care o f patients. Appropriate 
management not only reduces the number o f unnecessary hospital admissions, but 
also saves the lives of dengue patients (reduces the burden o f disease).
1.6.1. Clinical diagnosis
Diagnosis of dengue cases is based on clinical symptoms, hematology and 
laboratory findings. The definitive diagnosis is made using laboratory techniques. The 
key to accurate diagnosis and treatment is prompt recognition and understanding of 
the clinical problems during different phases o f the disease. In dengue, after an 
incubation period of 3-15 days with no signs or symptoms, illness progresses through 
three phases -  febrile, critical and recovery [1] (Figure 1-7).
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Figure 1-7: The course of dengue illness. (Taken from [1])
The acute febrile phase usually lasts 2-7 days. Early in this phase, patients 
typically develop a sudden high-grade fever and often experience facial flushing, skin 
erythema, body aches, myalgia (muscle pain), and headache. These may also be 
accompanied by anorexia, nausea and vomiting [64]. These signs and symptoms are 
not dengue specific and, thus, it can be difficult to clinically distinguish dengue from 
non-dengue febrile disease in the early febrile phase. Mild haemorrhagic 
manifestations such as petechiae and mucosal membrane bleeding (e.g. nose and 
gums) may also be seen [64, 65], Vaginal bleeding and gastrointestinal bleeding may 
also occur during this early phase but are less common [64]. The earliest and most 
frequent abnormality shown in a full blood count in this stage is leucopenia; leucocyte 
counts have been described to be decreased in dengue relative to other febrile 
illnesses [66-68], Elevated liver transaminases (Aspartate aminotransferase- AST and 
Alanine aminotransferase- ALT) also arise early in the course of the disease and have 
been documented to be higher in DEIF cases [64, 69, 70],
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The critical phase happens around the time of defervescence (temperature 
drops to and remains below 37.5-38°C or less), usually on days 3-7 of illness; this 
phase may begin with an increase in capillary permeability concurrent with increasing 
haematocrit levels [71]. Progressive leucopenia [64] followed by a rapid decrease in 
platelet count usually precedes plasma leakage. The severity of plasma leakage is 
reflected by the degree of increase above the baseline haematocrit. Plasma leakage 
may cause pleural effusion and/or ascites visible by chest x-ray or abdominal 
ultrasound. At this point, patients who can compensate for capillary permeability will 
improve while those with increased capillary permeability may become worse 
(progress to shock) due to the loss of plasma volume. With prolonged shock, 
progressive organ impairment, metabolic acidosis and disseminated intravascular 
coagulation occur as the result o f organ hypoperfusion. This in turn can lead to severe 
haemorrhage, which causes a decrease in haematocrit levels. Organ impairment such 
as severe hepatitis and encephalitis may also occur without signs of plasma leakage or 
shock. The period of clinically critical plasma leakage usually lasts for 24-72 hours.
The recovery phase begins with a gradual reabsorption of extravascular 
compartment fluid that occurs within 24-72 hours after the start of the critical phase. 
General health improves, the haematocrit stabilizes or may decrease and the white cell 
count starts to rise. However, the platelet count typically recovers later than the white 
cell count. Some patients may have a rash or may experience generalized itching 
during this phase. Some patients will have a so-called recovery rash -  a florid macular 
rash affecting the limbs (Figurel-8).
Figure 1-8: Recovery rash.
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1.6.2. Case classification
The classification scheme suggested by the WHO in 1997 [72] divided 
symptomatic DENY infections into three groups: undifferentiated fever, dengue fever 
(DF) and dengue haemorrhagic fever (DHF). DHF was then sub-classified into four 
severity grades; among these, grades III and IV were defined as dengue shock 
syndrome (DSS). This classification scheme is now widely used. However, there 
have been many problems with the use of the 1997 WHO definitions because of 
changes noted in dengue epidemiology in recent years (such as the expansion of 
dengue to many new geographical regions and its changing age profile in some areas) 
[11, 12, 73, 74]. The difficulties in using these classifications and misclassification of 
many clinically severe dengue cases due to the strict criteria used to define DHF 
prompted requests for the WHO scheme to be reassessed. The WHO issued revised 
guidelines in 2009 [1] that seems to overcome most of these problems. In the new 
guidelines, DENV infections are now separated into two primary groups, dengue and 
severe dengue. The dengue group is then further divided into two subgroups -  
patients with warning signs and those without warning signs. Severe dengue shows 
one or more o f the following manifestations: a/ plasma leakage that may lead to shock 
and/or fluid accumulation, with or without respiratory distress, b/ severe bleeding, 
and/or c/ severe organ impairment (hepatic damage, renal impairment, 
cardiomyopathy, encephalopathy or encephalitis). Criteria for the current 
classification scheme are shown in Figure 1-9.
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Figure 1-9: The W H O  dengue case classification [1].
The WHO classifies dengue cases into two main groups - severe dengue and dengue. 
The large group o f  dengue has two subgroups -  dengue with and without warning 
signs.
1.6.3. Differential diagnosis
Dengue fever can easily be confused with other infectious diseases [1]. 
Depending on the geographical origin of the patient and other etiologies, that may 
include malaria, leptospirosis and typhoid. Other diseases that mimic the early febrile 
phase o f DENV infection are flu-like syndromes (influenza, measles, chikungunya, 
etc.), illnesses with a rash (rubella, measles, chikungunya, drug reactions), diarrhoeal 
diseases (enteroviruses) or illnesses with neurological manifestations 
(Meningo/encephalitis).
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1.6.4. Treatment
There is no specific treatment currently available to combat DENV infection, 
although attempts to find an anti-viral therapy for dengue have been made. Case 
management is basically supportive and symptom-specific. With appropriate intensive 
supportive therapy, mortality may be reduced to less than 1% [75]. Maintenance of 
the circulating body fluid volume by encouragement of oral rehydration solution 
intake or adequate intravenous fluid replacement is the central feature of case 
management [1, 76-79]. Compounds or anti-viral drugs which block the viral entry 
pathway or virion replication have also been considered in an attempt to reduce 
viraemia and limit disease complications [22, 80]. Chloroquine which is used for 
malaria has been also taken into consideration for anti-DENV therapy; however, a 
randomized controlled trial o f Chloroquine for treatment of dengue in Vietnamese 
adult showed that Chloroquine did not reduce duration o f viraemia or NS1 
antigenaemia [81]. Furthermore, several studies have been using corticosteroids for 
treating dengue but they have shown conflictive or inconclusive results [82].
1.6.5. Prevention and control
In general, three main strategies are considered integral to the prevention and 
control o f dengue: control of mosquito vectors, development of vaccines and 
discovery of effective antiviral drugs. In the vector control aim, strategies include 
environmental changes (improved water supply, emptying or covering tanks, and 
underground reservoirs), personal protection (protective clothing, mats, and nets), 
biological control (fish, bacteria) and chemical control (insecticide) [3]. Problems 
with homotypic immunity (protective immune response against the same dengue 
serotype used for vaccine challenge), immune enhancement (which may lead to 
severe dengue) and lack of a suitable animal model for dengue disease [83] have 
hampered vaccine development. At the end o f 2009, at least five dengue vaccines, 
including monovalent and tetravalent vaccines and using live-attenuated or chimeric 
viruses, were being investigated in phase I or II clinical trials [4, 5]. Lastly, in the 
field o f antiviral drug development, efforts to find screening compounds are 
continually increasing. Most of the compounds currently under investigation target 
viral entry [84, 85], viral RNA polymerase/methyltransferase [8 6 , 87], nucleotide
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synthesis [8 8 ], viral helicase/NTPase [89], viral serine protease [90], R-glucosidases 
or kinases [91].
1.7. Current laboratory diagnosis
Diagnosis of DENV infection on the basis o f clinical symptoms alone is not 
completely reliable, and should be confirmed by laboratory methods. The methods 
used to confirm DENV infection include detection of virus, viral nucleic acid, dengue 
antigens and virus-specific antibodies. Depending on the stage o f the illness, an 
appropriate method or combination o f all methods should be used (Figure 1-10). 
During the early stages o f the disease, virus isolation, nucleic acid or antigen 
detection can be used to diagnose the infection. At the end o f the acute phase of 
infection, serology is the method of choice for diagnosis.
N Sl detection
VJirus isolation 
RNA detection
Viraemia
O.D
IgM prim ary infection
IgM secondary infection
HI
> 2 5 6 0
IgG secondary infection
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IgG prim ary  infection
onset of symptoms (days)
Figure 1-10: Approximate timelines of primary and secondary DENV infections 
and the diagnostic methods that can be used to detect DENV infection [1].
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1.7.1. Virus isolation
DENY in serum, plasma, peripheral blood monocytes or tissue collected 
during an early stage o f illness (usually before day 5) may be recovered by cell 
culture or inoculation in suckling mice or mosquitoes. Cell culture is the most widely 
used method for virus isolation, with C6/36 (a mosquito cell line) more efficient than 
mammalian cell lines (Vero, BHK-21 and LLC-MK2). The virus and serotype are 
identified by immunofluorescence assay using serotype-specific monoclonal 
antibodies. Although virus isolation is a gold standard for diagnosis o f dengue and 
allows the infecting DENV serotype to be identified, this method is not appropriate 
for use in routine diagnostic laboratories because the procedure usually takes 1-2  
weeks and requires specialized equiptment and reagents [1].
1.7.2. DENV nucleic acid detection
Several reverse-transcriptase polymerase chain reaction (RT-PCR) assays to 
detect DENV RNA have been developed since the early 1990s [92, 93]. Early 
methods allowed DENV serotypes to be detected and identified on the basis of their 
distinct amplicon sizes using specific primers. Later, real-time RT-PCR was 
developed and became an alternative method that used specific primers together with 
fluorescent probes for the detection of DENV RNA [94-96]. RT-PCR and real-time 
RT-PCR can be used to determine the presence o f DENV infection in the early days 
of illness when the patient is still in the viraemic stage [1], and offer relative 
sensitivity compared with viral isolation and much more rapid time to detection (less 
than one day). It is possible that DENV RNA levels in serum or plasma could have 
prognostic value since Thai children with DHF have higher DENV RNA levels than 
children with DF [97], However, these methods are expensive and necessitate 
specialized training as well as special equipment.
1.7.3. DENV NS1 antigen detection
Many studies have used NS1 as a target for the diagnosis o f DENV infection. 
NS1 glycoprotein is secreted from mammalian cells and may last in circulating 
peripheral blood for up to 9 days o f illness, even when DENV RNA cannot be 
detected by polymerase chain reaction (PCR) [98]. Several commercial kits (ELISA
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or rapid tests) are now available for the detection o f NS1 antigen- However, the 
sensitivity and specificity of these kits vary depending on the manufacturer [99, 100]. 
The sensitivity of NS1 testing also depends on the day o f illness that the sample was 
collected [101-103]. Higher sensitivity has been documented within the first three 
days o f illness and in primary cases [103-105]. Diagnostic methods based on NS1 
antigen detection generally are not capable o f identifying the infecting DENV 
serotype. However, a serotype-specific monoclonal antibody-based NS1 antigen- 
capture ELISA has recently been developed, and is suggested to be capable of 
detecting the infecting serotype and discriminating between primary and secondary 
DENV infections [106].
1.7.4. IgM/IgG antibody-capture enzyme-linked immunosorbent 
assay
IgM and/or IgG antibody-capture enzyme-linked immunosorbent assays 
(MAC-ELISA and/or GAC-ELISA) are cheap and easy methods used for diagnosis of 
DENV infection. MAC-ELISA has become an especially important tool in the routine 
diagnosis of dengue.
MAC-ELISA has good sensitivity and specificity but only when used on 
samples collected at 5 or more days after the onset o f fever [1]. Cross-reactivity with 
other flaviviruses such as Japanese encephalitis, St. Louis encephalitis and yellow 
fever [107] is a limitation of the test, likely due to the use o f whole cell virus antigen. 
This limitation can be overcome by using antigens from co-circulating flaviviruses as 
controls in MAC-ELISA. Different commercial kits (ELISA or rapid tests) are 
available, but sensitivities and specificities range from poor to acceptable or good; 
especially high rates of false positives were shown for sera obtained from patients 
with malaria, leptospirosis and past dengue infection [108].
GAC-ELISA is classically used for the detection o f a current infection (if 
paired sera are collected within the correct timeframe). This assay uses the same 
antigens as MAC-ELISA and also shows low specificity within the flavivirus groups 
[109, 110]. An IgG antibody level or IgG avidity allows the identification o f a case as 
resulting from a primary or secondary DENV infection [111-113].
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IgM or IgG seroconversion in acute and convalescent paired sera is used to 
document acute infections [1]. In addition, the IgM/IgG ratio can be used to 
distinguish primary from secondary DENY infections [114-118]. However, the cut­
off for the ratio is not well defined and varies between laboratories.
In general, tests with high sensitivity and specificity require more complex 
technologies and technical expertise, while rapid tests may compromise sensitivity 
and specificity for ease of performance and speed. Virus isolation and nucleic acid 
detection are more labour-intensive and costly but are also more specific than 
antibody detection using serological methods. Table 1-1 shows a comparison of the 
major dengue diagnostic methods.
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1.8. Pathogenesis and immunopathogenesis of dengue
Several hypotheses have been proposed to explain the pathogenesis o f severe 
DENV infection. These below points are among the explanations for the aetiology of 
severe dengue.
1.8.1. The roles of serotypes, genotypes and viraemia
DENV serotype and viraemia levels have been found to be correlated with 
disease severity. For example, DENV-2 appears to be significantly associated with 
more severe dengue compared to DENV-1 [97, 119]. Genetic variations also exist 
within each serotype, resulting in genetically distinct genotypes. Several 
epidemiological observations and in vitro studies revealed a rapid replacement of 
Asian/American viruses by Asian 1 DENV-2 viruses [120] and that predominantly 
Asian genotypes of DENV-2 are more virulent than the American genotypes [121], 
with lineages o f Asian origin known to produce higher viral titres [120, 122] and 
more strongly associated with DHF [123]. High levels o f viraemia [97] and continued 
active viral replication or delay in the clearance of viraemia are also suggested to 
contribute to the pathogenesis of DHF [124-126].
1.8.2. The role of DENV NS1 antigen
The NS1 antigen is secreted from infected cells and plays a potential role in 
vascular leakage in severe dengue. High levels o f NS1 are correlated with high 
viraemia levels [127] and associated with DF1F [39, 41]. NS.l can also mediate 
complement activation, thus resulting in high levels o f complement products (C5a, 
SC5b-9) in pleural fluids from DSS patients [41]. However, NS1 can protect DENV 
from complement-dependent neutralization in vitro because the binding of NS1 to C4 
leads to inhibit complement activation [128]. Further, NS1 selectively binds to many 
types of epithelial cells, including those of the lungs and liver, but not intestine or 
brain endothelium [129]. The differential binding o f soluble NS1 and subsequent 
recognition by anti-NSl antibodies induce apoptosis in endothelial cells. This 
evidence has been suggested to explain the selective vascular leakage syndrome that 
occurs during severe secondary DENV infection [129].
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1.8.3. Antibody responses
DENV-specific antibodies may have multiple functions in DENV infection. 
IgM and IgG antibodies against DENV provide immune protection through several 
mechanisms, including the blocking o f  cellular attachment, viral fusion [130] or 
increasing antibody-dependent cellular cytotoxicity (ADCC) [131, 132]. DENV 
infection induces a large repertoire of memory B cells that produce broadly cross­
reactive antibodies specific for domain I/II of the E protein, while only a minority of 
memory B cells produce antibodies that bind to Dili, prM and nonstructural proteins 
[35, 133, 134]. Human IgG antibodies that bind to domain III o f the E protein have 
greater neutralizing potency than those that bind to domain I or II (Appendix 1) while 
human antibodies that bind to prM don’t neutralize infections but potently induce 
ADE in vitro [134]. Furthermore, acute phase sera from patients with DHF or DSS 
contain significantly higher levels of anti-DENV antibodies (IgA, IgGl, IgG4 and 
IgE) than those from DF and non-dengue patients [135-137]. In primary infections, 
IgM to DENV is the first immunoglobulin isotype to appear at high levels that greatly 
exceed IgG levels for 2 to 4 weeks. In secondary infections, IgM to DENV appears 
late at low levels during the febrile phase of illness, whereas high levels of IgG are 
detectable even in the acute phase.
Notably, infection with one serotype of DENV does not generate protective 
immunity to other serotypes, but it may result in increased severity from future 
heterotypic infections. During secondary infections, pre-existing antibodies at 
subneutralizing titer or non-neutralizing antibodies form complexes with the dengue 
virus particles and facilitate the infection of large numbers o f Fey receptor-bearing 
cells [138]. This process is called antibody dependent enhancement (ADE). DENV- 
specific antibodies also exist in newborn infants [139]; when these antibody levels 
wane, DHF may occur during the first infection, possibly as a result o f ADE [140].
1.8.4. Cell-mediated immunity
Many cell types are involved in the pathogenesis o f dengue. Monocytes and 
macrophages have been considered as the primary target cells o f the infection [141- 
145]. In addition, Langerhans cells or immature dendritic cells were found to be the 
cells that were most permissive o f dengue infection, and were suggested as possible
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early targets o f infection [144, 146]; DENV infection stimulates the maturation of 
these cells and cytokine production. Furthermore, autopsy studies have suggested that 
hepatocytes may act as target cells for DENV [147, 148]. Infection causes liver injury, 
which leads to the elevation of serum levels o f liver enzymes (AST and ALT) early in 
the course of disease; these are especially pronounced in DHF [64, 69, 70].
During acute infection, DENV-infected patients are usually leucopenic (low 
total cell counts), as characterized by a reduction of neutrophils and monocytes [64]. 
A recent gene expression case-control study found 21 genes relating to neutrophil 
activation or degranulation were expressed abundantly in patients who developed 
DSS [149]. Natural killer (NK) cells are also activated early in the acute phase [ISO- 
152] and play a role in lysing DENV-infected cells through direct cytotoxicity or via 
ADCC [153]. NK cells expressing CD69 are significantly increased in children during 
the acute phase o f DHF compared to those with DF [151]. Besides, thrombocytopenia 
(low platelet count) is one of the key clinical manifestations in dengue and is an 
important cause of plasma leakage in severe dengue [154, 155]. Because platelets play 
an essential role in haemostasis, impairment of platelet function can increase the risk 
o f vascular fragility, leading to haemorrhage.
Furthermore, the defence response is mediated by cells in the adaptive 
immune system. Excessive activation o f T cells and B cells, especially o f cross­
reactive memory T cells, appears to augment the secretion of various cytokines during 
secondary infection [151]. Indeed, increased numbers of activated CD4+ and CD8+ 
T-cells and cytokine levels have been reported in DHF [156, 157]. The early T cell 
response to dengue epitopes has been defined in adults with secondary DENV 
infection, but the magnitude of this response was not found to correlate with disease 
severity [158]. Nonstructural proteins NS1, NS3 and the E protein were found to be 
recognized by HLA A ll ,  A24 and B27-restricted CD8+ cytotoxic T cells [158, 159]. 
However, CD8+ T cells specific for N S3133-142 were not detected before the 
commencement of haemoconcentration, thrombocytopenia or resolution o f viraemia 
in Vietnamese children and thus it was suggested that these cells didn’t play a crucial 
function in capillary leakage in DHF patients [160]. More studies are required to 
understand the contributions o f T cell responses in the protection and pathogenesis.
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1.8.5. Cytokine and chemokine responses
Monocytes/macrophages, B-cells, T cells and mast cells produce different 
cytokines and chemokines during the course of DENV infection, which may cause 
capillary leakage and in turn lead to shock in DHF cases. The types and levels of 
cytokines vary during the course of illness. Figure 1-11 summarizes the pattern of 
some cytokines relative to fever and viraemia during the course of the illness.
37 °C
Fever day
Figure 1-11: Temperature, virological and cytokine levels during the course of
dengue virus infection.
Fever day 0 indicates the day o f  defervescence; fever days -I, -2, etc., indicate days 
prior to defervescence and fever days +1, +2, etc., indicate days after defervescence, 
respectively. Plasma leakage in DHF usually occurs around the time o f  
defervescence, accompanied by a rapid decline in viraemia. Extracted from  [161].
In the first three days of DENV infection, tumor necrosis factor-a (TNF-a), 
interleukin (IL)-2, IL-6 and interferon-gamma (IFN-y) peak, whereas IL-10, IL-5 and 
IL-4 appear later [162]. High levels of IL-13 (an inhibitor of proinflammatory 
cytokines) and IL-18 (an inducer of IFN-y) are also observed during the illness, with 
the highest levels shown in patients with DHF grade IV and lowest levels in patients 
with DF [163], TNF-a, IL-10 and IL-8, cytokines with proinflammatory and vascular
Patterns of the cytokines of the innate and adaptive immunity
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permeability-enhancing activities, have been also reported to be elevated in DHF 
[164-168]. Moreover, multiplex cytokine profiles from adult dengue patients revealed 
that IL-ip, IFN-y, IL-4, IL-6 , IL-13, IL-7 and granulocyte-monocyte colony 
stimulating factor (GM-CSF) were increased in patients with severe dengue; in 
contrast, MIP-ip was higher in mild dengue [169]. Furthermore, the authors showed 
that MIP-lp and IFN-y were independently associated with both dengue severity and 
disease outcome. Conflicting with these results, IL-2, IL-6  and IFN-y have been 
shown to be equal in DF and DHF patients [170-172].
A study on gene transcription indirectly showed that multiple type I IFN- 
regulated genes were underexpressed in patients with DSS relative to those without 
DSS, suggesting important differences in the nature o f the host immune responses 
[173]. In addition, complement, TLR and RIG-I signaling pathways, IFN^stimulated 
genes and cytokine/chemokines and their receptors were documented as the major 
features of the transcriptional signature in DSS [149, 174, 175].
In summary, the dengue literature contains multiple reports o f increased 
plasma/serum cytokine concentrations during acute illness. However, because 
cytokine responses are common to all infections, it is very difficult to understand how 
sinigicant any o f these cytokines is for the pathogenesis o f capillary leakage. 
Furthermore, many studies on this topic come from different patient populations using 
different laboratory techniques making comparisions between studies difficult.
1.8.6. Host genetic influences
Although genetic mechanisms underlying the DENV-host interaction remain 
largely unknown, several host genes have been documented to contribute to the 
clinical outcome o f dengue. For example, polymorphisms in HLA class 1 loci [176] 
and in five non-HLA genes (IL-4, IL-1RA, MBL, VDR and FccRII) were found to be 
associated with increased susceptibility to DHF children [177-179]. In contrast, 
variants of the vitamin D receptor (t allele at position 352) and FcyR IIA (R at 
position 131) were found to be associated with resistance to severe dengue [180]. 
Furthermore, a functional mutation in the promoter region o f DC-SIGN was 
associated with susceptibility to mild dengue, but not DHF [181].
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1.9. Biological markers of dengue severity
Studies of biological markers are critical because such knowledge may assist 
clinicians in identifying cases that will eventually develop into DHF/DSS, and may 
also contribute to the clinical management o f disease. Many studies focused on 
identifying biological markers have suggested differences in markers present in the 
clinical samples of severe versus non-severe dengue cases. Such studies may provide 
early predictors that can be used to identify cases that are more likely to progress to 
DHF/DSS. Furthermore, such studies may assist investigators in finding novel 
approaches to combat plasma leakage and haemorrhage in severe dengue. 
Unfortunately, no remarkable biomarkers have yet been found. Table 1-2 summarizes 
the results of studies that found possible predictors with potential roles as biomarkers 
of dengue severity.
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Introduction
1.10. Summary and directions of this thesis
In the last 50 years, dengue incidence has steadily increased across the world, 
expanded to new countries, and spread from urban to rural settings. However, the 
pathogenesis o f dengue, especially that o f severe dengue, is not well understood. It is 
likely that multiple mechanisms are involved in the pathogenesis of DENY infection, 
although their relative roles have not been determined. Furthermore, there are no 
licensed dengue vaccines or anti-viral therapies available for prevention or treatment 
of the disease.
Taken together, all o f the issues described above have implications for the 
diagnosis and clinical management o f dengue, as well as for the targeting o f future 
vaccination strategies and therapeutic drugs. Moreover, in Viet Nam as well as other 
dengue endemic countries, it is not possible to admit all patients with clinical 
suspected dengue to hospital. Therefore, prompt diagnosis and classification are keys 
to case management and to reducing case fatality rates.
One o f the major challenges o f the disease is to identify cases in the early 
stages o f illness, and to rapidly and accurately determine who will develop severe 
disease as the illness progresses. Predictions of disease progression are usually only 
made once patients have shown severe DHF symptoms [194]. Thus, biological 
markers that can be used to predict or serve as association factors with disease 
severity are urgently needed.
Finally, in the absence of animal models that can mimic human DHF, studies 
in dengue patients remain very important. However, limitations of these studies 
include small sample sizes, the often-delayed timing of sample collection and issues 
with the assignation of disease severity. In light o f these problems, prospective studies 
with larger sample sizes, early recruitment and well-characterized patients with 
different degrees of severity are crucial in the effort to a better understand o f the 
underlying mechanisms of the disease and to uncover early markers o f dengue 
severity.
To contribute to these ends, the thesis is to identify some clinical or biological 
prognostic markers in a prospective study o f a large group of children with dengue or
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non-dengue recruited at an early stage of their illness. The following are three main 
objectives of the research:
1. Validate a serological test to confirm dengue and to classify primary and 
secondary infection;
2. Assess plasma NS1 levels in dengue patients and evaluate these for 
predicting disease severity;
3. Examine the clinical, haematological, virological and immunological 
characteristics o f Vietnamese dengue patients and identify some biomarkers that can 
be used to predict the Severity of dengue.
2. Materials & 
Methods
Materials and Methods
This chapter describes the general laboratory methods undertaken. Further 
relevant details are provided in subsequent chapters.
2.1. Definitions for terms used
Fever is defined as axillary body temperature above 37.5°C.
Day one of illness is defined as the first day of the period when axillary body 
temperature is above 37.5°C. Day o f the illness (DOI) was self-reported by patient 
himself, parents or guardian.
Day o f the defevescence is defined as the illness day on which the axillary 
body temperature first falls to <37.5°C with no subsequent rise. Fefer day is the day 
which is compared to defervescence day. For example, fever day -1 is one day before 
defevescence; and fever day +1 is one day after defevescence.
2.2. Case definition
Dengue cases were defined according to the WHO 1997 guideline [72] as 
shown in table 2 - 1 .
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Materials and Methods
2.3. Dengue Laboratory confirmed criteria
Together with the clinical syndromes of dengue, a diagnosis o f “confirmed 
acute dengue” was obtained using an algorithm (Figure 2-1). The algorithm was based 
on 3 assays- a/ detection o f DENY RNA in an acute plasma sample, b/ finding NS1 
antigen in an acute plasma sample and c/ changes in DENY-reactive IgM or IgG 
levels in paired plasma samples. The detection of DENV RNA and NS1 antigen were 
performed on the acute sample (enrolment sample). The serological diagnosis (using 
IgM and IgG capture ELISAs) requires 2 samples at least 2 days apart and the 2nd 
sample collected on day six (or later) after the illness onset or on the early 
convalescent phase (it was usually the discharge sample).
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Materials and Methods
2.4. Laboratory diagnosis
2.4.1. In house anti-  DENV IgM and IgG capture ELISA assay
This is an in-house assay for detection of anti-Dengue/ anti-JEV IgM 
antibody. Antigens (culture supernatants from DEN Vs, JEV and mock infected C6/36 
cells) and anti-DENV monoclonal antibodies were supplied by Venture Technologies 
(UNIMAS Research Park, University Malaysia Sarawak, Malaysia). Briefly, each 
well of ELISA plate (Maxisorp, Nunc Immuno plate, Cat# 442404) was coated with 
lOOuL of anti-human IgM (DakoCytomation, Cat# A0425) or IgG (Sigma, Cat# 
12136) diluted 1:2000 in 0.05M coating buffer (carbonate bicarbonate buffer, Sigma) 
then incubated overnight at 4°C. Plate was first washed three times with 300pL wash 
buffer (PBS containing 0.05% Tween 20) per well and blocked with 200pL PBS 
3%BSA per well for at least two hours at room temperature. Plasma samples, positive 
and negative controls were diluted at 1:100 in sample diluent buffer (PBS containing 
3%BSA). After a second washing of three times with 300pl wash buffer/ well, lOOul 
of diluted plasma and controls were added to triplicate wells and incubated for two 
hours at room temperature. After washing five times, lOOp.1 of antigens (culture 
supernatants) was added to each well and then incubated at 4°C overnight. After 
another washing step (five times), a mix of mouse monoclonal antibodies to DENV 
were added and incubated for one hour, washed five times then anti-mouse Ig 
Horseradish Peroxidase (DAKO, Cat#P260) (1:2000 dilution) was added. After the 
final washing step, substrate o-phenylenediamine dihydrochloride (OPD) was added 
then incubated 30 minutes then the colour metric reaction was stopped by addition of 
10% H2SO4. The Optical Density (OD) was read at 490nm.
Positive control was a mixture of plasma samples from acute dengue patients. 
Negative control was a mixture of plasma samples collected from 20 healthy 
Vietnamese donors. The cut-off value (CO) for positivity was defined as being 5 
times higher than the average OD of negative control samples (ODn) after the 
subtraction o f background OD (ODb). The sample ratio (Rs) was calculated by 
subtracting background OD from the test sample OD (ODs) then dividing by the 
assay cut-off. In summary, the formulas were calculated as below:
CO = 5x mean (ODn -  ODb)
Materials and Methods
Rs = (ODs -  ODb)/ CO.
Result interpretation as below:
-If Rs<0.8, result was interpreted as negative.
-If Rs>1.2, result was interpreted as positive.
-If Rs from 0.8-1.2, result was interpreted as equivocal.
2.4.2. NS1 qualitative ELISA
Bio-Rad Dengue NS1 Ag Platelia ELISA kit is a one step sandwich -  format 
microplate enzyme immunoassay for the qualitative or semi-quantitative detection of 
DENV-NS.l antigen in human plasma or serum. Tests were carried out according to 
the manufacturer’s instructions. Briefly, 50pl of plasma or control sera (including one 
calibrator, one negative and one positive control sera) were incubated directly and 
simultaneously with 50pl o f diluent and lOOpl o f diluted conjugate at 37°C for 90 
minutes in microplate wells. The plate was washed six times with lx  Washing solution 
(TRIS-NaCl -  pH 7.4, 1% Tween 20), then immune-complexes were detected by 
using a color development reaction [160pl, mix of TMB Substrate Solution (citric 
acid and sodium acetate pH 4.0, H2O2 - 0.015%, and DMSO - 4%), and TMB 
Chromogen (0.25% of 3,3’,5,5’ tetramethylbenzidine)]. After 30 minutes of 
incubation in the dark at room temperature, the enzymatic reaction was stopped by 
adding lOOpl o f IN sulfuric acid solution. The OD was read at dual 450/620 nm. The 
presence of NS1 antigen in each sample was determined by comparing the OD of the 
sample to the OD of the calibrator (Sample Ratio). The test would be validated if a/ 
mean o f calibrator OD was greater than 0.2, b/ the negative control was lower than 0.4 
time o f the calibrator and c/ the positive control was greater than 1.5 times of the 
calibrator.
Result interpretation as below:
-If the Sample Ratio <0.5, result was interpreted as negative.
-If the Sample Ratio >1, result was interpreted as positive.
-If the Sample Ratio from 0.5-1, result was interpreted as equivocal.
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2.4.3. RNA isolation
For screening and serotyping o f DENV, viral RNA was isolated by using 
RNA extraction kits supplied by Qiagen (Qiagen, Cat#52906). For quantitative 
viraemia in serial samples from patients, Nuclisens easy MAG Extraction 
(BioMerieux, USA, Cat# 280131, 280132 and 280133) kits were used. Before 
extraction, a standard amount of Equine Arteritis Virus (EAV) was added into each 
plasma sample as an internal control for extraction and RT-PCR process. The 
procedure o f RNA extraction was carried out following the manufacturer’s 
instructions. Each specimen (lOOpl) was mixed with a lysis buffer containing a 
chaotropic agent which disrupts the three dimensional structure in macromolecules 
and inactivates any nucleases present in the specimen, thereby releasing the nucleic 
acids. Nucleic acids present in the lysate bound to carriers (that are beads in the 
Qiagen kit or are magnetic silica in the Neclisens easy MAG kit) under the high salt 
conditions. The carriers were then washed several times using wash buffers. Next, the 
nucleic acids were eluted from the carriers and concentrated in a specified volume 
(50pl) o f the elution buffer. Finally* the concentrated nucleic acid solution was 
separated from the carriers by filter or magnetic field and then stored at minus 80°C 
until used.
2.4.4. Detecting and serotyping DENV
This method required two separate steps of PCR. RNA was first reverse- 
trancribed to cDNA and then the cDNA served as a template for real-time RT-PCR 
with appropriate DENV serotype-specific primers.
cDNA synthesis
cDNA was generated from viral RNA by reverse transcription using random 
hexamers. Random hexamers (Roche, Lewes, UK) were used at a working solution o f 
1.5pg/ml. A mixture of 8pl of RNA, 1 ptl o f 1.5jig/pl random hexamers, 1 pil o f lOmM 
dNTPs, and 3pl o f sterile distilled H2O was incubated at 65°C for 5 minutes and then 
immediately chilled on ice for at least 1 minute. Another mixture of 4 pi o f 5x First- 
strand buffer, lp l of dithiothreitol (DTT, Invitrogen), 0.4pl o f RNaseOUT (RNase 
inhibitor, Invitrogen) and 0.2pl o f Superscript III RT (reverse transcriptase,
Materials and Methods
Invitrogen) adjusted with H2O up to 7pl was added to make up a reverse transcription 
reaction volume o f 20pl. The content was mixed by gentle pipetting up and down then 
incubated at 25°C for 10 minutes. cDNA was then synthesized at 50°C for 60 minutes. 
The reaction was inactivated by heating at 75°C for 15 minutes.
Real-time RT-PCR for detecting and serotyping DENV
.We used a DENV serotype-specific, fluorogenic real-time PCR assay to detect 
DENV RNA and to define DENV serotype in plasma samples. The dengue serotype- 
specific primers and probes were adapted from previously published sequences [195] 
and are summarized in Table 2-2. Hotstar Taq polymerase was used in all assays 
(Qiagen, USA). PCR reaction mixture is described in Table 2-3. PCR conditions were 
95°C for 15 minutes then 45 cycles of 95°C for 30 seconds, 60°C for 30 seconds then 
fluorescence was captured and then ending by 72°C for 30 seconds. A sample was 
validated if its PCR results showed EAV signals and was considered as having a 
specific serotype o f DENV infection if any signal above the fluorescence background 
was seen in one o f four serotype-specific PCRs.
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Table 2-2: DENV Oligonucleotide primers, fluorescence-labeled probes
Serotype Oligonucleotide sequences (5’-3’) Position
DENV-1 - Forward 
DENV-1 - Reverse 
DENV-2 - Forward 
DENV-2 - Reverse 
DENV-3 - Forward 
DENV-3 - Reverse 
DENV-4 - Forward 
DENV-4 - Reverse 
EAV- Forward 
EAV - Reverse
ATCCATGCCCACCAYCAATG
CAGGGATCCACACCAYTGATC
ACAAGTCGAACAACCTGGTCCAT
GCCGCACCATTGGTCTTCTC
TTTCTGCTCCCACCACTTTCAT
TGGCGTTGGATGCYAGTCT
GY GTGGT G A AGCC YCTRG AT
AGTGARCGGCCATCCTTCAT
CATCTCTTGCTTTGCTCCTTAG
AGCCGCACCTTCACATTG
9960 - 9980 
10100-10121 
9938-9941 
10095- 10115 
9719-9741 
9915-9934 
9587-9607 
9744 - 9764 
1847- 1869 
1962- 1980
DENV-1-Probe 
DENV-2-Probe 
DENV-3-Probe 
DENV-4-Probe 
EAV- Probe
5’ (FAM) TCAGTGTGGAATAGGGTTTGGATAGAGGAA-3’ (TAMRA). 
5’(FAM) AGGGTGTGGATTCGAGAAAACCCATGG-3 (TAMRA)
5' (FAM) AAGAAAGTTGGTAGTTCCCTGCAGACCCCA 3'(TAMRA)
5' (FAM) ACTTCCGTCCTCTTYTTGAACGACATGGGA 3'(TAMRA)
5’(Cy5) CGCGCTCGCTGTCAGAACAACATTATTGCCCACAGCGCG 3'(BHQ)
Y: C/T nucleotide, R: AJG nucleotide
R/F Primer: reverse / forward primer, respectively.
EA V: Equine Arteritis virus (causing systemic infection in equids)
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Table 2-3: TaqMan RT-PCR mixture
Reagent Workingconcentration
Volume (pi) / reaction
DENV-1 DENV-2 DENV-3 DENV-4
DENV F+R primer lOpM 1.5 1.5 1.5 1.5
EAV F+R primer lOpM 1.5 1.5 1.5 1.5
MgC12 25mM 2.5 3.5 3.8 2.5
Buffer 10X 2.5 2.5 2.5 2.5
dNTP (Roche) lOmM 1 1 1 1
DENV Probe 2pM 2.5 1 3 2.5
EAV Probe 2pM 1.5 1.5 1.5 1.5
Hotstar Taq (Quiagen) 5U/pL 0.2 0.2 0.2 0.2
H2O (Sigma) 7.8 8.3 6 7.8
cDNA 4 4 4 4
2.4.5. Quantification of DENV by one step RT-PCR (qRT-PCR)
The dengue serotype-specific primers and probes adapted from DENV 
serotyping PCR with some modifications are summarized in Table 2-4. We used 
LC480 RNA Master Hydrolysis Probes (Roche, Cat# 04991885001) which contain all 
essential reagents for PCR reaction. The PCR mixture is described in Table 2-5. PCR 
Conditions included three steps. The first step was the reverse transcription step 
carried out at 61°C for 10 minutes. The second step was denaturation step carried out 
at 95°C for 02 minutes. And the amplification step was done with 45 cycles o f 95°C 
for 15 seconds, 60°C for 30 seconds and then a fluorescence measurement was made. 
After all, the PCR products were brought to 37°C for 1 minute.
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Table 2-4: DENV oligonucleotide primers, fluorescence-labeled probes using in
the one-step RT-PCR
Serotype Oligonucleotide sequences (5’-3’) Position
DENV-1 - Forward 
DENV-1 - Reverse 
DENV-2 - Forward 
DENV-2 - Reverse 
DENV-3 - Forward 
DENV-3 - Reverse
ATCCATGCCCATCACCAAT
TGTGGGTTTTGTCCTCCATC
TCCATACACGCCAAACATGAA
GGGATTTCCTCCCATGATTCC
TTTCTGCTCCCACCACTTTC
CCATCCYGCTCCTTGAGA
9865 - 9883 
9945-9964 
9859-9879 
9963-9983 
9591 -9610 
9691 - 9708
DENV-4 - Forward 
DENV-4 - Reverse 
EAV- Forward 
EAV - Reverse
GYGTGGTGAAGCCYCTRGAT
AGTGARCGGCCATCCTTCAT
CATCTCTTGCTTTGCTCCTTAG
AGCCGCACCTTCACATTG
9587 - 9607 
9744 - 9764 
1847- 1869 
1962- 1980
DENV-1-Probe 
DENV^2-Probe 
DENV-3-Probe 
DENV-4-Probe
EAV - Probe
5' (FAM) TCAGTGTGGAATAGGGTTTGGATAGAGGAA 3’ (BHQ-1). 
5’FAM AGGGTGTGGATTCGAGAAAACCCATGG 3’ BHQ1 
5’ (Cyan500) AAGAAAGTTGGTAGTTCCCTGCAGACCCCA 3’(BHQ1) 
5’ (Cyan500) ACTTCCCTCCTCTTYTTGAACGACATGGGA 3’(BHQ1)
5 ’ (Cy5) CGCGCTCGCTGTC AG AACAACATTATTGCCC ACAGCGCG 
3’(BHQ)
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Table 2-5: One step RT-PCR mixture
Reagents
Working
concentration
(MM)
pl/reaction
DENV Primer 20 1.00
DENV Probe 10 0.28
EAV Primer 20 0.20
EAV Probe 10 0.08
Activator (Roche) 1.40
Enhancer (x20) (Roche) 1.00
Master mix (Roche) 7.40
H20 (Roche) 2.64
RNA 6.00
Total 20.00
2.4.6. Cytokine detection by muitipiex micro-bead immunoassay
The principle of this assay is a multiplex biometric immunoassay, in which 
many fluorescent-dyed microspheres are used to detect cytokines (in our assay, 10 
kinds o f microsphere beads). Each kind o f microspheres is coupled with monoclonal 
antibodies specific for a desired target cytokine. Bound cytokines are then detected by 
biotinylated detection antibodies specific for different epitopes. Streptavidin- 
phycoerythrin is then added to bind to the biotinylated detection antibodies on the 
bead surface. In this study, kits (Bio-Plex Human Cytokine Assay, Bio-Rad Inc., 
USA) were used for cytokine measurement following the manufacturer’s instructions. 
The kit includes concentrated human recombinant cytokines as standards and coupled 
beads for 10 cytokines measurement, such as: IL-ip, IL-2, IL-4, IL-5, IL-6, IL-10, IL- 
12p70, IL-13, IFNy and TNFa. Briefly, 50pl plasma samples were incubated with 
coupled beads. Complexes were washed twice, then incubated with biotinylated 
detection antibodies and, finally, labeled with streptavidin-phycoerythrin prior to 
assessing cytokine concentrations. Cytokine concentrations were determined using a 
multiplex array reader from Luminex Systems (Bio-Plex Workstation from Bio-Rad 
Laboratories) and the analyte was calculated using software provided by the 
manufacturer (Bio-Plex Manager Software). Standard ranges o f cytokines that could 
be detected are shown in table 2-6.
- 4 6 -
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Table 2-6: Detection ranges of cytokines (in pg/ml)
Description IL-1b IL-2 IL-4 IL-5 IL-6 IL-10 IL12-p70 IL-13 IFN-g TNF-a
Minmum 0.23 0.84 0.14 1.5 1.23 0.96 0.2 1.19 0.34 0.14
Maximum 4,438 3,822 2,387 1,759 21,550 13,617 3,445 6,729 6,640 592
2 . 5 .  Statistical analysis
Data was analyzed with SPSS statistical package version 14.0.0 for Windows 
(SPSS, Inc, Chicago, III) or R 2.9.1 (R Foundation for Statistical Computing, Vienna, 
Austria); and GraphPad Prism version 5 (GraphPad software Inc., USA) was used to 
plot graphs. Dichotomous measures were compared using the Chi-square test or the 
Fisher Exact test where appropriate. The Mann-Whitney U test was used for 
continuous variables. A two-tailed p value of below 0.05 was considered statistically 
significant. Receiver operating characteristic (ROC) curves, which were made by 
plotting the true-positive rate (sensitivity) versus the false-positive rate (1 -  
specificity), were used to evaluate the diagnostic performance of bio-markers at 
various cut-off points. Using standard formulas, the following performance measures 
were used to quantify the performance o f the predictions from the selected models: 
the area under the ROC curve, sensitivity, and specificity, positive and negative 
predictive value o f the cut-off value that represented the appropriate discrimination.
The accuracy of the proposed model was evaluated through two methods. The 
model was first assessed by using the original data set that generated the model 
(training data set) to derive apparent (by simple resubstitution) and optimism- 
corrected value. The optimism-corrected value was derived by using bootstrap 
method (with 100 times repeated) to assess potential overfitting o f our models 
(including the model selection process) when using the same data set that had been 
used to generate the models [196]. And then, if another independent test data set was 
available, the performances of the models were calculated and compared.
3. Discrimination 
primary and 
secondary acute 
dengue virus 
infection
Discrimination primary and secondary...
3.1. Introduction
Many tests to classify serological responses during acute DENV infection 
have been employed around the world. The HI test has been widely used and relies on 
the ability of antibodies to block the haemagglutinating activity o f DENV, with high 
titres in the HI test highly suggestive o f secondary infection [197]. Later, the ratio 
between IgM and IgG has been employed to classify primary and secondary immune 
status. This approach is based on the observation that acute phase sera from patients 
with primary infections have higher IgM/IgG ratios than those from patients with 
secondary infections [114-118]. Matheus et al. proposed an IgG avidity test for the 
differentiation o f primary from secondary infection. This test is based on the changes 
in the avidity of IgG with the pathogen during the infectious episode, the avidity level 
of primary sera was always lower than that of the secondary sera [112, 113, 198]. An 
NS1 serotype-specific IgG ELISA for serological classification was first proposed by 
Shu et al. [106]. The assay is based on the fact that NS1 serotype-specific IgG 
antibody can’t be detected in primary sera until day 9 o f illness, so the NS1 serotype- 
specific IgG antibodies measured in acute sera must come from previous infections.
The HI test is still recommended by the WHO for discrimination between 
primary and secondary infection [1, 72]. However, the drawbacks of the HI test for 
routine laboratory diagnosis o f dengue include 1/ using two samples that had to be 
collected at an appropriate time interval, 2/ requirement for chemical pretreatment to 
remove non-specific inhibitors and agglutinins and 3/ the high rate of cross-reactions 
with other flavivirus-specific antibodies [199]. Instead, the simpler immunoglobulin 
M (IgM) and G (IgG) antibody capture enzyme- linked immunosorbent assays (MAC 
and GAC ELISA) have become practical assays for the diagnosis o f dengue [106, 
200] because they are generally fast, high throughput and use relatively inexpensive 
reagents.
Antibody profiles elicited by primary and secondary DENV infections differ. 
Detectable anti- DENV IgM and IgG antibody generally become measurable within
4-6 days of fever onset. IgM wanes after 60-90 days [114] [201] but IgG remains 
measurable for many years after infection. In primary infections, IgM antibodies 
develop rapidly with high level while IgG appears slowly afterwards. In secondary
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infections, high levels o f IgG are detectable even in the acute phase whereas IgM 
levels are low or even absent [202]. One of the challenges in dengue serology is 
determining primary from secondary infection on the basis o f ELISA results. In an 
ELISA assay developed in the AFRIMS (Armed Forces Research Institute of Medical 
Science) laboratory in Bangkok, Thailand, an optical density ratio o f IgM:IgG of >1.8 
in acute plasma classified a patient as having primary infection. The day o f illness that 
the sample was collected was not factored into this classification system. Moreover, 
the ratio of 1.8 is valid only in this particular assay and cannot be exported to other 
IgM and IgG ELISA assays that use different reagents from the AFRIMS assay.
In this study, we aimed to validate a DENV IgM and IgG capture ELISA in 
the detection and differentiation of primary and secondary infection. In detail, the 
objectives of this chapter are:
1. To evaluate the in-house Hospital for Tropical Diseases DENV IgM ELISA 
test for sensitivity and specificity.
2. To generate a classification model based on IgM and IgG levels and day of 
illness at the time samples were collected to classify primary and secondary dengue 
cases.
3. To evaluate the classification model.
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3.2. Methods 
3.2.1. Reference panel for evaluation of in-house IgM assay
To evaluate the Hospital for Tropical Diseases (HTD) in-house anti-DENV 
IgM ELISA test for detection o f IgM against DENV, a panel o f reference serum 
samples was used. The panel was described in detail by Hunsperger et. al. [108] and 
was collected by a consortia supported by the United Nations International Children’s 
Emergency Fund/United Nations Development Programme/World Bank/World 
Health Organization Special Programme for Research and Training in Tropical 
Disease and the Pediatric Dengue Vaccine Initiative. All samples were coded to 
ensure that the person performing the assay was blinded to sample identity.
3.2.2. Samples for discrimination of primary and secondary 
responses using the in-house assays
To generate and evaluate a classification model for primary and secondary 
dengue using the in-house assays, we used plasma samples from dengue patients 
enrolled in prospective studies at the HTD and a private, primary level health care 
clinic located in HCMC. All patients admitted to HTD were in-patients, and the clinic 
treated out-patients. The samples were from patients aged above 4 years old, had 
fever within 72 hours of study enrolment and were laboratory confirmed acute dengue 
cases. Two venous blood specimens were drawn from each patient at the time of 
enrolment (acute phase) and again 3-6 days later (at the time of discharge- early 
convalescent phase). Acute dengue cases were defined by having seroconversion in 
DENV-reactive IgM and IgG in paired plasma samples or detection of viral RNA by 
RT-PCR, as described in chapter 2 (section 2.3). All patients or patient’s guardian 
gave written informed consent. Plasma was separated, aliquot and stored at -20°C. 
One aliquot was sent to the “reference lab” (Dr Suttee Yoksan, Centre for Vaccine 
Development, Bangkok, Thailand) to determine IgM, IgG levels and classify primary 
and secondary DENV infection.
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3.2.3. The reference assay at the Centre for Vaccine 
Development,  Bangkok,  Thailand
The reference anti- DENV IgM and IgG antibody capture ELIS As have been 
described elsewhere and' were performed by a staff of the Centre for Vaccine 
Development, Bangkok, Thailand [114]. For paired specimens, an increase from less 
than 15 units of IgM against dengue virus to more than 30 units was considered 
evidence of an acute dengue infection. A dengue IgM: IgG ratio at discharge equal to 
or greater than 1.7 defined as primary dengue infection, otherwise defined as 
secondary infection.
3.2.4. The in-house assay at the Hospital for Tropical 
Diseases
The in house anti-dengue virus IgM and IgG tests were performed by a single 
analyst following the procedure described in chapter 2 (section 2.4.1). Results o f the 
samples were reported in units that reflect the fraction of IgM or IgG reactive with the 
test antigen relative to negative control plasma samples. Results were also reported as 
negative or positive. Samples with equivocal results were considered as negative if  
the retest results were still equivocal.
3.2.5. Statistical methods for devising the classification 
model
Logistic regression was used to model the probability of having primary acute 
dengue infection. The model was designed based on six covariates: IgM, IgG ELISA 
units measured in paired plasma samples (enrolment and discharge samples) together 
with the day o f illness at the time these samples were collected. A stepwise backward 
variable selection procedure was employed to find independent predictors o f primary 
infection with p-to-remove > 0.1. Once the final model was constructed, the rounded 
coefficients from the model were used to define a diagnostic score (DS). An 
individual was classified as having primary infection if  the probability o f primary 
infection was estimated to be > 0.5.
The accuracy of the proposed model was evaluated by resubstitution (apparent 
and bootstrap method) and by using an external test data set from a further 93 patients
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enrolled in the same manner. The sensitivity, specificity, negative and positive 
predictive values were calculated and compared. The evaluations were based on 
patients who were classified as primary or secondary acute dengue infections 
according to the reference laboratory assay results.
3.3. Results
3.3.1. Evaluation of the HTD in-house anti-DENV IgM 
ELISA
The evaluation reference panel consisted o f 313 well-characterized serum 
specimens (Table 3-1) collected by a TDR/WHO/PDVI sponsored consortia as 
described previously [108]. According to the results o f reference laboratories, there 
were 184 samples positive for IgM against DENV and 129 IgM negative samples. 
The positive samples were obtained from patients with primary (N=29) and secondary 
(N=155) infections with all four DENV serotypes represented; 28 infected with 
DENV-1, 19 DENV-2, 14 DENV-3 and 8 DENV-4. The negative samples included 
samples taken from virologically proven dengue cases with negative IgM serology 
(N=14), samples from patients with other confirmed infectious diseases (N=84), other 
diseases (N=4) and from healthy persons (N=27) resident in non-endemic dengue 
countries.
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Table 3-1: Summaries of serum specimens used for evaluation.
Evaluation panel Number of samples
DENV IgM positive
primary infections 29 ;
secondary infections 155
Total DENV IgM positive 184*
DENV IgM negative
DENV+/IgM- 14 .**
Related flavivirus
West Nile virus 26
Yellow fever virus 10
St. Louis encephalitis virus 2
Japanese encephalitis virus 8
Febrile illness
Malaria 31
New World hantavirus IgM positive 7
Systemic conditions
Rheumatoid factor 2
Systemic lupus erythematosus 2
Healthy persons*** 27 .
Total DENV IgM negative 129
DENV, dengue virus; Ig, immunoglobulin.
* Includes samples with virological information: 28 DENV-1, 19 DENV-2, 14 DENV- 
3, and 8 DENV-4. The serotype was not identifiedfor 115 samples.
** Includes samples with virological information: 7 DENV-1, 5 DENV-2, 1 DENV-3, 
and 1 DENV-4.
*** p rom areas where dengue is not endemic.
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Diagnostic accuracy of the HTD in house anti- DENV IgM ELISA
Overall, the in-house IgM test correctly diagnosed 94.6% (95% Cl 90.3% - 
97.4%) o f IgM positive specimens and 91.5% (95% Cl 85.3% - 95.7%) o f IgM 
negative specimens. The negative and positive predictive values were high; 92.2% 
(95% Cl 86.1% - 96.2%) and 94.1% (95% Cl 89.7% - 97%), respectively. Overall, the 
in-house assay performs comparably with the best available commercial assay tested 
in the recent TDR/PDVI evaluation [108] (Table 3-2).
Table 3-2: Accuracy of the HTD in-house test with some commercial tests.
Elisa test from Sensitivity (95% Cl) Specificity (95% Cl)
Panbio Diagnostics 
(Windsor, Queensland, Australia)
99.0%
(98.4%-99.5%)
90.6%
88.9%-92.3%
Focus Diagnostics 
(Cypress, CA, USA)
98.6% 
(98.0%- 99.2%)
77.8% 
75.5%—80.1%,
Standard Diagnostics 
(Kyonggi-do, South Korea)
97.6%
(96.8%-98.4%)
90.0%
(88%.3-91.7%)
The HTD in-house test
94.6% 
(90.3% - 97.4%)
91.5% 
(85.3% - 95.7%)
Influence of serological responses and dengue virus serotype
The sensitivities of the test layered by primary, secondary and each DENV 
serotype are shown in table 3-3. The sensitivity was lower in primary dengue 
infection than in secondary dengue infection but it was not statistical different; 
sensitivity o f 93.1% in primary compared with of 94.8% in secondary DENV 
infection (P =0.7). Similarly, there wasn’t any statistical difference in sensitivity 
across the 4 serotypes o f dengue virus, although the number o f DENV-4 samples was 
small. This suggests that the sensitivity o f the in-house anti-DENV IgM ELISA is 
affected by neither serological responses nor serotype of the dengue virus.
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Table 3-3: Sensitivity by serological responses and dengue virus serotype of the 
in-house test for detection of anti-DENV IgM
No. positive / total % 95%CI p *
Primary 27/29 93.1 77.2 -  99.2 0.7
Secondary 147/155 94.8 90.1 -9 7 .7
DEN-1 27/28 96.4 8 1 .7 -9 9 .9 0.3
DEN-2 17/19 89.5 6 6 .9 -9 8 .6
DEN-3 13/14 92.9 66.1 -9 9 .8
DEN-4 6/8 75 34 .9 -9 6
* Fisher’s exact test.
False-positive reactions in the HTD in-house IgM assay
The in-house test performance when samples from non dengue- patients or 
when samples from true dengue patients with undetectable IgM levels were tested is 
shown in table 3-4. The majority of samples from non-dengue cases demonstrated 
negative results with the test, except samples from malaria cases, where strikingly 
32.3% of samples gave a false-positive result. Amongst samples from true dengue 
cases but without measurable IgM, only one DENV-1 confirmed sample was positive 
with the test, representing a 14.3% false-positive rate. This suggests the in-house IgM 
test was very specific in detecting IgM of DENV infections rather than Other 
flaviviruses infections or other diseases except malaria. Further studies are needed to 
explain the cause o f this cross-reactivity in malaria.
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Table 3-4: False- positive rate of the in-house test compared with reference 
laboratory results for anti-DENV IgM antibody detection.
Evaluation panel No. of samples
No. of 
false-positive
False-positive rate 
(%)
DENV+/IgM-
DENV-1/IgM negative 7 1 14.3
DENV-2/ IgM negative V 5 0 ■ ■ -
DENV-3/ IgM negative 1 0 -
DENV-4/ IgM negative 1 0 -
Related flavivirus
West Nile virus 26 O' -
Yellow fever virus 10 0 -
St. Louis encephalitis virus 2 ‘ 0 -
Japanese encephalitis virus 8 0 -
Other febrile illness
Malaria 31 10 32.3
New World hantavirus IgM positive 7 0 - ■
Systemic conditions
Rheumatoid factor 2 0
Systemic lupus erythematosus 2 0 -
Healthy persons 27 0 -
3.3.2. Design of a classification model to classify 
primary and secondary DENV infection based on the in-house 
IgM and IgG ELISA test
We hypothesized that the in-house anti-DENV IgM and IgG tests could be 
used to discriminate between primary and secondary serological responses. To 
address this hypothesis, we measured IgM and IgG levels in paired plasma samples 
from a population of Vietnamese dengue cases in which a reference laboratory had a 
previously made a determination o f primary or secondary dengue using the same 
plasma samples.
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The study population
The panel used to generate a classification model consisted of paired plasma 
samples from 575 laboratory-confirmed dengue cases. Of these, 509 (88.5%) cases 
were classified primary and secondary dengue by the reference laboratory; 66 (11.5%) 
cases couldn’t be classified in the reference laboratory and were excluded from this 
analysis. A summary of the demographic characteristics of these patients is shown in 
Table 3-5. The male: female ratio was 1.6 and the number of cases o f secondary 
infection was higher than primary infection. There was a significant difference in the 
distribution o f age between primary and secondary infection (PO.OOl, Pearson Chi- 
square test), with secondary infection more prevalent in the older age groups, but 
there was no correlation between gender and serological responses (P=0.2, Fisher’s 
Exact test).
Table 3-5: Baseline characteristics of the patients.
Age (years)
Gender Serological responses3
Total
Male Female Primary Secondary
4-9 49 (50.5%) 48 (49.5%) 33 (34%) 64 (66%) 97(19.1%)
10-12 79 (60.3%) 52 (39.7%) 34(26%) 97 (74%) 131 (25.7%)
13-15 79 (64.2%) 44 (35.8%) 35 (28.5%) 88 (71.5%) 123.(24.2%)
16-24 75 (69.4%) 33 (30.6%) 13 (12%) 95 (88%) 108 (21.2%)
25-44 31 (62%) 19 (38%) 0 50(100%) 50(9.8%)
Total 313(61.5%) 196 (38.5%) 115(22.6%) 394 (77.4%) 509
a Primary and secondary infection was designated by the reference laboratory.
Values expressed as number (percentage within age group)
Plasma samples from four hundred sixteen cases were randomly selected as 
the training data set to devise a classification model; of these, 102 were primary 
infections and 314 were secondary infections based on the results from the reference 
laboratory. An independent test data set consisted o f the remaining cases; o f these, 13 
had primary infection and 80 had secondary infection, according to the reference 
laboratory’s results. All samples were evaluated for levels o f anti- DENV IgM and
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IgG antibodies by using the in-house IgM and IgG tests. The infecting DENV 
serotype was determined by RT-PCR and the serotypes present in the two sample sets 
is shown in Table 3-6. In total, DENV-1 was the most prevalent serotype, accounting 
for 51.1% of all dengue confirmed cases. The second most common was DENV-2 
(23.5%), then DENV-3 (17.3%). DENV-4 infection was detected in only 6 patients 
(1.2%). This pattern of serotype prevalence was seen in both data sets.
Table 3-6: Infecting DENV serotype in the study population.
Group Negative DENV-1 DENV-2 DENV-3 DENV-4 Total
Training data set 31 (7.5%) 211 (50.6%) 101 (24.3%) 69 (16.6%) 4 (1%) 416
Test data set 4 (4.3%) 49 (52.7%) 19(20.4%) 19 (20.4%) 2 (2.2%) 93
Total (%) 35 (6.9%) 260 (51.1%) 120 (23.5%) 88(17.3%) 6 (1.2%) 509
IgM and IgG levels of patients in the training data set
Figure 3-1 shows the levels of anti-DENV IgM and IgG antibodies in relation 
to the day of illness when the samples were collected, with stratification according the 
reference laboratory classification of primary or secondary infection. Generally, in 
primary dengue, IgM levels in the in-house assay were higher than IgG levels, whilst 
in secondary dengue the reverse was true. During the first 4 days of the illness, 
DENV-specific IgM and IgG antibodies were detected at low levels in either primary 
or secondary infection. IgM and IgG antibody levels increased rapidly between days
5-11. Significant higher IgM levels were observed in primary cases on day 6 (P< 
0.01), 7, 8, 9 (all P< 0.0001), and 10 (P=0.04) of the illness compared to secondary 
cases. On the other hand, IgG levels were significantly higher in secondary than 
primary infection, with the differences at day 6, 7, 8, 9 and 10 significant at P< 
0 .0001 .
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Figure 3-1: Dynamics of anti-DENV IgM and IgG antibody levels in acute and 
early convalescent-phase plasma samples from dengue patients with primary or
secondary dengue by day of illness.
Mean and standard deviation o f  anti-DENV IgM  and IgG levels are shown in (A) and  
(B), respectively. Blue bars represent primary dengue and red bars are secondary 
dengue. There were significant differences between primary and secondary at day 6, 
7, 8, 9 and 10 days o f  the illness, P<0.05 (*), <0.001 (**) and <0.0001 (***) 
(ANOVA, Bonferroni posttest).
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To further explore the relationship within the IgM and IgG levels measured by 
the in-house assays on the acute and early convalescent samples, we performed 
correlation analysis. Generally, anti-DENV IgM antibody levels were significantly 
correlated with anti-DENV IgG antibody levels (P<0.001, Spearman), though the 
correlations were weak (r =0.6). If using early convalescent samples only, there were 
two distinct populations o f primary and secondary infections with the correlation rates 
of r=0.5 and r=0.1, respectively (p<0.01, Spearman) but this phenomenon was not 
seen if using enrolment samples (Figure 3-2).
Collectively, the results suggested that IgM and IgG levels o f the early 
convalescent samples measured by the in-house ELISAs have potentially 
discriminative features to classify primary and secondary dengue virus infection.
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Figure 3-2: Correlation plots of DENV-reactive IgG and IgM antibody levels 
measured in acute and early convalescent samples by serological responses.
Each point represents the IgM  and IgG measurement attained with either enrolment 
(A) or early convalescent samples (B) using the in-house ELISAs. Blue points 
represent primary D ENY infections, and red points are secondary D EN Y infections 
according to the reference assay. IgM  or IgG shown in (A) are logarit scales, those 
in (B) are linear scales. The best distinction between primary and secondary 
infections was observed when IgM  and IgG levels o f  early convalescent samples were 
considered compared with those o f  acute samples.
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G e n e r a t i o n  o f  a  c l a s s i f i c a t i o n  m o d e l
Because of the difference between the enrolment and the early convalescent 
samples, we considered them as different variables (IgM of enrolment/ convalescent, 
IgG of enrolment/ convalescent and day o f illness at enrolment/ convalescent). All 
these variables o f the training data set were put into the stepwise logistic regression 
model to find independent predictors o f primary infection with p-to-remove > 0 .1 . 
The analysis found 3 variables which were independently associated with a diagnosis 
of primary infection. The final model is represented in table 3-7.
Table 3-7: The final logistic regression model for the diagnosis of primary
infection.
Primary Coefficient 95% Cl P
I § M Conval escent 0.09 0 .0 5 -0 .1 3 <0.0001
IgGconvalescent -0.21 -0.26- -0.16 <0.0001
DOIconvalescent °-61 0 .1 3 -1 .1 0.01
Constant -4 -7 .08--0 .9 0.01
DOI: day o f  illness when the samples were collected.
The classification model for diagnosis of primary infection was derived from 
the final logistic regression model by rounding the coefficients. An individual was 
classified as having primary infection if the probability o f having primary infection 
was estimated to be > 0.5. Of note, this cut-off implies that we implicitly qualified the 
cost o f a false positive classification as same as the cost of a false negative 
classification. So the classification score (CS) was calculated for each patient 
according to the formula:
CS —6x D O I convalescent “2x I g G COnvalescent I § M COnvalescent
The cut-off o f the classification model was a value o f 40. If an individual had 
a CS o f greater than 40, the individual was diagnosed as primary dengue, otherwise as 
secondary dengue. Using the proposed model gave an excellent discrimination 
between primary and secondary dengue (AUROC = 0.98, Figure 3-3).
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Figure 3-3: Receiver Operating Characteristic (ROC) curve of the model.
ROC curve generated from the logistic regression model fo r  discrimination o f  
primary from secondary acute DENY infection using IgM, IgG levels and DOI 
measured at early convalescence phase. The red point is the chosen cut-off level.
V a l i d a t i o n  o f  t h e  p r o p o s e d  m o d e l  u s i n g  t h e  t r a i n i n g  d a t a  s e t
The performance of the proposed model was estimated using the training data 
set itself to derive apparent and optimism-corrected estimates (summarized in Table 
3-8). Resubstitution misclassified 19 cases (8 primary and 11 secondary cases) giving 
92.2% sensitivity, 96.5% specificity, 89.5% positive predictive value and 97.4% 
negative predictive value. The validation by bootstrap method also gave similar 
sensitivity, specificity, negative and positive predictive values. Overall, the test 
correctly diagnosed 95.1% of cases.
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Table 3-8: Performance of the proposed model for the diagnosis of primary acute
dengue infection.
Accuracy of the test Apparent* Optimism-corrected **
Sensitivity 92.2% (94/102) 92.1%
Specificity 96.5% (303/314) 96.2%
Positive predictive value 89.5% (94/105) 88.8%
Negative predictive value 97.4% (303/311) 97.3%
Correctly classified 95.4% (397/416) 95.1%
Area under ROC curve 0.98 0.98
Accuracy o f  the test was calculated by * resubstitution or **  bootstrap method using 
the training data set that generated the model.
V a l i d a t i o n  o f  t h e  p r o p o s e d  m o d e l  u s i n g  t h e  t e s t  d a t a  s e t .
The accuracy o f the proposed model in the diagnosis o f primary infection was 
also tested on an independent set o f samples, obtained from 93 dengue patients (in the 
test data set). Of these, 13 cases were classified as primary infection and 80 cases 
were secondary infection according to the reference laboratory results. The infecting 
serotypes in these cases are shown in Table 3-6. The accuracy o f the classification 
model is shown in Table 3-9. The model misclassified only 4 out o f 93 cases (1 
primary case, 3 secondary cases) and was 92.3% sensitive and 96.3% specific.
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Table 3-9: Overall sensitivity and specificity of the proposed model using the test
data set.
Accuracy of the test % 95% Cl
Sensitivity 92.3 (12/13) 6 3 .9 -9 9 .8
Specificity 96.3 (77/80) 89.4 -  99.2
Negative predictive value 98.7 (77/78) 9 3 .1 -1
Positive predictive value 80(12/15) 5 L 9 -9 5 .7
Correctly classify 95.7(89/93) 8 9 .4 -9 8 .8
Area under ROC curve 0.97 0.93 - 1
We also used the test data set to break-down the estimates of accuracy 
depending on different ranges of illness day at discharge, serological status or the 
infecting DENV serotypes (Table 3-10). The estimates varied with categories, 
however there were no significant difference between them (P>0.5, Chi-square test), 
except with serology status (P=0.02). This showed that the accuracy o f the model in 
detection o f primary cases was not influenced by day o f illness when the early 
convalescent samples were collected nor DENV serotype. However, the specificity of 
the model would be higher in a group o f patients who had detectable IgM and IgG.
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Table 3-10: Break-down of the accuracy of the proposed model.
Categories
Sensitivity Specificity
% (N) 95%CI % (N) 95%CI
Days of illness
4-7
8-11
100(5/5) 
87.5 (7/8)
4 7 .8 -1 0 0
4 7 .3 -9 9 .7
96.2 (25/26)
96.3 (52/54)
80.4 -  99.9 
87 .3 -9 9 .5
Serology status+
IgM+/ IgG- 
IgM+/ IgG+
100 (10/10) 6 9 .2 -1 0 0 66.7(2/3) 
96.3 (77/80)
9.4 -  99.2
89.4 -  99.2
DENV serotype
DENV -ve 
DENV-1 
DENV-2 
DENV-3 
DENV-4
90.9(10/11) 
100 (2/2)
5 8 .7 -9 9 .8
15 .8 -100*
75 (3/4) 
94.7 (36/38) 
100 (19/19) 
100 (17/17) 
100(2/2)
1 9 .4 -99 .4  
82.3 -  99.4
8 2 .4 -  100*
8 0 .5 -100*  
15 .8-100*
N: number test observed /  total number. Cl: confidence interval. + P=0.02, comparing 
specif city between IgM+/IgG-and IgM +/IgG+* one-sided, 97.5% Cl.
3.4. Discussion
Accurate dengue diagnosis is important for case management, surveillance, 
outbreak investigation and research. Whilst the laboratory confirmation o f dengue 
cases can sometimes be difficult depending on i/ the number o f the days which the 
patient has had the symptoms and ii/ which diagnostic tests that are accurate, 
economic, easy to handle and speed are available. Results of this chapter showed the 
accuracy o f the HTD in-house anti-DENV IgM ELISA in detecting low levels of IgM 
in plasma samples, and the HTD in-house anti-DENV IgM and IgG ELISAs could be 
used for distinction between primary and secondary acute dengue. Accordingly, these 
methods and classifier model are being used for the routine serodiagnosis o f dengue 
in patients enrolled in research studies conducted by the OUCRU and HTD.
Commercially manufacturered anti-DENV IgM ELISA tests are widely 
available but only a few o f them have adequate sensitivity and specificity for use in
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dengue diagnosis especially for cases with low IgM response [108, 203]. Indeed, one 
of the common problems with these assays is the occurance o f false-positive results 
on sera from patients with malaria, rheumatoid factor, Japanese encephalitis, or 
leptospirosis [107, 108, 203]. The HTD in-house IgM assay showed 94.6% sensitive 
and 91.5% specificity in detecting anti-DENV IgM when compared with the reference 
laboratory results and it did not have any cross-reactivity with other flaviviruses. 
Moreover, the sensitivity o f the test was equal across four DENV serotypes as well as 
primary and secondary infections.
The in-house test failed to detect 10 samples that were determined by the 
reference test as being IgM positive and 11 samples that were IgM negative. Reasons 
may be because o f differences between the two methods. Firstly, antigens were 
different between them. The in-house method used culture supernatants harvested 
from C6/36 cells infected with each o f four dengue serotypes instead of sucrose 
acetone-extracted suckling mouse brains injected with prototype vaccine. Secondly, 
difference in the calculation o f results. The reference laboratory reported results in 
units that reflected the fraction o f IgM and IgG reactive with the DENV antigen 
relative to positive standards while the units of the in-house method were the fraction 
relative to negative standards.
A further limitation of the in-house IgM test was false-positive results with 
sera from malaria cases. This is consistent with findings from other MAC ELISA 
assays, which are also prone to giving false-positive results from malaria cases [108]. 
The explanation may be that they share some epitopes. Since DENV and Plasmodium 
parasites co-circulate in some parts of Southeast Asia, including in some parts of 
central Viet Nam. It’s important to understand this limitation o f the MAC ELISA in 
this regard. An alternative explanation is that false positive reactions occurred because 
malaria elicits polyclonal B cell plasmacytosis resulting in the generation of many low 
avidity IgM antibodies. Some o f which may bind non-specifically with DENV 
antigens.
We also observed a small false-positive rate (14.3%) in a serum sample that 
was DENV IgM negative according to the reference test but came from an acute 
dengue patient with DENV-1 infection. The simplest explanation here is that the in- 
house assay was more sensitive than the reference assay on this sample.
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Collectively, these results suggest the in-house IgM assay is a robust method 
for the detection of anti-DENV IgM and therefore allows the presumptive laboratory 
diagnosis of dengue, albeit usually after 3-4 days of fever. Due attention is required to 
the fact that false-positive IgM results are possible in malaria cases and therefore it 
would be good patient management to include a malaria blood smear for patients 
whose history or clinical presentation suggests that malaria is a possible diagnosis.
Many methods have been proposed to differentiate primary from secondary 
DENV infections. The HI assay, based on antibody tittering o f paired or single serum 
specimens has been recommended by WHO for this purpose [1]. The plaque 
reduction neutralizing test may be also used but is known to be an assay that requires 
stringent standardization [204]. The challenges around the use o f these two assays in 
resource limited settings are to find i/ a suitable cell line and viruses which can give 
visible results (suspension or plaque) and ii/ right endpoint titers that can meet the 
criteria for virus activity (a percentage reduction o f virus activity). The major 
drawbacks of these techniques are difficulty to perform, time to conduct and cross­
reactions among flaviviruses [109, 199, 205].
Since the development o f antibody-capture ELISAs, an IgM/IgG ratio of  
above 1.7 or IgM elevated early while IgG appeared later with low titer has been used 
to define a primary case using a single serum specimen [114-118]. The difficulty with 
using a simple ratio of 1.7 is that it is highly unlikely to be translatable to antibody- 
capture ELISAs that are performed in different laboratories under different 
environmental conditions, with different analysts and with different reagents and 
plasticware. Moreover, this cut-off approach does not take into account the day of 
illness on which the samples were collected, and because the IgM/IgG response is 
dynamic, the day of illness must be considered as an important factor.
To our knowledge only two approaches have factored the day of illness in the 
classification o f primary versus secondary dengue. Matheus et al described an IgG 
avidity test using a single acute-phase serum sample for the discrimination o f primary 
from secondary dengue and included the day of illness as a variable [112, 113]. Not 
long ago, a 2-D classifier model based on anti-DENV IgG units for the classification 
of primary and secondary DENV infections was reported [111]. Their results showed 
sensitivities o f 82.7% and 91.6% respectively and specificities of 77.5% and 92.5%,
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respectively. However, their sample size used to generate the models was small (50 
and 109 patients, respectively) and serum samples were mainly from adult patients 
[111]. Besides, the cross-reactivity of flavivirus- specific IgG antibodies wasn’t 
considered in these methods.
Collectively, our classification model, a 3-D classifier, took advantage of IgM 
and IgG capture ELISA data together with the illness day of the sample collection to 
distinguish primary from secondary dengue. The test method described assays a single 
dilution of plasma and results were reported in units. This method appears to be 
superior to other assays in which titers are measured using serial dilution o f samples. 
There is no requirement for specimen pretreatment and only a small volume o f sample 
(lOpl) is required.
To generate the classification model, the results from serology assays in the 
reference laboratory at the Centre for Vaccine Development (Bangkok) were used. 
We selected this laboratory to generate the reference results because it is widely 
recognized internationally as a centre of excellence in dengue diagnosis and indeed is 
the main Asian dengue reference laboratory in the WHO/TDR dengue diagnostic 
network. The reference laboratory couldn’t determine the serological status of 66 
cases, and these cases were excluded from our analysis. These virologically- 
confirmed dengue cases had undetectable anti-DENV IgM and IgG levels in the 
reference lab. One explanation for this is that the antibody-capture ELISA used in the 
reference laboratory is less sensitive than our in-house assay. This situation might 
lead to the classification model weighted toward populations that had higher levels of 
IgM and/or IgG.
In conclusion, our data showed plasma collected within the first week of the 
illness could be used for dengue diagnosis as well as the differentiation between 
primary and secondary DENV infections. The classification model worked well with 
discharge samples on day 4 onward o f the illness and the in-house tests gave greater 
than 90% sensitivity and specificity if we compared with the reference laboratory 
results. These sensitivity and specificity values were consistent across serology status, 
dengue serotype and day of illness. On the back o f these results, the HTD in-house 
ELISAs and the 3-D classifier has now become the routine serological method of 
dengue diagnosis in the HTD.
4.NS1 in dengue - a 
diagnostic tool 
which may help in 
prognosis
NS1 as a prognostic marker
4.1. Introduction
DSS typically occurs between day 4 and 6 of illness. There are no reliable 
mechanisms in the first few days of illness o f identifying patients who will develop 
DSS. Several studies have explored the risk factors associated with the progression of 
disease from mild disease, dengue fever (DF), to severe disease, dengue haemorrhagic 
fever (DHF) and/or dengue shock syndrome (DSS) [9, 97, 206-208]. Issues related to 
age, immune status [208, 209], population genetics [210], viraemia titers, distinct 
serotypes [97, 126], early NS1 concentrations [39, 41] and the proinflammatory 
cytokines elicited [169, 186, 188] were investigated and had different degrees of 
correlation with severe dengue.
Commercially available NS1 detection tests have been widely used as dengue 
diagnostic tools to complement the existing approaches of PCR, serology and, less 
frequently, virus isolation [211-214]. In the first 3 days of illness, sensitivity and 
specificity of the Platelia NS1 tests were -80% and 100% respectively in laboratory- 
confirmed Vietnamese paediatric dengue cases [99, 103, 105, 215]. Soluble NS1 
levels were higher in serum in the first 72hrs o f fever in Thai children who developed 
DHF, leading to the suggesting that NS1 concentrations could be prognostic for 
severe dengue [39, 41]. Nevertheless the potential for early NS1 plasma 
concentrations to predict severe clinical outcomes (e.g. DHF/DSS) has not been 
systematically assessed.
The aims of this chapter are to examine whether plasma levels o f NS1 in the 
first 4 days of fever can be used as a prognostic marker of DSS. This chapter also 
investigates the kinetics o f NS1 and viraemia in children with DSS and milder 
presentations of dengue.
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4.2. Methods
4.2.1. Study design and patient recruitment
There were two patient populations for two purposes. The first population 
provided data for a “training” data set in which the purpose was to identify a threshold 
of NS1 concentration that could predict DSS progression. The second patient 
population represented the “testing” set which was used to independently evaluate the 
results generated in the training data set.
The training patient population was paediatric inpatients at the Hospital for 
Tropical Diseases, Ho Chi Minh City, Vietnam. These children were enrolled into a 
prospective clinical study of dengue if there was a clinical suspicion of dengue and 
the children had a fever history of 4 days or less. The children were enrolled in the 
hospital ward. Plasma samples from these patients were collected at the time of 
enrolment and the time o f discharge from hospital.
A second patient population was enrolled at Dong Thap Hospital, Dong Thap 
province, Viet Nam. The inclusion criteria included patients who were both NS1 
positive and had the illness duration o f no more than 4 days. Patients underwent 
screening in the outpatient clinic if there was a clinical suspicion of dengue and the 
illness duration o f no more than 4 days. Enrolment plasma samples from eligible 
patients were tested with the Platelia dengue NS1 Ag test (Biorad, California, USA). 
All patients that were NS1 ELISA positive were admitted for further observation and 
participation in this prospective, hospital-based, study o f dengue in Dong Thap 
hospital. Plasma samples from these patients were collected at the time of study 
enrolment, then every two days until they were discharged from hospital. A subset o f  
these patients who had DENV-1 or DENV-2 infection identified by RT-PCR was 
selected to provide the test data set. The disease severity classification was based on 
the WHO classification [72] (section 2.2 in Chapter 2). The study protocols were 
approved by the Oxford Tropical Research Ethics Committee and Scientific and 
Ethical Committee o f Hospital for Tropical Diseases and Dong Thap Hospital. The 
parents/guardians of all participants gave written informed consent for their children 
to participate in the study.
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4.2.2. Serological responses
IgM and IgG against DENV were measured by capture ELISA in plasma 
samples collected at enrolment and at the time o f hospital discharge using the method 
described in section 2.4.1 in Chapter 2). Primary infections or secondary infections 
were determined by using the classification model described in Chapter 3.
4.2.3. NS1 quantitative ELISAs
To measure concentrations of plasma NS1 Ag, the DENV NS1 Ag Platelia 
ELISA kit was used as previously described (section 2.4.2 in Chapter 2). The NS1 
values were expressed as ng/ml if  using the absolute-quantitative method or shown in 
N Sl Ag Bio-Rad units (BRU/ml) if using the semi-quantitative method.
Absolute-quantitative ELISA
The quantitative assay procedure was performed following the manufacturer’s 
instructions. To calculate the concentration of plasma N Sl Ag, two-fold serial 
dilutions o f recombinant DENV-2 N Sl Ag (supplied by Hawaii Biotech) were run in 
duplicate on each plate to establish standard curves in the assay together with the 
serially diluted plasma samples (from neat to 1000 dilution in 10-fold dilution). The 
standard curve was diluted from lng/ml to 0.03ng/ml. Samples with levels above the 
maximum optical density were diluted more and had to be retested. The NSl 
concentrations o f samples were expressed as nanogram per milliliter (ng/ml). The 
limit of this detection was 0.05ng/ml.
Semi-quantitative ELISA
The plasma N Sl levels were expressed in N Sl Ag Bio-Rad Units per milliliter 
(BRU/ml) by using the same reagents and assay procedure that were used in the 
original ELISA (NSl qualitative ELISA, section 2.4.2 in Chapter 2). If samples had 
OD<3, the N Sl Ag BRU/ml o f the samples corresponded to the sample ratio [Sample 
N Sl (BRU/ml) =sample OD/cut-off OD]. If samples had OD>3, the assay procedure 
was repeated with a 1:5000 dilution o f the conjugate instead o f 1:50 dilution. The 
N Sl Ag BRU/ml of the samples were calculated by multiplying the OD of the re­
tested samples by 150 [Sample N Sl (BRU/ml) =sample OD* 150/cut-off OD].
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4.2.4. Statistical methods
Comparisons of plasma N Sl concentrations between serotypes (6 
comparisons) or between serological statuses within serotypes (4 comparisons) were 
based on linear regression models adjusted with day of illness when the samples were 
collected. We corrected for multiple comparisons using a single step approach based 
on the joint asymptotic multivariate distribution of the contrasts [216].
4.3. Results
4.3.1. Patient population
The baseline characteristics o f the study patients are shown in Table 4-1. 
There were 566 suspected pediatric dengue patients enrolled into the study at HTD 
from May 2006 to October 2007. Among these, according to the dengue laboratory 
algorithm, 497 patients had laboratory confirmed dengue, 50 o f them were excluded 
from the analysis because their day o f illness were more than four days from the 
illness onset, 6 had recent DENV infections, 9 cases had recent flavivirus infections 
and the remaining (54 cases) were “other febrile illnesses”. Among laboratory- 
confirmed dengue cases, 22 patients developed DSS at some time after their 
enrolment and were transferred to the intensive care unit. The remaining 425 patients 
who didn’t progress to DSS were managed throughout in the general dengue ward 
(described here as uncomplicated dengue patients -  UC dengue). There were no 
differences in age, sex, serological status or day of illness between UC dengue and 
DSS patients on study entry.
Compared with laboratory diagnosis of dengue cases by either RT-PCR or 
serology test, the N Sl Platelia test had a sensitivity of 80.1% (95%CI, 76% -  83.7%) 
and specificity of 96.7% (95%CI, 91.4% -  99%). Among the 447 laboratory 
confirmed dengue cases (either by RT-PCR, N Sl or serology test), the DENV RT- 
PCR results were positive for 415 (92.8%) cases. Secondary infection was diagnosed 
in 343 (76.7%) cases. N Sl was undetectable in all patients with OFIs, while the 
proportion of UC dengue and DSS cases to be N Sl positive was 80% (340/425) and 
86.4% (19/22), respectively (p>0.05).
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Table 4-1: Baseline table summarizing key clinical, viral and antigenic 
information of the study population.
Variable UC dengue (N =425) DSS (N =22) P
Male sex 268 (63.1%) 16(72.7%) 0.3
age(years) 1 1 (5 -1 5 ) 1 1 (6 -1 4 ) 0.4
Day of illness at enrolment
2
3
4
3 ( 1 - 4 )  
59(13.9%) 
177 (41.6%) 
188(44.2%)
3 ( 1 - 4 )
2(9.1%)
12(54.5%)
7(31.8%)
0.07
Serological status*
Primary infection 
Secondary infection
98(23.1%) 
325 (76.5%)
3 (13.6%) 
19(86.4%)
0.3
Infecting serotype
DENV-1
DENV-2
DENV-3
DENV-4
234(51.1%) 
113 (26.6%) 
43(10.1%) 
3(0.7%)
13 (59.1%) 
9(40.9%) 
0 
0
0.2
LoglO Viraemia ** (copies/ml) 7.2 (5.9 -  8.2) 7.7 (6 .1 -9 ) 0.22+
NSl (+) 340(80%) 19 (86.4%) 0.6
NSl (ng/ml)
All patients 
DENV-1 
DENV-2
22.7 (0.95-292.9) 
124.5 (5.7-436.4) 
1.3 (0 .005-7 )
22.8 (4.6 -  774.3) 
472 (4.3 -1276) 
7.2 (5 .3-17 .8)
cO.OOOl4
0.03
0.02
Data are expressed as N  (%) or median (IQR). UC dengue: uncomplicated dengue, 
DSS: dengue shock syndrome. * 2 indeterminated results in UC dengue group. ** 
viraemia was detected in 393 patients in UC dengue.+ P adjusted for serotype, 
serological status and day o f  illness.
4.3.2. NS1 concentrations and correlations with viraemia
We quantified plasma N Sl concentrations in patients with a detectable N Sl 
antigenaemia at enrolment. N Sl concentrations were determined by the semi- 
quantitative method (reported in BRU/ml) and the absolute-quantitative method 
(reported in ng/ml) using recombinant N Sl (DENV-2) as a standard. Figure 4-1 
describes the correlations between N Sl values and those with viraemia observed in 
the study population.
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Figure 4-1: Correlations between viraemia and N Sl concentration in UC dengue
or DSS patients.
(A) Spearman correlation between loglO N Sl ng/ml and N S l BRU/ml (r=0.78), (B) 
correlation between N S l BRU/ml and loglO viral load (copies/ml) (r=0.3) and (C) 
correlation between loglO N Sl ng/ml and loglO viral load (copies/ml) (r=0.4) with 
all p< 0.0001 derived from partial correlation after controlling fo r  serotype, 
serological status and day o f  illness. DSS patients were shown in red triangle (A)  
and their fi t  line in red; non-DSS patients were shown by blue circle (O) and their f i t  
line in blue.
Overall, the absolute N Sl concentrations highly correlated with values from 
the semi-quantitative method (partial correlation controlled for serotype, serological 
status and day of illness with r=0.78, p<0.0001).
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Patients who were N Sl negative had significantly lower median viraemia 
levels than N Sl positive patients with the same serotype, serological status and 
duration of illness history [log 10 viraemia-median (IQR), 5.7 (4.6 -  6.7) vs. 7.6 (6.2 -  
8.4), respectively, adjusted pO.OOOl] (Figure 4-2). Actually, the N Sl concentrations 
correlated with viraemia levels in the same group of samples (r=0.4 if N Sl 
concentrations were reported in ng/ml and r=0.31 if N Sl concentrations were reported 
in BRU/ml, both pO.OOOl, partial correlation controlled for serotype, serological 
status and day o f illness). Besides, similar significant associations were also observed 
within subgroups of patients with DENV-1 or DENV-2 infection (Table 4-2).
15-i
P<0.0001
o  10-
NS1- NS1+
Figure 4-2: Plasma viraemia in patients with NSl positive or negative
Box and whisker plots o f  plasma viraemia levels in enrolment samples represent 
median, 25th and 75th percentile, minimum and maximum o f  the data classifying by 
NSl quanlitative results.
Table 4-2: Partial correlations between plasma NSl levels and viraemia at
enrolment.
Parameter
All serotypes* DENV-1 DENV-2
NSl
(BRU/ml) Viraemia
NSl
(BRU/ml) Viraemia
NSl
(BRU/ml) Viraemia
NSl 
log 10- (ng/ml) 0.78 0.4 0.76 0.47 0.73 0.48
NSl
(BRU/ml) 0.31
. /
0.37 - 0.3
Viraemia levels in LoglO- (copies/ml) scale. Numbers represent the correlation rate 
(r), all partial correlations had p<0.0001. P values were derived from partial 
correlation controlled for serological status, day o f  illness and (*) serotype was extra 
added for controlling the correlation.
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4.3.3. Differences in plasma NS1 levels between serotypes 
and serological status
N Sl concentrations at enrolment in the patients stratified by serotype and 
serological status are presented in Table 4-3. Comparisons between serotypes were 
done by using logistic regression adjusted for day of illness. This revealed that N Sl 
levels were significantly higher in DENV-3, followed by DENV-1 and lowest in 
DENV-2 infections (all adjusted p<0.05, in the footnote o f Table 4-3). No significant 
differences were observed in comparisons between DENV-4 and other serotypes due 
to the small number of DENV-4 infections (n=3). Interestingly, the differences 
between serotypes disappeared after adjustment for loglO-viraemia on the same day 
(all adjusted p>0.2). However, comparisons between serotypes after adjustment for 
day of illness and for multiple comparisons showed no significant differences in 
viraemia levels between serotypes (medians o f loglO-viraemia in DENV-1 to 4 
infections were 7.2, 7.4, 6.6 and 5.1, respectively. All adjusted p values>0.2). 
Comparisons between primary and secondary infections using logistic regression 
adjusted for day o f illness showed non significant differences between primary and 
secondary serological state among subgroups, although in univariate analysis 
significantly higher N Sl concentrations were observed in children with primary 
DENV-1 infection compared with those in children with secondary DENV-1 infection 
(Figure 4-3).
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Table 4-3: Plasma N Sl concentrations in children at enrolment stratified by
serotype and serological status.
DENV-1 DENV-2 DENV-3 DENV-4
All*
N
Median
IQR
247
142.3 . 
(5 .4 -4 4 7 .9 )
122
1.8
(0 -8 .1 )
43
346.3
(21 .7-1231 .5)
3
30.1
(15 .4 -48 .1 )
Primary
N
Median
IQR
80
191.7
(64 .5 -454 .9 )
6
9.9
(3 .6 -1 6 .1 )
12
347
(264 -910 .4 )
-
Secondary
N
Median
IQR
166
80
(2 .6 -4 4 3 .6 )
115
1.5
(0 -7 .1 )
31 
319.1 
(1 0 .6 -  1384)
3
30.1
(15 .4 -48 .1 ),
* Serological status was indeterminate in 2 patients (1 DENV-1 and 1 DENV-2). 
Comparisons between serotypes or between serological status were controlledfor day 
o f illness, p  values were adjusted for multiple comparisons: DENV-1 -  DENV-2, 
DENV-1 -  DENV-3, DENV-2 -  DENV-3, allp<0.001. DENV-3 -  DENV-4, p=0.045. 
All others p>0.1. I f  the comparisons between serotypes were adjusted for log 10- 
viraemia on the same day, all p  values were >0.25.
Because DENV-1 or DENV-2 infections represented 88.2% of the serotypes 
detected, and none of the DENV-3 or DENV-4 infections resulted in DSS, we 
selected DENV-1 and DENV-2 infected patients for all further analysis. Figure 4-3 
shows NS l concentrations in enrolment plasma o f children with DENV-1 or DENV-2 
infection stratified by serological status with p values derived from univariate 
analysis. Among patients with primary or secondary infections, N Sl concentrations 
(measured by semi- or absolute quantitative methods) were significantly higher in 
DENV-1 infected patients than DENV-2 infected patients (p<0.001, Mann-Whitney 
test). Besides, among DENV-1 infected patients, plasma N Sl concentrations from 
primary infections were significantly higher than those from secondary infections. 
This difference between primary and secondary infections wasn’t observed among 
DENV-2 infections.
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Figure 4-3: Plasma NSl concentration at enrolment in children with DENV-1 or 
DENV-2 infection by serological status.
Box and whisker plots o f  plasma NSl levels in enrolment samples represent median, 
25th and 75th percentile, minimum and maximum o f the data classifying by infecting 
DENV serotype and, serological status. Plasma N Sl concentrations, measured by 
absolute quantitative method (A) or semi-quantitative method (B), were significantly, 
lower in DENV-2 patients than DENV-1 patients (within primary or secondary 
infections), and were significantly higher in primary than secondary infections with 
DENV-1. P values were from Mann-Whitney tests.
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4.3.4. Plasma concentrations of NS1 in patients who 
developed DSS
To understand the interaction between infecting serotype, serological status, 
day o f illness, N Sl concentration and clinical outcome, we performed a multivariate 
logistic regression to identify variables that were independently associated with DSS 
(Table 4-4). The result shows that plasma N Sl concentrations in enrolment plasma 
were significantly lower in UC dengue versus DSS patients [median and inter-quartile 
range (IQR), 22.7 (0.95-292.9) ng/ml vs. 22.8 (4.6-774.3) ng/ml, respectively, 
PO.OOOl, Table 4-4]. In addition, DENV-1 serotype was also independently 
associated with DSS (p=0.046).
Table 4-4: Logistic regression model identifying variables associated with DSS
Variable OR 95% Cl P
Day o f illness 0.7 0 .4 -1 .3 0.26
Primary 0.46 0 .1 -1 .9 0.28
DENV-1 0.32 0 .1 -0 .9 8 0.046
N Sl concentration (ng/ml) 1.002 1.001 -  1.003 <0.0001
OR: odd ratio. 95% Cl: 95% confident interval.
When we stratified patients by their infecting serotypes, plasma N Sl 
concentrations at enrolment were significantly higher in DENV-1 infected patients 
who progressed to DSS than in DENV-1 infected patients who didn’t develop DSS 
[median (IQR), 472 (4.3-1276) vs. 124.5 (5.7-436.4), respectively, p=0.03, Mann- 
Whitney test] (Figure 4-4). Similarly, N Sl concentrations were significantly higher in 
DENV-2 infected patients who progressed to DSS than in DENV-2 infected patients 
with an uncomplicated disease evolution [median (IQR), 7.2 (5.3-17.8) vs. 1.3 (0-7), 
respectively, p=0.02, Mann-Whitney test] (Figure 4-4).
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Figure 4-4: Plasma NSl concentrations at enrolment by disease severity and
serotype.
Box and whisker plots o f  plasma NSl levels at enrolment represent median, 25th and 
75th percentile, minimum and maximum o f  the data classifying by disease severity. 
Showing in the graphs are concentrations o f  plasma NSl measured by absolute 
quantitative method (A) or by semi-quantitative method (B). Plasma NSl levels 
measured by absolute quantitative method were significantly higher in DSS patient 
with DENV-1 infections or DENV-2 infections than in UC dengue patients with  
DENV-1 infections or DENV-2 infections (p= 0.03 or 0.02, respectively, Mann- 
Whitney test) (A). Significant trends between two groups were also observed when 
results reported using the semi-quantitative method (p=0.06, Mann-Whitney test). 
UCD: uncomplicated dengue. DSS: Dengue shock syndrome.
4.3.5. NS1 concentrations in prognosis of DSS
To identify a threshold of plasma N Sl concentration that might be predictive 
of DSS in the first few days o f illness, we analyzed receiver operating characteristic 
(ROC) curves o f N Sl concentrations which were stratified by infecting serotype with 
DSS as the endpoint (Figure 4-5). Maximum of sensitivity plus specificity was chosen 
as a cut-off value for each serotype, DENV-1 or DENV-2. Among patients with 
DENV-1 infection, plasma N Sl concentrations o f greater than 875ng/ml on day 1-4 
of illness predicted the subsequent development of DSS with a sensitivity o f 50% and 
a specificity o f 92.94% (Figure 4-5A). Among DENV-2 infected patients, plasma
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N Sl concentrations greater than 6.3ng/ml at enrolment predicted DSS progression 
with a sensitivity and specificity of 77.8% and 73.4%, respectively (Figure 4-5B).
Using the semi-quantitative N Sl method, plasma N Sl concentrations of 
greater than 638 BRU/ml on day 1-4 of illness in patients with DENV-1 infection 
predicted DSS with a sensitivity of 61.5% and a specificity of 78.3% (Figure 4-5C). 
Among DENV-2 infected patients, plasma N Sl concentrations o f greater than 214 
BRU/ml at enrolment predicted DSS with 75% sensitivity and 66.95% specificity 
(Figure 4-5D).
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Figure 4-5: ROCs of plasma NSl concentrations as prognostic marker for DSS 
progression among DENV-1 and DENV-2 infected patients.
There were 13 patients with DENV-1 who developed DSS and 9 patients with DENV- 
2 who developed DSS. Data shown in A and B are generated from absolute 
quantitative method and those in C and D  are from semi-quantitative method. Red  
points represent the chosen cut-off values. 95%CI: 95% central interval range. 
ROCs: receiver operating characteristic curves.
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4.3.6. Evaluation of NS1 cut-off levels for prognosis of DSS
To evaluate the NSl cut-off values for prognosis of DSS in a second, 
independent sample set, we used enrolment plasma samples obtained from children 
recruited into another prospective study in Dong Thap hospital. Between May 2007 
and December 2007, we enrolled 3 16 inpatients with laboratory confirmed dengue 
(NSl positive). There were 294 patients who were eligible to enter the test data set 
(Table 4-5). The patients who were excluded had insufficient volume of plasma 
samples for quantitative N Sl (n=22). Sex, age, DENV serotypes and day Of illness at 
enrolment were distributed similarly between two patient groups. However, almost all 
DSS cases had serological evidence o f secondary dengue (94.6%) whilst amongst the 
UC dengue cases, secondary infections accounted for 79.4% of the total (p=0.02, 
Fisher’s Exact test).
Consistent with the first cohort, enrolment plasma NSl concentration was 
higher in the DSS group than in the UC dengue group (pO.OOOl, adjusted for 
serotype, serological status and day of illness). In univariate analysis, among patients 
with DENV-1 infections, plasma N Sl concentrations were also significantly higher in 
the DSS group at the time of enrolment than in UC dengue cases. Amongst DENV-2 
infected patients, there was a non-significant trend for higher N Sl concentrations in 
DSS cases (p=0.08, Table 4-5).
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Table 4-5: Baseline table summarizing key clinical, viral and antigenic 
information of the patients in the test data set
Variable UCD (N =257) DSS (N =37)* P
Male sex 138 (53.7%) . 25 (67.6%) 0.2
age(years) 11 (7 —16) 10(7 -1 4 ) 0.5
Day of illness
2
3
4
3 ( 2 - 3 )  
57(21.1%) 
171(68.4%) 
20 (6.6%)
3 ( 2 - 3 )  
9(29.1%) 
23 (58.3%) 
4(8.3%)
0.9
Defervescence day -3 (-4 --2 ) -3 ( -3 --2 ) 0.7
Serological status
Primary infection 
Secondary infection
53 (20.6%) 
204 (79.4%)
2 (5.4%) 
35 (94.6%)
0.02
Infecting serotype
DENV-1
DENV-2
DENV-3
DENV-4
207(80.5%)
35(13.6%)
11(4.3%)
2(0.8%)
30(81.1%)
6(16.2%)
0
0
0.5
NSl (+) 257(100%) 37(100%) -
NSl (ng/ml)
All patients 
DENV-1 
DENV-2
145.5 (17.9-428)  
217.4 (52-464.5) 
2.4 (1 .2 -7 .7 )
1002.3 (73 -  1638.3) 
1166.4 (6 6 6 - 1815.34) 
19.6 (6 .1 -34 .9)
<0 .0 0 0  r  
<0.0001 
0.08
Data are expressed as N  (%) or median (IQR). UCD: uncomplicated dengue, DSS: 
dengue shock syndrome. * One DSS patient who had undetectable DENV serotype 
progressed to shock a day after enrolment. + P adjusted fo r serotype, serological 
status and day o f illness.
In this second cohort, the subgroup of 278 patients with DENV-1 (n=237) or 
DENV-2 (n=41) infection were further analysed. The patients that were excluded 
from the analysis were those with DENV-3 (n = ll) or DENV-4 (n=2) infections or 
undetectable DENV serotype (n=3). Thirty six of the DENV-1 or DENV-2 patients 
subsequently progressed to DSS as defined by the WHO criteria and they were treated
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for DSS. The remaining 242 patients with DENV-1 or -2 infections were defined as 
UC dengue cases and they did not require any clinical interventions and were 
managed in the general infectious disease ward.
We applied the previously determined plasma N Sl cut-off values o f 875 ng/ml 
or 6.3 ng/ml for each serotype, DENV-1 or DENV-2 respectively, to determine its 
accuracy for the prognosis o f DSS. Out of 30 DSS patients with DENV-1 infections, 
19 had plasma N Sl concentrations at enrolment that were above the 875 ng/ml 
threshold, yielding a sensitivity of 63.3% (95%CI, 43.8% -  79.5%). Amongst UC 
dengue with DENV-1 infection, 25/207 had plasma N Sl concentrations above the 875 
ng/ml threshold, giving a specificity o f 87.9% (95%CI, 82.5% -  91.9%). The numbers 
with DENV-2 were small, but nonetheless four out of six DENV-2 infected patients 
who developed DSS had plasma N Sl concentrations that were above the 6.3 ng/ml 
threshold The sensitivity and specificity for DENV-2 was 66.7% (95%CI, 24.1% -  
94%) and 68.6% (95%CI, 50.6% -  82.6%), respectively (Table 4-6).
Table 4-6: Sensitivity and specificity of the test using cut-off values to predict
DSS.
Serotype Cut-off
No. of  
positive test
Sensitivity 
[% (95%CI)]
Specificity 
[% (95%CI)]
DENV-1
875 (ng/ml) 44 63.3 (43 .9 -79 .5 ) 87 .9 (82 .5 -91 .9 )
638 (BRU/ml) 66 60 (40.8 -  76.8) 76.8 (70.3 -  82.3)
DENV-2
6.3 (ng/ml) 15 66.7 (24.1 -9 4 ) 68.6 (50.6 -  82.6)
214 (BRU/ml) 14 66.7(24.1 -9 4 ) 71.4 (53 .5 -84 .8 )
When using the semi-quantitative N Sl method, the plasma N Sl cut-off value 
of 638 BRU/ml was applied to predict DSS progression of DENV-1 infected patients 
and 214 BRU/ml was used among DENV-2 infected patients. Among patients with 
DENV-1 infections, there 18 cases tested positive out o f 30 DSS patients, the 
sensitivity was 60% (95%CI, 40.8% -  76.8%) and the specificity was 76.8% (95%CI, 
70.3% -  82.3%). Among patients with DENV-2 infections, there were four cases 
tested positive out of six DSS patients and 10/35 UC dengue patients tested positive,
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the sensitivity and specificity were 66.7% (95%CI, 24.1% -  94%) and 71.4% (95%CI, 
53.5% -  84.8%), respectively (Table 4-6).
Collectively, these results suggest that N Sl concentrations have potential as 
prognostic markers of DSS, although surprisingly this has a serotype dependent 
nature.
4.4. Discussion
A  timely diagnosis and an accurate prognosis o f severe dengue in the first few 
days o f illness could be helpful for clinical management, disease surveillance and 
clinical research activities. In this study, we demonstrated that at initial presentation, 
within 1- 4 days of illness, the plasma N Sl concentrations correlated with viraemia 
levels and that a N Sl threshold could be used for the prognosis of DSS. This is the 
first time that N Sl concentrations have been used for the prognosis of DSS.
It’s important to point out that the Platelia N Sl Ag test has been evaluated 
widely [103, 104, 217, 218]. The test has been shown to be suitable for early 
diagnosis o f dengue with high sensitivity (82-93%) and specificity (100%) [103, 104, 
217], and could be considered as first-line testing for acute dengue diagnosis in a 
single serum sample [104, 217]. However, the test has some limitations: the 
sensitivity o f the test was reportedly lower in DENV-2-infected patients than DENV- 
1 or DENV-3 infected patients [103, 105, 219] and the sensitivity was also lower in 
those with secondary infections relative to primary infections [103-105, 217-219].
In our study, we had three N Sl negative patients who developed DSS and 
those patients all had secondary infections (2 DENV-1 and 1 DENV-2 infection, 
viraemia <106 copies/ml). The inabiliy to detect N Sl might be due to the lower 
sensitivity o f the test with secondary infection and perhaps reflects the presence of  
N Sl specific-antibody in secondary immune responses [212]. This could lead to the 
clearance o f N Sl or else NSl would bind to the antibodies to form immune 
complexes so that the target epitopes were not recognized by mAbs in the N Sl ELISA 
test. Another possible reason for undetectable N Sl in those DSS cases might be that 
most o f the soluble N Sl had bound to endothelial cells in tissues, such as in the lung 
and liver [129]. A final possibility is that the self-reported illness history for these 
patients was inaccurate and this is suggested by the low viraemia detected in these
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cases (<106 copies/ml).
We demonstrated that at initial presentation, the plasma N Sl concentration 
correlated with viraemia levels. This observation is consistent with previous findings 
in Vietnamese infants [219] and children and adults [103, 105, 220] and also in other 
patient groups [39, 41, 127]. However, the strength o f the correlation between N Sl 
and viraemia as measured by qRT-PCR was not particularly strong in our study and in 
this regard it was similar to the study by Duyen et. al [220] (partial correlation r=0.4 
and 0.6, respectively). One reason for this was the difference in methods. Unlike N Sl 
detection by N Sl ELISA, the detection of RNA by RT-PCR was not influenced by 
the presence o f DENV-IgG antibodies in the test samples. The direct detection of 
viraemia by RT-PCR shares a similar window to that o f N S l. However it has become 
apparent that there was not a precise correlation between the two markers, with N Sl 
often detected in the absence o f RNA and vice versa [98, 221, 222]. Although 
originally viewed as a surrogate marker for viraemia, circulating levels of N Sl are 
perhaps the measure o f infected cell mass. Degradation and/or clearance from 
circulation o f these two products from infected cells are also likely to vary [219].
Duyen er. <2/. reported that N Sl levels among patients with DENV-1 infections 
were higher in primary than secondary infections; and DENV-1 infections were 
associated with higher plasma N Sl concentrations than DENV-2 infections even after 
adjusting for viraemia [220]. Consistent with this, we observed that plasma N Sl 
concentrations were higher in DENV-1 infected patients than those in patients with 
DENV-2 infections, but the difference was absent after adjusting for viraemia on the 
same day. Possible reasons to explain the difference in N Sl levels between DENV-1 
and DENV-2 are differences in viraemia burden and/or different avidity of binding to 
N Sl from DENV-1 and DENV-2 by Mabs in the commercial Platelia assay kit.
Plasma N Sl concentrations at enrolment were significantly higher in children 
who subsequently developed DSS than in UC dengue patients. This is consistent with 
the observation that higher levels of N Sl were found in the plasma o f a small number 
of Thai children with DHF/DSS during the early febrile phase than in children with 
DF [39, 41]. Avirutnan et. al. proposed that complement activation mediated by N Sl 
may contribute to pathogenesis o f the vascular leakage o f DHF/DSS patients [41] 
although later he has also observed in vitro that N Sl could protect DENV from
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complement-dependent neutralization in solution due to the binding o f N Sl to C4 and 
inhibition o f complement activation [128]. N Sl binding to C4 could directly limit 
opsonization and neutralization o f virions, thereby facilitating local dissemination.
We identified cut-off concentrations of N Sl that could detect DSS patients 
with DENV-1 or DENV-2 infections. The specificities of our cut-off values were 
lower in the test data population because the training data set included N Sl positive 
and N Sl negative patients, while the test data set recruited only N Sl positive cases. 
Thus, if the test data set contained N Sl positive and N Sl negative patients the 
specificities o f the proposed N Sl levels for predicting patients who progress to DSS 
could be much higher.
A previous study showed that a free N Sl concentration of above 600ng/ml on 
presentation predicted the subsequent development of DHF with a sensitivity of 72% 
and a specificity of 79% [39]. These numbers were derived from a small number of 
subjects with Secondary DENV-2 infections (n=32). Our cut-off, sensitivity and 
specificity for DENV-2 serotype were lower than those of Libraty et. al.'s study 
possibly because they used a DENV-2 specific MAbs and an in-house assay for 
detecting DENV-2 N Sl antigen, while our method was based on a commercially 
available N Sl test.
Our study had several limitations. First limitation is that this study was biased 
to patients admitted to hospital whereas the majority o f DENV infections resulted in 
clinically inapparent or mild disease that are managed entirely in the community. 
Second, we only focused on DENV-1 and DENV-2 because DSS wasn’t seen among 
DENV-3 and DENV-4 infections and the number of patients who were infected with 
DENV-3 and DENV-4 was small. Third, the quantitative N Sl method used a standard 
from DENV-2 which might have less efficiency of being recognized by Mabs in the 
commercial Platelia assay kit. And the final limitation is that the second study 
population contained only N Sl positive patients.
There were significant limitations in using the cut-off N Sl concentrations for 
DSS prognosis. First, not all patients who developed DSS had detectable N Sl in their 
acute phase plasma, either because o f viraemia declining or immune-complexes 
forming. Indeed, it was recognized that the sensitivity of N Sl detection was reduced 
in patients with secondary infection [103-105, 217-219]. And serotyping o f DENV
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infection was an expensive ahd time-consuming method that is rarely performed as a 
routine diagnostic in endemic settings and therefore the serotype dependent nature of  
the cut off values is a serious hurdle to its practical application.
In brief, the research showed that there was a sturdy correlation between the 
absolute and semi-quantitative methods for calculation of plasma N Sl concentration 
and N Sl concentration in enrolment plasma sample of patients could be useful for 
predicting DSS in patient with DENV-1 or DENV-2 infection but it was only useful 
alongside information on the infecting DENV serotype.
5. Early clinical and 
laboratory features 
predictive of dengue 
haemorrhagic fever
Early clinical presentation
5.1. Introduction
The initial symptoms of dengue -commonly, fever, headache, myalgia, and 
malaise- are nonspecific and similar to those of other viral illnesses. This can create 
challenges in both clinical management and disease surveillance. DHF is uncommon 
given the total number of infections in endemic areas, but it is a severe presentation of 
DENV infection and requires hospitalization and adequate management. Thus, early 
clinical diagnosis of dengue and especially the detection o f early clinical signs and 
symptoms of DHF are difficult but necessary for improving patient triage and 
management. The WHO guidelines for diagnosing DHF rely on laboratory and 
clinical signs that are usually not present in the first few days o f illness. The definitive 
diagnosis of DHF is made only with the development o f  thrombocytopenia and 
haemoconcentration (or pleural effusion), which usually occurs around the time of 
defervescence [194].
Attempts to identify clinical features as well as early laboratory features for 
prognosis of DHF have been made in many hospitals and laboratories [69, 124, 169, 
182-184, 223-225]. Such studies provided a list o f markers that showed correlations 
with disease severity at eiarly illness, but their application in early prognosis of DHF 
were not apparent because they didn’t establish cut-offs for predict DHF.
Several hypotheses have been proposed, to explain the pathogenesis of severe 
DENV infection. Some have suggested a role for high viraemia levels and delay in the 
clearance of viraemia in the pathogenesis of DHF [97, 124, 125]. Others have 
nominated a critical role for cytokines in DHF pathogenesis [164-172]. The most 
likely scenario is that DHF pathogenesis is multifactorial and that virus and host 
immune responses are contributing factors.
The principal aims o f this study were to define the early clinical presentation 
and laboratory features of DHF in a large prospective cohort o f patients under 18 
years old admitted to Dong Thap (DT) and Tien Giang (TG) hospitals in Vietnam 
within 72 hours o f their illness, and to identify some clinical signs, symptoms or 
laboratory biomarkers that can be used to predict the severity o f dengue or may assist 
in differentiating DHF from DF or from other common febrile illnesses.
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5.2. Methods 
5.2.1. Study setting
Recruitment took place at Dong Thap (DT) (Dong Thap Province) and Tien 
Giang (TG) (Tien Giang province) hospitals (both located in southern Vietnam). 
Patients eligible for enrolment were between 18 months and 18 years o f age, with a 
fever history o f less than 72 hours and the treating doctor believed dengue was a 
possible diagnosis. All patients or their guardians provided written informed consent. 
Ethical approval was from the Scientific and Ethical Committee of DT and TG 
hospitals and the Oxford Tropical Research Ethical Committee. Patients were seen 
daily by the hospital’s physicians until they were clinically well enough to be 
discharged from hospital. Detailed clinical and hematological information were 
recorded every day in a standard case report form.
Each patient had a venous blood sample drawn on the day of enrolment and 
daily thereafter during hospitalization Until discharge. Plasma was separated, 
aliquoted and stored at -20°C. Serological assays (IgM/IgG ELISA), RT-PCR and 
N S1 ELISA (Platelia, BioRad) were used to confirm all dengue cases.
After completion of the case records, a single physician, who was not directly 
involved in patient care, assigned a final diagnosis of DF, DHF or OFI based upon the 
WHO guidelines [72].
5.2.2. Serological status, viraemia and cytokine 
measurements
IgM and IgG against DENV were measured in all patients’ plasma at 
enrolment and discharge by anti-DENV IgM/ IgG ELISAs (described in section 2.4.1 
of chapter 2). Primary and secondary infections o f the patients were determined by 
using the model described in chapter 3.
DENV RNA was detected by RT-PCR (described in section 2.4.4 o f chapter 
2) in enrolment plasma samples. For those patients who were DENV RT-PCR 
positive, viraemia were measured in all o f their serial daily plasma samples by the
Early clinical presentation
qRT-PCR assay (described in section 2.4.5 of chapter 2). Every individual sample 
contained an internal control and external controls were used in every assay.
Patients who had positive results with all PCR, N Sl and serology tests were 
chosen to measure cytokine concentrations. Cytokine measurement was performed on 
their enrolment and discharge plasma samples using the method described in section 
2.4.6 of chapter 2.
5.2.3. Data record
Case Report Forms (CRFs, Appendix 7) were filled in by doctors at DT/TG 
hospital. Data were then entered and managed by the Data entry department of 
OUCRU.
5.2.4. Statistical methods
We aimed to detect early markers for DHF (DHF vs. DF/OFIs) by examining 
a pre-defined list o f 7 laboratory and 13 clinical covariates. We first performed 
univariate summaries o f covariates in the two groups and compared them using the 
Wilcoxon rank-sum test for continuous and Fisher’s exact test for categorical data. 
We then aimed to develop predictive models for DHF based on all clinical or/and 
laboratory covariates, respectively. We used logistic regression for model 
development and report the full model and a model with stepwise model selection 
according to the Bayesian information criteria (BIC, [226]). The performance of the 
selected models was then calculated at the cut-off value at which probability of DHF 
progression is greater than 20%. The validation (including the model selection 
process) was based on bootstrap method (with a 100 time repeated process) to 
overcome the optimism from resubstitution.
To compare viraemia and cytokine measurements between disease severity 
(two groups: DF and DHF), we pre-defined the following contrasts to be of primary 
importance: pairwise comparisons of total (DF vs. DHF), o f DENV serotypes within 
disease severity (9 comparisons, e.g. DF with DENV-1 vs. DHF with DENV-1, DF 
with DENV-1 vs. DF with DENV-2, etc.), and comparisons o f serological statuses 
within disease severity (4 comparisons, e.g. DF with primary vs. DHF with primary, 
DF with secondary vs. DHF with secondary, DF with primary vs. DF with secondary
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and DHF with primary vs. DHF with secondary). Comparisons o f (log-transformed) 
viraemia and cytokine measurements were based on linear regression models adjusted 
with day of illness when the samples collected and with serotype (in comparisons of 
serological status within disease severity) or serological status (in comparisons of 
serotypes within disease severity) or both serotype and serological status (in 
comparisons of total). Comparison of the time to viral clearance was based on a Cox 
regression model. In all cases, we included dummy covariates for each serotype- 
disease severity combination (e.g. Dl.DF means DF patient with DENV-1 infection, 
etc.) or serological status-disease severity combination (e.g. P.DF means DF patient 
with primary infection, etc.) and then tested for significance o f the pre-specified 
contrasts. We corrected for multiple comparisons using a single step approach based 
on the joint asymptotic multivariate distribution of the contrasts; this method serves 
the same purpose as the Bonferroni correction but is more efficient [216].
We used the statistical software R version 2.11.1 (R Foundation for Statistical 
Computing, Vienna, Austria) and the companion R packages BMA 3.13 (Bayesian 
Model Averaging) and RPART 3.1-46 (Recursive partitioning and regression trees) 
for analyses. Missing values were imputed by using the companion R packages mice 
2 . 1 .
5.3. Results
5.3.1. Number of patients and laboratory diagnosis
Between December 2007 and November 2009, 574 patients were enrolled in 
the study at Dong Thap hospital (n=61) and Tien Giang hospital (n=513). Seventeen 
patients were excluded from the analysis, 14 of them had incomplete hospital 
information records and 3 entered the cohort later than 72 hours from the self-reported 
illness onset. Of those which were included, according to our dengue laboratory 
algorithm (Figure 2-1 in section 2.3), 333 (59.8%) patients had laboratory confirmed 
dengue, 22 (3.9%) had serological evidence for a recent DENV infection (n=16) or 
for a recent flavivirus infection (n=6). Among the remaining cases, 179 (32.1%) were 
conclusively negative on all diagnostic tests (defined as other febrile illness -  OFI), 
and 23 (4.1%) had indeterminate results.
Early clinical presentation
Figure 5-1 shows the geographic locations of study patient addresses in DT 
and TG provinces, which were deduced by GPS logging of each patient’s residential 
address. The majority of patients lived in close proximity to the study hospitals and 
there was no evidence of any particular spatial clustering of dengue cases, which is 
reflective Of the endemic nature of dengue in southern Vietnam.
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Early clinical presentation
Amongst cases with acute DENV infections, 272 (81.7%) patients were RT- 
PCR positive in the enrolment plasma sample, an extra 43 (12.9%) had NSl Ag 
recognized by qualitative NSl ELISA and a further 18 (5.4%) had IgM/IgG 
seroconversions by IgM/IgG ELISA (Figure 5-2).
Serology (321+)
NS1 (284+)
Figure 5-2: Summary of results from the three diagnostic tests.
The venn diagram shows 333 laboratory confirmed acute dengue cases according to 
whether they tested positive by RT-PCR, N Sl, or/and serological tests. Blue 
represents PCR+ test; green is NS1+ test and pink represents IgM  or IgG  
serocon versions.
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5.3.2. Demographics and disease severity in the study 
population
For the present analysis, we included all OFI cases (n=179) and 318 laboratory 
confirmed dengue cases; we excluded 15 cases (4.5%) because a final clinical 
classification o f DF or DHF could not be determined by the WHO criteria [72]. 
Among the laboratory confirmed dengue cases, the characteristics o f the study 
population are shown in table 5-1. The median age o f patients enrolled in Dong Thap 
hospital was higher than those in Tien Giang hospital (10 vs. 9 years old, respectively, 
p=0.04). There were no significant differences in male to female ratio, duration of 
fever before study entry or proportion of patients with DHF between the two study 
sites. There were more females in the DHF group than the group of DF and OFI 
patients (54.1% vs. 43.3%, p=0.05, Chi-square). Children were older in the DHF 
group than the group o f DF and OFI patients [median (IQR) age o f 11 (7-14) vs. 9 (6 - 
12) years, respectively, p=0 .0 0 1 ].
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Early clinical presentation
5.3.3. Infecting serotype and serological status
Plasma samples collected from patients at enrolment were analyzed by RT- 
PCR as described previously (section 2.4.4). This enabled determination of the 
infecting DENV serotype in viraemic patients. The DENV RT-PCR was positive for 
265 of 318 dengue patients (83.3%); 45 of 53 RT-PCR negative patients (84.9%) had 
secondary infections. DENV-1 (52.8%) was the most prevalent serotype in the study 
population; the second most common serotype was DENV-3 (18.2%), then DENV-2 
(11.6%). DENV-4 infection was detected in only two cases (Table 5-2). The 
proportion of DENV serotypes was similar between DF and DHF groups (p=0.3, Chi- 
square).
The majority of dengue patients had secondary infection (n=250, 78.6%), 
primary infection was more common in DENV-1 infections (Table 5-2). Secondary 
infections were more common in DHF patients all grades than in DF patients (99/109, 
90.8% vs. 151/209, 72.2%, respectively, p<0.001, Fisher’s Exact). Among the 
children with DENV-2, 3 or 4 infection, the distribution o f secondary infection 
between groups was similar; but among DENV-1 infected patients, the proportion of 
patients with secondary infection was significant higher in DHF patients than DF 
group (52/59, 88.1% in DHF group vs. 68/109, 62.4% in DF group, p=0.001, Fisher’s 
Exact).
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5.3.4. Patient management
Each patient stayed a median o f 5 (IQR 4-6) days in hospital until they were 
discharged from hospital. 113/497 (22.7%) o f study patients received some 
intravenous fluid replacement. The frequency of parenteral fluid intervention given to 
patients who did not have dengue (17/179, 9.5%) was significantly lower than that o f  
laboratory confirmed dengue patients (96/318, 30.2%) at p<0.0001 (Chi-square test). 
Fluid was primarily for shock resuscitation (14 DHF III cases, 1 OFI), for rehydration 
(9 OFI, 36 DF, 3 DHF I, 35 DHF II, and 1 DHF III) or for maintenance only (6  OFI, 2 
DF, 6  DHF II). Three cases were given inotropes (2 DHF III, 1 DHF I), 3 were given 
diuretics (all DHF III) and 4 needed oxygen support (1 DHF II, 3 DHF III).
5.3.5. Clinical signs and symptoms at enrolment
The most common clinical symptoms and signs in dengue patients at 
presentation were high body temperature (median o f 39°C, IQR 38°C -  39°C), 
vomiting, bleeding, flush, abdominal pain and tenderness. To identify early clinical 
markers o f DHF, we compared signs or symptoms in DHF patients at the time of 
presentation with the rest o f the patient population (DF and OFI). Vomiting, 
spontaneous bleeding, tenderness and liver enlargement at presentation were 
significantly associated with DHF by univariate analysis (P<0.05). Gender and age 
were also associated with DHF (Table 5-3). Spontaneous bleeding, especially skin 
bleeding which was the most common bleeding sign seen in this study, had a 
significant correlation with DHF (OR 2.2, 95%CI 1.4-3.4, PO.OOOl).
Early clinical presentation
Table 5-3: Demographic and clinical signs and symptoms at enrolment that were 
associated with progression to dengue hemorrhagic fever.
Variable Total
Dengue hemorrhagic fever
N / median % / 'IQR OR 95% Cl p
Total 497 109 . _ .
Age (median-IQR) 497 11 7-14 1.09 1.04-1.15 0.001
Gender (female) 227 59 26 1.54 0.99-2.42 0.05
BMI (median-IQR) 497 16.6 14.6-18.3 1 0.95-1.03 0 .6
Vomiting 189 32 16.9 0.55 0.32-0.92 0.02
Joint pain 10 3 30 1.54 0.25-6.88 0.46
Skin or facial flush 134 35 26.1 1.38 0.84-2.24 0.18
Generalized body rash 7 3 42.9 2.71 0.39-16.29 0.18
Abdominal pain 68 2 0 29.4 1.59 0.85-2.9 0 .1 2
Watery stools 17 4 23.5 1.1 0.26-3.65 0.77
Spontaneous bleeding 181 56 30.9 2.22 1.41-3.5 <0.001
Skin 164 ; 55 33.5
GI 4 0 0
Vagina 3 1 33.3
Nose 16 1 6.3
Abdominal tenderness 48 19 39.6 2.61 1.32-5.06 0.003
Liver enlargement 8 5 62.5 6.14 1.17-40.18 0.01
Lethargy 31 4 12.9 0.51 0.13-1.51 0.27
Values in b o ld  are significant at P <0.05. BMI: body mass index. IQR: inter-quartile 
range. GI: Gastrointestinal track
Early clinical presentation
5.3.6. Haematological profile at enrolment
We considered the haematological and liver transaminase results in study 
participants at the time of enrolment and whether any of these variables were 
associated with progression to DHF. Box-plots showing differences between DHF 
group and the DF/OFI group are presented in Figure 5-3. At the time o f enrolment, 
the haematocrit was significant higher in DHF patients relative to the rest o f the 
patient population (DF/OFI group (40% vs. 38%, respectively, PO.OOOl, Wilcoxon 
test). In contrast, platelet and white blood cell counts were significantly lower in DHF 
patients (Table 5-4). The percentage o f patients who had AST or ALT levels greater 
than 40IU (upper limit of normal range) was also significantly higher in DHF patients 
than the DF/OFI group (both PO.OOOl, Fisher’s Exact).
Table 5-4: Hematological profile of patients at enrolment.
Variable
DF/OFI
N=388
DHF
N=109
P
Haematocrit (%)
38
(36-41)
40 
(37—43)
0 .0 0 1 +
Platelet count 
(xlOOO cells/pl)
181
(141.8-239.3)
138
(98-172)
0 . 0 0 0 1
White blood cell 
( 103 cells/nl)
5
(3.6-7.5)
3.7 . 
(2.4-4.6)
0 . 0 0 0 1
Neutrophil (%)
6 6
(53-75)
6 6
(54-73)
0.9
Lymphocyte (%)
2 0
(14-31)
21
(13-29)
0 .8
AST >40U/L 
N (%)
20 1  (51.8%) 88  (80.7%) 0 .0 0 0 1 *
ALT >40U/L 
N (%)
69(17.8%) 54 (49.5%) 0 .0 0 0 1 *
Values are shown in median (IQR) or n (% total). + adjusted for age. * Fisher’s Exact 
test.
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Early clinical presentation
5.3.7. Prognostic models
Multivariate analyses were performed to construct prognostic models that 
might be useful for the identification of patients who progress to DHF. We used 
logistic regression for model development and report full models and selected models 
with stepwise model selection according to the Bayesian information criteria (BIC). 
Models were developed upon clinical and/or haematological features of patients at 
enrolment.
Logistic regression models based on clinical features at 
enrolment to predict DHF
The full clinical model includes age, gender, vomiting, spontaneous bleeding, 
abdominal tenderness and liver enlargement covariates seen at enrolment. A number 
of variables were excluded due to non-significant (p>0.05) results in univariate 
analysis. While the clinical model selected by BIC includes only age and bleeding 
signs at enrolment (Table 5-5). The performances o f the models in predicting DHF 
cases at enrolment are shown by ROC curves in Figure 5-4. The full model had higher 
area under ROC curve than the selected model (AUROC-O.6 8  vs. 0.64, respectively)
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Figure 5-4: Receiver-operator characteristic (ROC) curves for prognosis of DHF 
using clinical symptoms and signs at enrolment.
The clinical full model derived from age, gender, vomiting, spontaneous bleeding, 
abdominal tenderness and liver enlargement covariates seen at enrolment and the 
clinical selected model includes only age and bleeding signs at enrolemnt.
Logistic regression models based on haematological profile 
at enrolment to predict DHF
Similarly with the clinical models, we constructed a full model and a selected 
model based on BIC using haemotological parameters at enrolment. The 
haematological full model includes gender, age, haematocrit, platelet, white blood cell 
count, AST and ALT covariates, the excluded covariates were percentages of 
lymphocyte and monocyte because o f their non-significant (p>0.05) results in 
univariate analysis. The numbers of covariates that were excluded by BIC were age, 
gender and AST>40 (Table 5-6). The ROC curves o f those two models are presented 
in Figure 5-5. The area under ROC curve o f the full model is similar to that of the 
selected model (AUROC=0.81 vs. 0.80, respectively).
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Figure 5-5: Receiver-operator characteristic (ROC) curves for prognosis of DHF 
using haematological profile at enrolment.
Comparison to other models
Since several models may explain the data similarly well and there is no 
guarantee that any model selection criteria selects the true model, we also analyzed 
the data using Bayesian model averaging and reported all models (Appendix 2 and 3 
show models from the clinical and haematological parameters, respectively). The best 
models using Bayesian model averaging method were similarly plausible as the 
models selected by BIC. We also constructed other models with clinical and 
haematological parameters altogether (Appendix 4). However, model selection by 
BIC based on clinical and haematological covariates led to exactly the same 
covariates as the haematological selected model. This indicated that further adding 
other clinical to haematological covariates doesn’t improve prediction.
Furthermore, we also constructed tree models based on clinical or 
haematological parameters (Appendix 5 and 6 , respectively) then analyzed them. 
However, the performance o f the tree model based on clinical covariates was similar 
to that of the clinical logistic model selected by BIC while the tree model based on 
haematological covariates was difficult to interpret with 6  covariates and 12 terminal 
nodes. Thus, the haematological logistic model selected by BIC was the simplest but
- 112-
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had the best area under ROC curve (AUROC=0.8). For practical utility, we built a 
nomogram from the haeamtological selected models (Figure 5-6 with an instruction 
on the footnote) corresponding with probability o f DHF. The smaller the probability 
of DHF is the higher sensitivity and the lower specificity are gained (i.e. at 
probability of 0 .8 , sensitivity and specificity are 2 .8% and 1 0 0 %, respectively; at 
probability of 0.1, sensitivity and specificity are 91% and 43%, respectively).
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95Points . ................................... ................ .. i ... i ... i... i ... i... i i    ......... ..I
Haematocrit 1 ■ 1 ■ > 1 ■ 1 ■ ■ 1 1 11 ■ 1 1 ■ 1 • 1 1 1 > • 1 1 1 1
25 28 31 34 37 40 43 46 49 52
Platelet i ■ i i i i i i r i i i i i i i i r~ i i i i i i
480 440 400 360 320 280 240 200 160 120 80 40
WBC 1 1 11 1 1 11 1 1 1 1 1—1—1—1—1—1 1 1-----1------ 1-------—1-----------r------------- ;-------1
25 21 18 15 12 10 8 7 6 5 4 3 2 1
yes
ALT .40------------------------- i-------=-------:-------:------------- - 1 ,
no
Total Points • I ■ in I m ■ I n ■ 11 ■ 111 p 111 III ri'p'i H| 111111II11111 n il TiTmT|iTir|TiTiTrnT| 11111 111111 in 111111 1111111 n | 111111111) 1111| 111 ipi nrp i ri|
0 20 40 60 . 80 100 120 140 160 .180  200 220 240 260
Probability of DHF 1—:— t----r—1— 1— 1— 1--- r
0.1 0.2 . 0.3 0.4 0.5 0.6 0.7 0.8
Figure 5-6: Nomogram for prognosis of DHF using haemotological profile at
enrolment.
ALT. 40 means ALT level> 40 U/L. Platelet and WBC are in (xlO3 cells/pi) unit. Add  
up points which correspond to values o f  the parameters o f  an individual then from the 
total points we have, we can know the probability o f  the individual progress to DHF.
For example, a patient who is clinically suspected dengue within the 3 days o f  his
illness presents with 46% haematocrit, 160xl& platelet cells/pi, 5 x l 0s WBC and 
ALT 50 U/L. Thus, he has a total o f 200points (from 46+67+50+37). The probability 
o f  the patient progressing to DHF is 0.45.
Early clinical presentation
5.3.8. Performances of the models for prognosis of DHF
The performances of the clinical and haematological selected models are 
summarized in Table 5-7. A probability o f greater than 0.2 (20%) was chosen as the 
cut-off value for the predictive models. Of note, as clinically defendable thresholds, 
this cut-off implies that we implicitly qualified the benefit o f a correct DHF 
classification as 4-times greater than the harm Of a false DHF classification. 
Resubstitution o f the original data set into the prognostic model that was generated 
from clinical parameters had 64% sensitivity and 54% specificity. While the model 
generated from haematological parameters had 79% sensitivity and 6 8 % specificity. 
The sensitivity, specificity, NPV and percentage o f correctly classified patients of the 
model constructed from haematological parameters were significantly higher than 
that o f the model constructed from clinical parameters (p<0.05) while, the PPV was 
similar between the two models.
Table 5-7: Performance of the models for the prognosis of DHF at the
cut-off 0.2
The clinical selected model The haematological selected model
P+
Apparent* Optimism-corrected Apparent
Optimism-
corrected
Sensitivity 70/109(0.64) 0.59 86/109 (0.79) 0.76 0 .0 2
Specificity 208/388 (0.54) 0.53 262/388 (0.68) 0.67 <0 .0 0 0 1
PPV 70/180 (0.28) 0.26 86/212 (0.41) 0.39 0.76
NPV 208/247 (0.84) 0.82 262/285 (0.92) 0.91 0.007
Accuracy 278/497 (0.56) 0.54 348/497 (0.7) 0.69 <0 .0 0 0 1
AUROC 0.64 0.60 0 .8 0.78 _
AUROC: Area under ROC curve, PPV and NPV are positive and negative predictive 
value, respectively. Accuracy o f  the test was calculated by * resubstitution or by ** 
bootstrap validation (repeated 100 times) using the original data set that generated 
the model to overcome the optimism from resubstitution. + Comparison between 
apparent values o f  the two models using Fisher’s Exact test.
Early clinical presentation
The results show that the haematological was the best model for prognosis of 
DHF using haematological profile at enrolment. It was simplest and had the best 
performance of all models that were generated.
5.3.9. Plasma viraemia
A summary of plasma viraemia characteristics between DF and DHF are 
shown in Table 5-8 and 5-9 by serotype and serological status, with p-values for all 
pre-defined group comparisons in the footnote. The kinetic changes in viraemia were 
plotted by day after fever onset (Figure 5-7). Viraemia AUCs and viraemia 
concentration at enrolment were highly correlated with each other (partial correlation 
between log-values after controlling for gender, age, day of illness, serotype and 
serological status, r=0.93, p<0.0001).
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Early clinical presentation
Children with DHF had almost one log 10-copies/ml higher plasma viraemia at 
enrolment and AUCs than children with DF (comparisons were adjusted for serotype, 
serological status and day of illness, p=0.0009 and p=0.03, respectively) (Table 5-8). 
However, time to viral clearance was borderline statistically longer in DHF cases than 
children with DF (p=0.051). The percentage o f patients with a viraemia that was till 
detected in the plasma sample collected at discharge was similar between two groups, 
37.3% (66/177) in DF group compared with 38.6% (34/88) in DHF group (p=0.9, 
Chi-square test). When we stratified patients by serotype and disease severity, the 
comparisons revealed that viraemia levels at enrolment in DHF patients were not 
significantly higher than DF patients infected with the same serotype, DENV-2 or 
DENV-3 (both adjusted p values>0.1). In DENV-1 infected patients however, 
viraemia levels at enrolment were higher in patients with DHF than DF (adjusted 
p=0.02). The comparisons between serotypes revealed that viraemia levels were 
significantly higher (~1 log 10 higher) in patients with DENV-1 infection compared 
with the other serotypes (all p<0.1 for enrolment measurements, all p<0.05 for AUCs, 
footnote of Table 5-8) and DENV-i had a significant longer viral clearance time than 
other serotypes (all pO.OOl).
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Early clinical presentation
When we stratified patients by serological status and disease severity (Table 5- 
9), viraemia levels detected in DHF patients with secondary infection were 
significantly about 1 log 10-copies/ml higher than in DF patients with secondary 
infection (adjusted p=0.003 for viraemia at enrolment and adjusted p=0.04 for AUCs) 
and the viral clearance time was also longer in DHF group with secondary infections 
than DF group with secondary infection (p=0.045). Among primary infections, the 
results suggest that higher plasma viraemia (at enrolment and AUC) occurs in DHF 
patients compared to DF patients, but the number o f DHF patient was small (n=8 ) and 
no statistically significant differences were observed. Besides, most of the 
comparisons between serological statuses revealed that enrolment viraemia, AUCs 
and viral clearance time weren’t significant lower in secondary than primary 
infections. However, DF patients with secondary infections had a significant shorter 
viral clearance time compared with those of DF patients with primary infections 
(median time= 6  vs. 8 , p=0.006, comparisons adjusted for age, gender, day of illness 
and serotype).
In summary, viraemia levels were higher in DHF than DF patients (in term of 
levels at enrolment and AUCs). The differences between DHF and DF were observed 
in the group o f patients with secondary infection. Viraemia levels at enrolment, AUCs 
and viral clearance time measured in DENV-1 infected patients were higher than 
those in DENV-2 or DENV-3 infected patients. Finally, there wasn’t any difference 
between primary and secondary infections in term o f viraemia at enrolment and 
AUCs. However, patients with primary infection had longer viral clearance time than 
patients with secondary infection.
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Early clinical presentation
5.3.10. Plasma cytokine
Various pro- and anti-inflammatory cytokines have been implicated in the 
pathogenesis o f DHF. To explore whether there were early differences in cytokine 
concentrations between DHF and DF patients, and if these could be o f prognostic 
value, we measured concentrations of IL-lp, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, 
IL-13, IFNy and TNFa in enrolment plasma samples of the patients who had 
serological confirmed dengue, detectable viraemia and NS1 at enrolment. Table 5-10 
summaries characteristics of the patients at enrolment.
Table 5-10: Characteristics of subgroup of patients who had plasma cytokine
measurements performed.
Parameters
DF 
N= 134
DHF 
N= 66
Age 1 0 (7 -1 3 ) 1 2 (7 -1 5 )
Female 55(41%) • 31(47%)
DOI at enrolment 3 ( 2 - 3 ) 3 ( 2 - 3 )
Fever day at enrolment -3 ( -4 - -2 ) -4 ( -5 - -2 )
Length o f hospitalization* 5 ( 4 - 6 ) 6 ( 5 - 7 )
Log 10 plasma viraemia* (copies/ml) 7.5 (6 .4 -8 .2 ) 8.3 (7.7 - 9 )
Numbers are reported as median (IQR) or N (% total). * Comparisons between two 
group show both p<0.0001 (Wilcoxon rank sum test).
At enrolment, the concentrations o f IL-lp, IL-2, IL-4, IL-6, IL-10, IL-12p70, 
IL-13, IFNy and TNFa were significantly higher in plasma samples from children 
with DHF than those in samples from children with DF (all p<0.05, comparisons of 
log-10 values adjusted for age, gender, serological status and day of illness). Of the 
cytokines measured, only concentrations o f IL-5 were not significantly different 
between DHF and DF patients (p= 0.063) (Table 5-11, Figure 5-6). In the 
multivariable analysis adjusted for age, gender, serological status and day o f illness, 
IL-6 and IL-13 were independently associated with DHF (OR=1.2 and 1.1, p=0.024 
and 0.014, respectively).
Early clinical presentation
Comparisons between the disease severity among patients with secondary 
infections (Table 5-11) revealed that IL-6, IL-10, IL-13 and TNFa concentrations at 
enrolment were significantly lower in DF than DHF patients (log 10 pg/ml 
comparisons, 1.4 vs. 1.6, p=0.04 for IL-6; 1.1 vs. 1.3, p=0.02 for IL-10; 0.93 vs. 1.16, 
p=0.048 for IL-13 and -0.1 vs. 0.1, p=0.01 for TNFa). IL-1 and IFNy were also lower 
in DF than DHF patients with secondary infection, but were of borderline significance 
(adjusted p=0.07 and 0.09, respectively). Among primary infections, these cytokines 
at enrolment were also generally lower in DF patients compared with DHF patients, 
but there were no significant differences due mainly to the small number of the 
primary infection patients with DHF (6 patients). These results suggested IL-6, IL-10, 
IL-13 and TNFa might play an important role in pathogenesis of DHF in secondary 
infections. Interestingly, no statistically significant difference was seen when 
comparisons between primary and secondary infections were made. This implies that 
primary or secondary infection didn’t effect on cytokine production.
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Early clinical presentation
Surprisingly, plasma concentrations o f IL-lp, IL-4, IL-6, IL-12p70, IL-13, 
IFNy and TNFa were significantly higher at the time o f discharge from the hospital in 
children with DHF than those in children with DF; only IL-2 and IL-5 were not 
significantly different between the two groups at this time point (Figure 5-8). 
Interestingly, IL-10 concentrations measured at discharge had an inverse trend with 
that measured at acute phase. Thus, at discharge, IL-10 was lower in plasma sample 
collected from children with DHF than those from children with DF (median of 
loglO-pg/ml, 1.13 vs. 1.19 pg/ml; p=0.0002, adjusted for age, gender, day of illness 
and serological status). The results suggested that IL-lp, IL-4, IL-6, IL-10, IL-12p70, 
IL-13, IFNy and TNFa still play their role in pathogenesis o f DHF during 
convalescence phase.
5.3.11. Correlations between viraemia and cytokine 
concentrations at enrolment
At enrolment, higher viraemia levels were significantly associated with higher 
concentrations o f IL-lp, IL-2, IL-4, IL-12p70, IL-13 and TNFa (partial correlation 
controlled for age, gender and day of illness, all r<0.3, p<0.04). Higher viraemia 
levels were also significantly correlated with lower concentrations of IL-10 (partial 
correlation r= -0.21, p=0.004); while, IL-5, IL-6 and IFNy had no statistically 
correlation with viraemia burden (Table 5-12). It shows that the high levels o f  
viraemia stimulated concentration o f IL-lp, IL-2, IL-4, IL-12p70, IL-13 and TNFa, 
but conversely, inhibited concentration o f IL-10. Production o f IL-5, IL-6 and IFNy 
weren’t effected by the levels of viraemia.
Early clinical presentation
Table 5-12: Correlations between viraemia levels and cytokine concentration at
enrolment.
Cytokine loglO-ILip(pg/ml)
Iogl0-IL2
(pg/ml)
Iogl0-IL4
(pg/ml)
IoglO-IL5
(pg/ml)
IoglO-IL6
(pg/ml)
Correlation, r 0.20 0.25 0.23 0.12 0.07
P (2-tailed) 0.01 0.0007 0.002 0.11 0.37
Cytokine loglO-ILlO(pg/ml)
logl0-IL12p70
(pg/ml)
Iogl0-IL13
(pg/ml)
loglO-IFNg
(pg/ml)
loglO-TNFa
(pg/ml)
Correlation, r -0.21 0.15 0.30 0.02 0.21
P (2-tailed) 0.004 0.04 <0.0001 0.84 0.004
Partial correlation controlled fo r age, gender, day o f  illness o f  the samples.
5.4. Discussion
The ability to identify in the early stages o f dengue those patients who will 
develop clinical complications could significantly influence clinical management and 
the use o f health care resources. In this prospective study o f  497 patients with 
suspected dengue and enrolled within the first three days o f illness, we characterized 
clinical, virological and cytokine profiles in dengue cases and identified early features 
that were associated with DHF. We developed models to predict patients with DHF 
that had high specificity but unfortunately also had low sensitivity.
Our study proposed a model that has the ability to make a quite accurate 
prediction o f DHF (AUROC=0.8) in the first few days o f  illness. It could help 
physicians immediately pay attention to patients who are at high risk o f DHF/DSS 
and give them suitable care to reduce mortality. Additionally, our understanding o f  
the dynamics o f viraemia, host response and clinical complications in dengue is 
widened; it is likely that the success o f novel interventions with anti-viral drugs or 
corticosteroids to modulate the host pro-inflammatory response will be dependent on 
early (<3 days o f  illness) clinical, or better, laboratory diagnosis.
In the first 3 days o f illness, we observed that a higher proportion o f DHF 
cases had vomiting, spontaneous bleeding, abdominal tenderness and liver 
enlargement. DHF cases also had higher haematocrits, lower platelet counts, more 
pronounced leucopenia and increased AST or ALT levels. Most o f  these variables 
have been shown to distinguish between dengue and patients with other acute febrile
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illnesses [69, 227-232]. These results implied that clinical and haematological 
parameters might be useful for the prognosis o f  DHF. The logistic models or 
classification tree models built on these clinical and/or haematological parameters had 
moderate to adequate performances (AUROCs range from 0.6 -  0.8)
Previous studies have developed classification trees which had sensitivities 
and specificities for the diagnosis o f  dengue that ranged from 70%- 96% [228, 233]. 
Other studies have considered the prognosis o f  severe dengue and had sensitivities 
and specificities o f  78%, 80% [233], 100%, 46% [227] and 98%, 44%, respectively 
[182]. The study populations in these publications were adults [227, 228, 233] and 
were enrolled late in their illness (more than 3 days) [227, 228]. Two o f the 
algorithms have limited routine clinical utility in prediction o f DHF [227, 233] 
because their models were generated using virological or serological data which is 
not known routinely, while our models identify those with DHF from all cases with 
clinically suspected dengue.
Our study had a similar study setting with that o f Potts’s et. al. [182] but we 
had a smaller sample size (497 vs. 1230 patients) and a shorter time in recruiting 
patients (2 vs. 13 years) thus our study might have fewer confounders due to the 
changes in technology and/or human resourse (doctors, nurses, etc.). Furthermore, if  
we use the cut-off value at probability o f DHF greater than 0.1 for our models, the 
sensitivity is better (91%) but the specificity is reduced (43%) which are similar with 
those o f  the classification tree from Potts’s et. al. [182]. Moreover, our model built on 
logistic regression o f haematological covariates had a broad utility in practical clinical 
prognosis and research because it can have a floating cut-off level, i.e. we can flexibly 
choose the cut-off level for our own purpose. For example, if  we were conducting a 
trial o f  a therapeutic drug, where we have to weigh the benefit/risk o f the intervention 
to the patient, we can select patients who have a higher probability o f  developing 
DHF (greater than 0.8 for example). Alternatively, for routine clinical care we can opt 
for high sensitivity (at probability o f DHF greater than 0.1 for example) to make sure 
that we don’t miss any DHF cases.
DENV-1 was the dominant serotype in this study and it accounted for most o f  
the primary infections (70.6% o f primary infections). The prevalence o f DENV-1 in 
the study population was consistent with virological surveillance data for the southern
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20 provinces o f  Viet Nam, in which DENV-1 was the most common serotype 
detected during the study period, followed by DENV-2, DENV-3 and DENV-4[18]. 
After adjustment for multiple testing among different levels o f  disease severity (DF or 
DHF) and day o f  illness, higher levels o f viraemia and longer viraemia clearance time 
were significantly associated with DENV-1 relative to patients with DENV-2 or 
DENV-3 infections. It’s possible then that DENV-1 viruses are intrinsically more 
virulent than DENV-2 or DENV-3 viruses, although all four serotypes can clearly 
cause severe dengue.
Viraemia levels have previously been shown to be associated with severe 
disease, in DENV-2 and DENV-3, but in smaller datasets [97, 124-126]. With the 
advantage o f our large data set collected early in the illness phase and an analysis that 
adjusted for serotype, serological status and day o f  illness, we confirmed that viraemia 
levels were significantly greater in DHF patients than in DF patients at early 
timepoints as well as during the dengue illness. This is an important justification for 
the development and test o f  antiviral drugs as an early rapid reduction in the viral 
burden in vivo which might help alleviate symptoms and prevent the development o f  
severe complications.
We did not find any significant differences in viraemia between primary and 
secondary infection, with the only exception o f  the viral clearance time which was 
shorter in the secondary infections among DF patients. This finding agrees with 
Murgue’s study [126], but contrasts with other studies on DENV-1 or DENV-2 
infections [97, 220, 234], The possible reason might be the difference in classifying 
primary and secondary infections. Vaughn, Yeh and Duyen et. al. classified 
secondary infection based on a clear rise in IgG level by day 5-7, while our study 
classified primary and secondary infections based on IgM, IgG levels together with 
day o f  illness. The other reasons are DENV-2 infections were not common in our 
study, and DENV-2 primary infections in particular were rare. However, we also did 
not find any differences between primary and secondary DENV-1 infections and thus, 
this is somewhat inconsistent with the ADE theory and its role in pathogenesis. It is 
possibly explained that at the beginning o f  a secondary infection, ADE boosts viral 
infection in a very short time so plasma viraemia at the time o f  study enrolment has
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already began decreasing. The other explanation is that we were biased toward 
children in hospital with clinically apparent dengue.
With regard to cytokine profiles in dengue cases, our study was biased to a 
subgroup o f  dengue patients who had high viraemia because all o f  the patients whose 
plasma samples we measured cytokines had serologically confirmed dengue, 
detectable viraemia and NS1 at enrolment. However these patients accounted for 
62.9% (200/318) o f  all laboratory confirmed dengue cases. Furthermore, this 
subgroup o f  patients didn’t skew the analysis toward DHF patients because the 
percentage o f  DHF cases in the subgroup was not significantly different from that in 
all dengue cases (31.9% vs. 35.9%, p=0.57, Fisher’s Exact).
Our findings showed a greater virus burden in DHF patients at enrolment 
leading to an augmented cascade o f  immune responses as indicated by plasma 
concentrations o f IL-lp, IL-2, IL-4, IL-10, IL-12p70, IL-13 and TNFa in DHF 
patients compared to DF patients. Significant trends were also seen at discharge. This 
observation was novel and suggested that the timing o f cytokine responses to DENV  
infection could play an important role in the disease pathogenesis. A previous study 
showed in the first three days o f  DENV infection, TNF-a, IL-2, IL-6 and IFN-y 
reached high levels [162]. TNF-a and IL-10 were also reported to be elevated in DHF 
[164-168]. Besides, in the studies from adults with DENV infection, IL-6 [186], IFN- 
y, IL-ip , IL-4 and IL-13 were increased in patients with severe dengue [169]. 
Conflicting with these results, concentrations o f  IL-2, IL-6 and IFN-y shown were not 
different in DF and DHF patients [170-172]. The difference in the literature might be 
related to the different methods o f  detection, the different case populations and the 
timing o f  specimen collection. Increased levels o f  IL-10 and other type 2-effectors in 
DHF were thought to play a role in down-regulating the prior, augmented, release o f  
IFNy and type 1-effectors [235]. Strikingly, our observation that IL-10 measured at 
discharge had an inverse trend with that measured at acute phase and was also 
associated with DHF might suggest the role o f IL-10 was different before and after 
the time o f defervescence.
Interestingly, no statistically significant difference in pro-inflammatory 
cytokine levels was seen between primary and secondary infections. This was 
inconsistent with results from Prinyadarshini et. al. [186], which showed higher levels
-  128 -
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o f IL-6, IL-8 and IFN-y in the secondary cases compared to the primary dengue cases. 
The differences might be because o f the differences in the study populations in age 
and day o f  illness. In our study, cytokines were measured in plasma o f children with 
dengue within the first three days o f  illness whilst Priyadarshini et. al. measured 
cytokines between 2-15 days o f illness onset in plasma from patients aged from 1- 64 
years old.
While the strength o f this study was its prospective nature in which we 
recruited a large number o f patients within 72 hours from illness onset, the study also 
had several weaknesses. Firstly, it was hospital based and therefore does not represent 
the wider dengue case burden. We also had a small number o f patients progressing to 
DSS (n=15). Secondly, we didn’t follow up the patients after discharge; this limitation 
resulted in 37.7% o f  patients being still viremic at discharge (as defined by RT-PCR) 
and that might explain why the time to viral clearance was similar between DHF and 
DF patients. Thirdly, DENV-1 infections (63.4%) and secondary infections (78.6%) 
were the majority in our study and therefore, we could make few conclusions 
regarding DENV-3 and DENV-4.
In conclusion, we showed a simple model using early haematological 
indicators obtained within 72 hours o f illness that might be effective in predicting 
DHF in the clinical setting for pediatric patients with clinically suspected dengue. 
This might reduce unnecessary hospitalization while optimizing clinical outcome for 
hospitalized DHF patients. Although, the model needs to be validated in other data 
sets, the study emphasized the usefulness o f  haematological profiles at an early stage 
o f illness and is broadly consistent with findings by Potts et. al.. Our findings also 
demonstrated the plasma cytokine profiles in Vietnamese children with dengue. We 
showed here for the first time that in dengue, different cytokine profiles might be 
present and vary according to clinical manifestations. Moreover, at the early stage o f  
the disease, there were many biomarkers that could be used to distinguish between 
DHF and DF patients such as viraemia, IL-lp, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL- 
13, IFNy and TNFa.
6. Conclusion
Conclusion
The goals o f this thesis were to characterize a serological assay for dengue 
diagnosis and then in prospective studies, identify early clinical, haematological, 
virological, and immunological factors associated with severe presentations o f dengue 
and then use them to develop predictive algorithms. The specific aims o f  the study 
were to:
• Define the diagnostic accuracy o f the in-house IgM/IgG ELISA for the 
diagnosis o f acute dengue and the classification o f primary or secondary serological 
status (Chapter 3).
•  Determine and evaluate early plasma NS1 cut-off levels for discrimination o f  
DSS from uncomplicated dengue (Chapter 4).
• Develop prognostic algorithms for early identification o f severe dengue 
among patients suspected o f having dengue using routine clinical findings and/or 
routine haematological laboratory markers (Chapter 5).
•  Discover early immunological biomarkers o f severe dengue (Chapter 5) and 
strengthen the knowledge o f  dengue pathogenesis (Chapter 3, 4 and 5).
This study addressed these important questions:
6.1. Why strategies for the early diagnosis and prognosis 
of severe dengue should be developed?
In the southern 20 provinces o f Vietnam, the annual incidence o f dengue 
ranges from 100 to 500 hospitalized dengue cases per 100,000 population [18] and 
dengue annually represents 4 -  18% o f  all inpatient diagnoses at three referral 
hospitals in southern Vietnam [19]. In Vietnam and many other endemic countries, it 
is not possible to hospitalize all patients with clinically suspected dengue for 
observation and therefore triage is an important and necessary step. However, the 
inability to make an early and accurate prediction o f which clinically suspected 
dengue patients might develop complications results in a large number o f  dengue 
cases being admitted to hospital who never require any clinical interventions and this 
patient burden contributes to overcrowding and strain on the health care system. 
Conversely, some patients are treated as outpatients but who develop complications
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that require emergency admission to hospital. The inability to make an early 
prognosis o f  severe dengue is also an impediment to novel treatment interventions 
that target the virus or the host immune response. In patients who are at risk o f  
developing severe complications, the balance o f risk versus benefit may favour the 
use o f  an intervention. O f note, OUCRU (Vietnam) is conducting randomized 
controlled trials o f  short course oral corticosteroids and separately, an anti-viral drug, 
in dengue patients with fever less than 72hrs (corticosteroids) or less than 48hrs (anti­
viral). There is therefore a pipeline o f  potential therapies for dengue that will be 
dependent upon making an early diagnosis, and in particular, identifying those 
patients at the highest risks for complications and who might benefit most from an 
early treatment intervention. An early prognosis o f DHF can assist in patient 
management by directing clinical attention to the appearance o f  capillary 
permeability, for which supportive oral and/or intravenous fluid therapy is 
recommended in order to prevent circulatory compromise [1, 76, 77] and reduce 
mortality rate [75]. Furthermore, an accurate dengue diagnosis and prognosis helps to 
exclude other diagnoses and prevents unnecessary antibiotic usage. A prompt 
diagnosis o f  index cases can also facilitate early vector control activities in the 
community therefore mitigating further transmission.
It is clear that rapid point o f care tests would be very useful for diagnosis and 
prognosis o f  dengue and severe dengue in outpatient or primary care level facilities. 
Similarly, they would be useful for intensive care facilities where the differential 
diagnosis o f  a patient with shock could include sepsis or other syndromes.
6.2. How did the studies in this thesis strengthen 
knowledge around diagnosis and prognosis?
Efforts to enhance further understanding o f DHF pathogenesis should be 
priority. The aetiology o f DHF appears to be multifactor. These include antibody- 
dependent enhancement (ADE) [138], cell-mediated pathogenesis [236], cytokine 
overproduction phenomenon [237], individual genetic background [238], differences 
among the serotypes [239], levels o f virus circulating in the body during the acute 
phase [97, 240], nutritional status o f the infected individual [209, 241]. The results 
from this thesis support some o f  them: evidence presented in Chapters 4 and 5 suggest 
that severity o f  dengue is dependent upon the relationship between viraemia, antigenic
-  132 -
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levels and the host immune response within the first three days o f  illness and is best 
predicted by haemotological profile at presentation.
Chapter 3 validated the diagnostic accuracy o f in-house ELISA used at the 
Hospital for Tropical Diseases using a reference panel o f serum samples. Chapter 3 
also confirmed that antibody profiles elicited by primary infection are different from 
those caused by secondary DENV infections. This is in line with a previous study 
done by Gubler et al [202]. In primary infections, IgM antibodies develop rapidly 
with high level while IgG appears slowly afterwards. In secondary infections, high 
levels o f IgG are detectable even in the acute phase whereas IgM levels are low or 
even absent. Furthermore, chapter 3 proposes an algorithm for discrimination o f  
primary and secondary infection by using the in-house ELISA assays to measure IgM 
and IgG levels in a single plasma sample collected within 4-14 days o f illness. 
Collectively, these results establish the in-house dengue serology assays as robust 
diagnostic and research tools.
Chapter 4 supports the hypothesis that the high levels o f plasma NS1 within 
the first few days o f  illness correlated to high levels o f viraemia [127] and high levels 
o f plasma NS1 were associated with progression to DSS [39, 41, 97]. Chapter 4 also 
shows plasma NS1 cut-off levels within the first 4 days o f  illness that can predict DSS 
patients with DENV-1 or DENV-2 infections.
Chapter 5 reveals that increased virus burdens in DHF patients in early phase 
o f illness (within the first three day o f illness) correlated with high plasma 
concentrations o f  IL -ip , IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13, IFNy and TNFa in 
DHF patients compared to DF patients, the trends were also seen at the time o f  
discharge. The differences in concentration o f  these cytokines were also observed by 
others with smaller study populations [162, 164-169] or not long ago, with a larger 
sample size in both children and adults [186].
Higher haematocrits, lower platelet counts, more pronounced leucopenia and 
increased AST or ALT levels have been shown to distinguish between dengue and 
patients with other acute febrile illnesses [69, 227-231]. These laboratory features 
were also seen frequently in severe dengue [72, 232, 242]. Chapter 5 emphasizes 
these trends in haematological profile at early illness are connected with development
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of DHF; especially, higher haematocrits, lower platelet counts, more pronounced 
leucopenia and increased ALT levels are independently associated with DHF among 
clinical and haematological covariates.
The models that are based on early NS1 levels (Chapter 4), clinical and/or 
haematological or immunological (Chapter 5) profiles would be directly or indirectly 
used to predict dengue severity with sensitivities and specificities ranging from low to 
acceptable levels. The models that are based on clinical and haemotological features 
at enrolment may be used in clinical practice because they are simple and feasible 
while the models based on NS1 cut-off levels is more difficult for practical utility due 
to its serotype dependence.
6.3. What are the further directions?
This thesis reveals new basic findings that might assist investigators in 
establishing novel approaches to combat plasma leakage and haemorrhage in severe 
dengue. In the future, it is possible that we will use micro-particles and autoloaders to 
simplify ELISAs (to measure serotype-specific NS1 concentrations, and in parallel, 
IgM and IgG levels) that can give results within minutes or just a few hours and this 
may help in diagnosis and prognosis o f severe dengue. However, further research is 
required to evaluate the predictive models using plasma NS1 levels measured within 
three days o f illness. Another study is also needed to evaluate the usefulness o f the 
model using haematological factors in diagnosis and prognosis o f DHF for pediatric 
patients with clinically suspected dengue.
A combination o f  clinical symptoms, signs, laboratory parameters such as 
haematological profile, viraemia, NS1, cytokine levels within the first few days o f  
illness and perhaps even host transcriptional profile or genetic background will be 
crucial in generating “second generation” predictive algorithms capable o f  identifying 
severe cases early in the course o f  the illness. Importantly, any algorithm must be 
applicable in settings with limited resources such as dengue-endemic countries where 
these tools are most needed. In terms o f biomarkers, detection o f  multiple biomarkers 
together might provide the best avenue for accurate diagnosis and prognosis o f  severe 
dengue. Newly developed techniques capable o f  measuring multiple analytes should 
become important for research in this area. Suitable tests must be cheap, easy and
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quick to perform and give an accurate result, ideally without the use o f  laboratory 
equipment (lateral flow rapid tests, for example). Since dengue is often a disease o f  
children, an ideal test would require small blood volumes, ideally capillary blood or 
even other specimens, such as urine or saliva.
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7. Appendices
Appendix 1. The human immune response to dengue virus is 
dominated by  highly cross-reactive antibodies endowed with 
neutralizing and enhancing activity [35].
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My contributions in the work o f this paper were:
- Collecting plasma and doing diagnostic tests (PCR, serology, culture for DENV) 
to confirm dengue cases
- Isolating DENV from the patients.
- Following up and collecting PBMC o f the patients.
- Co-operating in doing memory B-cell immortalization then cloning and screening 
B cell clones.
- Preparing autologous DENV-infected C6/36 cells for intracellular staining.
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Abstract
Dengue virus (DENY) infection and disease is a large and glowing global health 
problem. Antibodies are postulated to confer protection from DENV infection but have 
also been implicated in enhancing secondary heterotypic infection and increasing risk for 
severe disease. To understand better the functional repertoire o f human antibodies in the 
context of DENV infection, we studied a large panel o f human monoclonal antibodies 
(mAbs) that were isolated from memory B cells o f individuals who recovered from 
primary or secondaiy DENV infection. The majority of the isolated antibodies bound to 
domain I and II o f the envelope (E) protein. Notably, these antibodies were broadly cross- 
reactive against the four DENV serotypes and neutralized poorly, while potently 
enhancing infection of Fey receptor (FcyR)-bearing cells. In contrast, the few mAbs that 
boimd domain III of the E protein showed a more restricted pattern of cross-reactivity and 
potently neutralized while still modestly enhancing DENV infection. Three E-reactive 
mAbs that together targeted two epitopes on the four DENV serotypes were engineered 
with mutations in the Fc region that prevent binding to the FcyR. This niAb cocktail 
retained full neutralizing activity but failed to enhance infection in vitro and protected as 
post-exposure therapy in a mouse model of Dengue shock syndrome. Our findings 
indicate that human antibody response to DENV is skewed towards the production of 
highly cross-reactive antibodies with infection enhancing activity and illustrate the 
potential feasibility o f an antibody based therapeutic to control severe dengue in humans.
Appendices
Introduction
'Dengue.virus (DENV) is a mosquito-bome Flavivirus responsible for -50  million human 
infections annually, including 500,000 hospitalizations and 20,000 deaths, with an 
economic burden rivalling that of malaria. A primary infection is believed to provide 
effective, durable and possibly life-long protection against re-infection with the same 
serotype, but only short-term protection against other serotypes (1, 2). Classical 
epidemiologic studies suggested that immunity to one o f the four DENV serotypes can 
increase disease severity upon subsequent challenge with a different serotype leading, in 
some cases, to severe dengue, a disease characterized by plasma leakage and hemorrhagic 
manifestations (3). Poorly neutralizing cross-reactive antibodies raised in response to a 
previous serotype are believed to contribute to pathogenesis o f severe dengue by 
promoting virus entry via Fey receptors (FcyR) and infection of myeloid cells (4, 5) 
leading to antibody-dependent enhancement (ADE) of infection. The role o f antibodies in 
severe dengue is supported by epidemiological studies showing that infants with waning 
levels o f maternal antibodies (age 6-9 months) are most vulnerable to severe DENV 
disease (6, 7), and that serum from these infants enhance DENV infection in vitro (8-10). 
The difficulty of balancing immunity to the four serotypes and minimizing incomplete 
response and ihe risk o f ADE are major hurdles in the development o f a tetravalent 
vaccine against DENV (11).
The 10.7 Kb RNA genome of DENV encodes three structural proteins, the capsid 
protein (C), a membrane-associated protein (prM), and an envelope protein (E), and 
seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The E 
protein is structurally conserved among flaviviruses and consists o f three distinct
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domains. Domain I (DI) participates in the conformational changes required for viral 
entry and uucleocapsid escape from the endosomal compartment, domain II (DII) 
contains the fusion loop, and domain III (DEI) lias been suggested to bind cellular 
receptors (12, 13). Partially mature virions also express varying levels of prM protein on 
their surface, which is normally cleaved by a furin-like cellular protease to generate the 
mature virion (14).
The most potent neutralizing antibodies against DENV, or other flaviviruses such 
as West Nile Virus (WNV), bind to DEI and are effective as passive prophylaxis or 
therapy in rodents (15-21). The role o f antibodies to DI/E is less clear as they tend to be 
more cross-reactive and less potent in neutralization (22-24). Antibodies to prM generally 
have poor neutralizing and enhancing activity (25, 26), although recent studies suggest 
that some anti-prM mAbs can augment infectivity of poorly infectious immature virions 
(27). Antibodies against NS1, a secreted non-structural glycoprotein that is absent from 
the virion but expressed on the cell surface, can also protect against infection in vivo, 
through FcyR-dependent and -independent mechanisms (28, 29) or possibly contribute to 
pathogenesis (30, 31).
Our current knowledge on the human antibody response to DENV is based
exclusively on serological studies. In this study we used an improved method o f memory
B cell immortalization (32) combined with a broad screening approach to isolate a large
panel of DENV-reactive mAbs. Most mAbs bomid to E protein D IE  or prM and were
broadly cross-reactive with the four DENV serotypes. These mAbs neutralized poorly,
while potently enhancing infection of FcyR+ target cells. The few mAbs that bound to
DIE of the E protein, showed a more restricted pattern of cross-reactivity and potently 
neutralized, while still modestly enhancing DENV infection. Based on an improved
understanding of the functional humor al response against DENV, we produced a cocktail
o f three variant recombinant mAbs that neutralized all four DENV serotypes without
causing immune enhancement in vitro and in vivo.
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Results
High frequency of DENV-specific memory B cells in immune donors
IgG~ memory B cells were isolated from frozen PBMC of donors who were diagnosed 
with either a primary (Donor 76 and Donor 7) or a secondary (Donor 12 and Donor 92) 
DENV infection and were immortalized with EBV and CpG in multiple replicate wells 
(from 960 to 2,844), as previously described (32). Culture supernatants of immortalized 
B cells were collected after two weeks and analyzed using different screening assays 
(Table 1). Supernatants o f Donor 76, (primary DENV3) and Donor 12 (secondary 
DENVl) were screened for their capacity to stain fixed and penneabilized C6/36 
mosquito cells infected with DENV isolated from the same donors. For Donors 92 
(secondary DENV2) and Donor 7 (primary DENV4) die autologous isolates were not 
available and tiierefore the screening was performed by ELISA using as antigen lysates 
of DENVl, 2, 3, and 4 infected cells (Donor 92) or recombinant E protein from 
heterologous DENV4 (Donor 7). The fr equency of cultures containing specific antibodies 
ranged from 2.8% to 45% (Table 1), depending on the donor and the screening assay 
used. From these values, by correcting for the efficiency o f immortalization, we 
estimated the frequency of DENV-reactive cells ranging from 1.5% (Donor 7) to 16% 
(Donor 76) o f IgG^ memory B cells. These findings indicate that in DENV immune 
donors maintain a very large pool of memory B cells even several months after infection.
Isolation and characterization of human DENV-specific mAbs
A panel of fifty7 B cell clones were isolated by limiting dilution from independent cultures 
and the mAbs produced were characterized using binding and functional assays.
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All o f the mAbs efficiently stained Vero cells infected with at least one o f the four 
DENV serotypes and generally showed distinct patterns o f cross-reactivity (Fig. 1 and 
Table SI). Thirty-one mAbs bound DENV E protein, as assessed by ELISA or Western 
blot (Table 2). Of these, 19 (mostly from Donor 92) cross-reacted with E protein from all 
four DENV serotypes . Staining o f yeast displaying different DENV E protein domains on 
their surface revealed that these broadly cross-reactive mAbs were specific for DI/II 
(Table 2). Three additional DI/E-directed mAbs from Donor 76 were specific for 
DENV3 and one E-reactive mAb from Donor 1 was specific for DENVL Out o f 31 
mAbs, only 3 recognized DEI o f E protein; mAbs DV55.1 and DV87.1 cross-reacted 
with DENVl, DENV2 and DENV3, whereas mAb DV63.1 cross-reacted with DENVl 
and DENV3. Finally, 4 mAbs (DV66.1, DV61.2, DV57.4 and DV77.5), which were 
selected for binding to DENV-infected cells (Table SI), did not bind to recombinant E 
proteins in ELISA but bound to E protein in Western blot (Fig. 2A).
Some of the broadly reactive E-specific mAbs isolated from Donor 92 were 
analyzed for reactivity against West Nile virus (WNV). Seven mAbs stained yeast cells 
expressing DI/E of WNV E protein (Table 3). Using site-directed mutagenesis (22, 23), 
we localized binding o f three mAbs to the fusion loop peptide at the tip of DE (W101R, 
G106E) and o f a fourth mAb to the W233F residue on DE. The binding of the other three 
cross-reactive mAbs was not affected by these mutations, indicating that they map to 
DI/E but outside of the fusion loop region.
Next, we analyzed the capacity o f E-reactive mAbs to neutralize or enhance 
infection by four candidate DENV vaccine strains using flow cytometry assays with Vero 
and K562 cells, respectively (33, 34). The DIE-specific mAbs DV55.1, DV63.1 and
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DV87.1 potently neutralized DENV infection of Vero cells, with EC-50 values as low as 4 
ng/ml, whereas DI/E-specific mAbs showed in general a 10-50-fold lower potency (Fig 
3A and Table 2). In contrast, the E-reactive mAbs that bound E protein only in Western 
blot were not neutralizing (Table 2), a finding that is consistent with the possibility that 
the epitopes recognized are not accessible on intact virions. Consistent with what is 
known about stochiometric relationship between neutralization and enhancement (35), all 
mAbs that neutralized also enhanced infection over a given range o f concentrations (Fig. 
3B and Table 2).
In summary, analysis of the memory B cell repertoire o f DENV-infected donors 
. revealed a high frequency of anti-E protein antibodies that were skewed away from DEI- 
specific neutralizing epitopes and towards cross-reactive determinants with inherently 
less inhibitory potential.
Human monoclonal antibodies to prM and to non-structural proteins
We next characterized eighteen mAbs that stained DENV-infected cells but did not 
recognize E protein. Six mAbs bound prM in Western blots (Fig. 2A). With the single 
exception of mAb DV52.1, all the prM-specific mAbs were broadly cross-reactive since 
they stained cells infected with all four DENV serotypes (Table SI). Surprisingly, four of  
these mAbs also stained a band corresponding to the E protein, and two o f them also an 
additional band of higher molecular weight. The reactivity of mAbs with both prM and E 
suggests a quaternary epitope with shared sites on the heterodimeric prM-E protein; a 
similar finding has been reported for mouse antibodies (26, 36). All piM-reactive mAbs
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enhanced DENV infection over a broad range of concentrations, while some neutralized 
infection, although with low potency (Table 4).
Eleven mAbs were mapped to NS1 or NS3 protein, as determined by ELISA with 
recombinant proteins and Western blot (Fig. 2B and Table 5). Five NS1-specific mAbs 
cross-reacted broadly with all DENV serotypes, while the remaining two mAbs were 
specific for DENVl or DENV3 NS1 (Table SI). The four NS3-specific mAbs were all 
DENV 3 -specific.
Finally, only one mAb (DV86.2) recognized the capsid protein. Another mAb 
(DV 34.4) was not assigned to a specific protein, although it showed high neutralizing 
activity against DENV2 and, to a lower extent, DENV4 (Table 4). This mAb likely 
recognizes a conformationally-sensitive epitope on E (e.g., hinge or dimer interfaces) as 
was obseived recently with two human mAbs against WNV (37).
A broadly neutralizing antibody cocktail lacking enhancing activity
Given the availability o f human anti-DENV mAbs, we set out to develop a candidate 
antibody-based therapy for dengue consisting of a “cocktail” o f neutralizing mAbs. 
Ideally this cocktail should: i) neutralize all DENV serotypes, ii) target at least two non 
overlapping epitopes on each virus in order to minimize the selection o f escape mutants, 
and iii) fail to enhance infection. We therefore selected two mAbs with potent and 
complementary neutralizing activity: DV87.1 specific for DEE o f DENVl, 2 and 3 and 
DV22.3 specific for E protein of DENV4 (Table 2). As a complement we selected a 
DEE-specific mAb (DV82.11) that neutralized with comparable efficiency all four 
DENV serotypes. Cross-competition experiments Were consistent with the notion that the
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target epitopes recognized by the three mAbs did not overlap (Fig. SI). Thus, a cocktail 
of DV87.1, DV22.3 and DV82.11 is expected to neutralize all DENV serotypes by 
targeting on each vims two distinct sites, thus minimizing the chance o f selecting escape 
mutants.
We generated variants o f DV87.1, DV22.3 and DV82.11 in which leucine 
residues at positions 1.3 and 1.2 of CH2 domain (according to the EMGT unique 
numbering for C-domain) were substituted with alanine residues. This modification, also 
known as “LALA” mutation, abolishes antibody binding to both FcyRI and FcyRII (38). 
The variant and unmodified recombinant uiAbs were expressed in HEK293T cells and 
the purified mAbs were compared for their capacity to neutralize and enhance infection 
by the four DENV serotypes. As shown in Fig. 4, LALA variants retained the same 
neutralizing activity of modified mAbs, but were completely devoid o f enhancing 
activity. In addition, the LALA cocktail, even at very low concentrations (DV82.11 = 
2ug/ml; DV87.1 = DV22.3 = 0.2tig/ml), blocked ADE induced by enhancing mAbs or 
immune serum (Fig. 5).
To determine whether the combination of LALA mAbs might achieve increased 
neutralization we used a variable ratio approach (39). The concentration of one mAb was 
varied in the presence o f a fixed amount of a second mAb (added at a weakly neutralizing 
concentration) and the titration curves o f the first mAb alone or in combination were 
compared. Hie EC90 values shown in Table S2 indicate a two- to four-fold increase in 
neutr alization potency consistent with an additive effect.
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Taken together, the above results suggest that a cocktail o f three variant mAbs 
targeting different epitopes on each vims can efficiently neutralize DENV infection while 
avoiding and actually preventing DENV infection enhancement.
LALA variant mAbs do not enhance DENV infection and show therapeutic efficacy 
in vivo
To assess the ability o f LALA variants to neutralize DENV in vivo, we utilized a 
recently-described mouse model of DENV ADE where sub-lethal infection is enhanced 
by passive transfer o f anti-DENV antibodies leading to lethal disease characterized by 
plasma leakage, elevated serum cytokines and thrombocytopenia, all features associated 
with severe dengue in humans (40). Unmodified or LALA variant mAbs were transferred 
into AG129 mice 24 hours prior to a sub-lethal infection with DENV2 strain D2S10. 
While mice pretreated with 1 or 5 ug unmodified mAbs DV82.11 and DV87.1 showed 
enhanced lethal DENV infection, mice receiving the same amoimts o f LALA variants did 
not siiccmnb to infection (Fig. 6A; p<0.0.5, both DV82.11 and DV87.1, n = ’3/group) or 
show? signs o f illness. In contrast, mice receiving 5 pg o f the mouse mAb 4G2 (pan- 
flavivims, E DI/H-specific), succumbed to an enhanced, lethal D2S10 infection as 
observed previously (40), whereas 5 o f 6 mice receiving PBS alone survived infection 
(Fig. 6A). The ability of the unmodified mAbs to enhance DENV in mice was not 
affected by differences in the interaction between the human Fey constant region and the 
murine FcyR, since murine/human chimeric mAbs in which the human hinge, CH2 and 
CH3 domains were replaced with the homologous, murine Igy2a constant region 
enhanced the DENV-infection comparably in vitro and in vivo (data not shown).
Appendices
To determine wlietlier survival, associated with transfer of the DV82.11 and 
DV87.1 LALA variants was associated with reduced viral load, we measured the viral 
burden in serum and tissues 3.5 days following D2S10 antibody-enhanced infection. 
Serum viremia and tissue viral load measured in liver, small intestine and lymph node 
were significantly decreased in mice receiving 5 pg o f either LALA variant as compared 
to mice receiving 5 pg o f the parent unmodified mAbs (Fig. S2).
To explore whether the LALA variants could serve as a possible therapy 
following DENV infection, we administered 50 pg o f the LALA variants or unmodified 
mAbs to mice 24 horns after infection with DENV2 D2S10 under enhancing conditions 
(24 hours after transfer of heterotypic anti-DENVl serum) (40). Mice receiving either the 
DV82.11 or DV87.1 LALA variant survived the normally lethal infection, whereas mice 
receiving the unmodified parent mAbs succumbed to infection, as did mice receiving 
non-binding isotype control (DV22.3 LALA mAb that only recognizes DENVl) or PBS 
(Fig. 6B). In summary7, these results demonstrate that engineering of the LALA mutation 
on strongly neutralizing mAbs abrogates the capacity for ADE and confers a protective 
phenotype as a post-exposure therapy in mice.
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Discussion
In this study we have shown that individuals that recover from primary7 or secondary 
DENV infection have a large repertoire o f memory B cells which is skewed towards 
broadly cross-reactive antibodies specific for DEE of the E protein while only a minority 
of memory B cells produce potently neutr alizing antibodies that bind to D ili. Out of the 
fifty mAbs characterized, three were selected based on neutralizing potency and breadth 
and expressed as recombinant mAbs carrying mutations in the CH2 domain that prevent 
binding to the FcyRs. These mAbs did nor cause ADE in vitro and in vivo and showed 
therapeutic efficacy in a mouse model o f antibody-enhanced lethal DENV infection.
This study represents the first attempt to interrogate the human memory B cell 
repertoire o f Dengue immune donors in order to identify the antigenic specificity and 
cross-reactivity of the antibody response. In the tw7o donors that were analyzed 
systematically using a broad screening strategy, the memory7 B cell repertoire appears to 
be strongly skew7ed towards recognition o f E-DIE, with relatively fewer'B cells specific 
for E-DHI, pr-M and NS proteins. Our findings that the human memory7 B cells are 
primarily skewed for recognition o f E-DEE are consistent showing with serological 
studies with WNV and DENV that suggest that the human humoral response is directed 
away from E-DIII (41-44). Moreover/two recent studies described recombinant anti- 
WNV antibodies that w7ere generated after phage display screening o f scFv (Vh-Vl) 
molecules (45, 46). both of wrliich observed immimodominance o f DEDII mAbs against 
WNV E protein. It should be noted that binding efficiency and neutralization of DEE 
mAbs was higher with the homologous serotype and 2 tolO-fold lower with heterologous 
serotypes, a finding that may7 explain their role in enhancing heterologous infections. For
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uncertain reasons, it appears that E-DIII-specifk antibodies are more rare in the human 
repertoire although they still could contribute significantly to protection (43).
Previous studies using moirse mAbs established that E-DHI is the primary target 
of the most potent neutralizing antibodies against WNV and DENV (18-20, 42, 47, 48). 
Our findings in human sirbjects are in line with these observations, as the E-DHI-specific 
mAbs isolated were indeed the most potently neutralizing, with EC50 values in the low 
ng/ml range. However, within the limitations o f the available data, it appears that the 
human antibodies to DHI have a considerable breadth being able to neutralize two to 
three serotypes while antibodies produced by mice immunized by recombinant E can 
only neutralize a few genotypes within a given serotype (2 1 ).
ADE was evaluated in vitro by measuring the capacity o f the mAbs to augment 
infection of FcyRII+human K562 cells, which are poorly susceptible to DENV infection 
in the absence o f antibodies. All neutralizing antibodies mediated ADE at sub- 
neutralizing concentration while some E-specific mAbs and most prM-specific mAbs 
mediated ADE but lacked neutralizing activity. A recent study reported the isolation of 
three human E protein-specific mAbs, two of which showed enhancing but not 
neutralizing activity (49). It is possible that neutralization and enhancement are linked 
directly by their relative stoichiometry o f binding to the virion (35, 50). Nonetheless, the 
percentage o f infected cells and the range of mAb concentration that promoted ADE 
varied widely among the antibodies, independent of their neutralizing capacity.
Most o f the prM-specific mAbs described in the present study were highly cross- 
reactive and showed ADE activity over a broad range o f concentrations. Previous studies 
reported that mouse anti-prM mAbs neutralized infection weakly, if  at all, (26, 51-53).
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Additionally, some prM-specific mAbs passively protected mice from flavivirus in vivo, 
but the mechanism of protection remains unclear (26, 54-56). Anti-prM mAbs also have 
been reported to mediate ADE infection in cells with FcyR (51) or without FcyR, (25), 
indicating a possible role for anti-prM inAbs as auto-antibodies mediating antibody- 
dependent cell cytotoxicity. Our finding of broadly cross reactive prM-specific human 
mAbs that promote ADE robustly suggest a potential role this class of antibodies in 
enhancing DENV infection in humans. Accordingly, recent studies in infants have also 
implicated anti-prM antibodies in the susceptibility of infants to severe dengue (57). 
Alternatively. anti-prM antibodies could enhance DENV propagation by enhancing the 
infectivity of immature, “non-infectious” virions, as was recently reported (27).
Recently, a nine amino acid-deletion in the Fc region of a humanized chimpanzee 
antibody was shown to abrogate antibody-dependent enhancement o f DENV infection in 
vitro and in monkeys (58), and a single amino acid mutation (N297Q) in the Fc region of 
a humanized mouse mAb tha t eliminated Fc-yR interaction also abolished ADE of DENV 
infection and lethal disease in a mouse model (40). These data confirm that ADE causes 
enhanced disease in vivo and can be prevented by modifying the antibody to abolish 
binding to Fc receptors. Here, we produced recombinant variants o f three neutralizing 
mAbs designed as component of a cocktail capable o f targeting two distinct epitopes on 
each of the four DENV serotypes. These LALA variants, carrying two mutations in the 
CH2 region that prevent binding to Fc-yR, retained neutralizing activity and lacked 
completely ADE. When combined in vitro, we observed an increase in neutralization 
potency (two- to four-fold) of all four DENV serotypes, consistent with an additive 
effect. When tested in mice, the LALA variants prevented ADE and disease induced by a
Appendices
different fusion-loop specific mouse mAb (4G2). Further examination revealed a 
significant reduction in tissue viral load and serum viremia by Hie LALA variants, 
indicating that in the absence of FcyR binding, the LALA variants still efficiently 
neutralize DENV infection and prevent disease. Thus, even though effector functions can 
enhance protective efficacy of anti-flavivirus antibodies (28, 47, 59, 60), they are not 
required for highly neutralizing antibodies.
The development of a vaccine against DENV has been problematic in part due to 
the possible risk of eliciting suboptimal immune responses that might lead to ADE and 
severe disease after challenge with heterologous virulent, strains. In the absence o f an 
effective DENV vaccine, passive therapy with neutralizing antibodies may provide an 
alternative for the treatment o f dengue. A post-exposure prophylaxis approach is 
currently being pursued for treatment o f several viral diseases such as respiratory 
syncytial virus (RSV), rabies, hepatitis B and WNV (61). Humanized mAbs obtained 
from mice or primates have been used for this purpose, but fully human mAbs generated 
during a natural infection represent an attractive alternative with a reduced risk of cross- 
reactivity with self-antigens and of stimulation of allo-antibody responses. In an attempt 
to explore the feasibility o f a passive serotherapy approach for dengue, we identified 
three human mAbs (DV87.1, DV22.3 and DV82.11) that neutralize all four DENV 
serotypes by targeting two distinct epitopes on each virus. We showed that when tested as 
a post-exposure therapeutic 24 hours after infection, both the DV82.11 and DV87.1 
LALA mAbs protected against an antibody-enhanced lethal infection. Thus, at least in 
mice, even if  ADE is initiated, there is a time window when neutralizing antibodies that 
lack the ability to enhance infection can still protect against lethal disease. It should be
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noted that the LALA substitutions do not affect interactions with the neonatal FcRn (38), 
thus preserving long half-live and sustained immune protection.
Overall, our results indicate that strongly neutralizing Dili-specific antibodies are 
relatively rare in the human natural anti-DENV antibody response. Instead, is the 
response is dominated by cross-reactive, weakly and'non-neutralizing antibodies that 
recognize DI and DII and, in the context o f DENV infection, have a high potential for 
promoting ADE. However, since the vast majority (>99%) of humans experiencing 
secondary DENV infection do not develop severe life-threatening disease, the E-DI/II- 
specifrc antibodies or the rare highly neutralizing E-DIII-specitrc antibodies are likely 
protective, along with other components o f the innate and adaptive immune system. 
These results are a foundation for further investigation to address whether antibody-based 
therapeutic can control severe DENV disease in humans.
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Materials and Methods
Reagents. Cell lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). Vero and K562 cells were cultured in DMEM or RPMI 1640 medium 
(Invitrogen) supplemented with 10% FCS (Hyclone), 1% penicillin, 1% streptomycin and 
L-glutamine (all from Invitrogen) (complete DMEM or RPMI). C6/36 cells (Aedes 
albopticus mosquito cells) were cultured at 28°C in 5% CO2 in EMEM (Invitrogen) and 
supplements as before. Attenuated DENV7 vaccine strains used in this work were: 
1-DEN1A30 (62), rDEN2/4A30 (ME) (63), rDEN3/4A30 (ME) (64) and rDEN4A30 (65). 
The DENV2 strain D2S10 used for in vivo experiments was derived from the parental 
DV2 PL046 Taiwanese isolate as described (66). The for mouse 4G2 hybridoma was 
purchased from ATCC, grown in serum-free medium (Invitrogen), and purified using 
protein G affinity chromatograpy (Thermo Scientific). To generate mouse anti-DENV 
sera, six- to eight-week old AG129 mice were infected intra-peritoneally (i.p.)with 103 of 
DENVl strain 98J, a strain isolated in the Harris laboratory from a patient from Guyana, 
in 1998. Mice were sacrificed by terminal bleed 6-8 weeks after infection, sera collected 
and stored.
Memory B-cell immortalization and cloning. Peripheral blood samples were obtained 
from four adult donors who had been diagnosed with DENV infection. The study 
protocol was approved by the Scientific and Ethical Committee o f the Hospital for 
Tropical Diseases as well as the Oxford Tropical Research Ethical Committee. All 
patients provided written informed consent. The determination of primary7 or secondary 
dengue was made on the basis of acute serology7 and results of PRNT50 assays in late
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convalescence. Peripheral blood mononuclear cells were isolated by Ficoll-Paque (GE 
Healthcare) density gradient centrifugation and ciyopreserved. On the day of use, PBMC 
were thawed and B cells were enriched using CD22 microbeads (Miltenyi) and IgG+ 
memory B cells were further purified by cell sorting using a FACSAria (BD Biosciences) 
as described (32). Cells were immortalized using EBV and CpG oligodeoxynucieotide 
2006 (Microsynth) as described and cultured at 20 cells/well in multiple 96-well plates 
with irradiated allogeneic PBMC in complete RPMI. After 2 weelcs the culture 
supernatants were screened for the presence of DENV-specific Abs. Positive cultures 
were expanded and cloned by limiting dilution.
Intracellular staining with DENV-infected cells. C6/36 cells or Vero cells were 
infected with the DENV3 isolate recovered from Donor 76, with die DENVl isolate 
recovered from Donor 12, or with attenuated DENVl , 2, 3, and 4 viruses at MOI leading 
to 70-90% of infected cells. After 5 days, cells were harvested, fixed with 2% 
formaldehyde (Sigma), and permeabilized in PBS containing 1% FCS and 0.5% saponin 
(Sigma). Fixed and permeabilized DENV-infected cells were incubated for lh on ice with 
B cell culture supernatants, washed and stained with Gy5-conjugated goat anti-human 
IgG (diluted 1:500) (Jackson Immunoresearch). Cells were analyzed on a FACSArray or 
FACSCanto equipped with high throughput sampler (BD Biosciences).
ELISA. 96-well micro-ELISA plates (Coming) were coated overnight at 4°C with 
recombinant E protein from DENV 1-4 (67) or with recombinant E-DIEI from the DENV3 
of Donor 76 (68) (all at lug/ml in 0.1M Na carbonate buffer, pH 9.3). After washing and
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blocking, serial dilutions of mAbs in 10% FCS-PBS and added for lh at 37°C. After 
further wash, mAbs bound were revealed using goat anti-liuman IgG coupled to alkaline 
phosphatase (diluted 1:500) (Jackson Immunoresearch). In same experiments ELISA 
plates were coated with the mouse mAb 4G2 (1 ug-'ml overnight) followed by a mixture 
of DENVl-4 antigens. ELISA with recombinant non-structural protein were performed 
as described (69).
Yeast expression and staining. Yeast expressing E-DL'H and E-DIII of DENV2 were 
generated as previously described (18, 22), Briefly, yeast expressing the amino acid 
sequence of E-DI/II (residues 1 to 295) and E-DIII (residues 296 to 415) of DENV2 
(strain 16681) were made by engineering BamHI and Xhol restriction enzyme sites at the 
5 ’ and 3 ’ ends of the ectodomain construct using PCR amplification. This fragment was 
cloned into the BamHI and Xhol sites of the pYDl vector (Invitrogen) and expressed in 
the S. cerevisiae strain EBY100. Yeast cells expressing wild type or mutant E-DI/II or E- 
DEH of DENV or WNV (strain New York 1999) were stained with 50 ul of human mAb 
supernatant on ice for 30 ruin. The cells were then incubated with a 1:500 dilution of goat 
anti-human IgG conjugated to Cy5 (Jackson Immunoresearch) for 30 min on ice. After 
fixation with 1% formaldehyde (Sigma) in PBS, yeast cells were analyzed by flow 
cytometry.
Immunoblot analysis. Equal amounts of concentrated supernatant from DENV3- or 
DENV2-infected or uninfected Vero cells were separated under non-reducing conditions 
by SDS-PAGE and transferred onto nitrocellulose membranes. Filters were blocked with
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10% dry skim milk and probed with monoclonal antibodies at 37°C. Blots were 
incubated with horseradish peroxidase-conjugated mouse anti-human IgG or donkey 
anti-rabbit IgG secondary antibody and developed with ECL Plus Western Blotting 
Detection System (GE Healthcare). E protein was identified using DV55.1, NS1 protein 
using a rabbit anti-NSl serum. The protein prM and C were identified as 20-kD and 10- 
15 kd bands, respectively.
Production of recombinant IgG wild-type and LALA mutants. RNA was isolated 
with RNeasy kit (Qiagen) from EBV-immortalized B cell clones DV82.11, DV87.1, and 
DV22.3 and cDNA synthesized with M-MLV reverse transcriptase (Invitrogen). Variable 
regions of heavy-chain and light-chain genes were sequenced and cloned by PCR into 
human Igyl, IgK and Igk expression vectors (provided by M. Nussenzweig, Howard 
Hughes Medical Institute, The Rockefeller University, New York) using gene-specific 
primers and Pfu Turbo (Stratagene) (70). The vectors contain a murine Ig gene signal 
peptide sequence and a multiple cloning site upstream of human Igyl, IgK and IgX 
constant regions, with either wild-type or with leiicine-to-alanine mutations at positions 
CH2 1.3 and 1.2 of Igyl, according to the IMGT unique numbering for C-DOMAIN 
(LALA mutant) (38) introduced by site-directed mutagenesis (GenScript). Equal amoimts 
of heavy7 and light chain vectors were mixed with an equal amoimt of polyethylenimine 
(Sigma), incubated for 15 min and added to 80% confluent HEK293T cells (ATCC) in 
DMEM supplemented with 1% Nutridoma (Roche). Antibodies were recovered from 
supernatants harvested 3 days after transfection and purified using protein A affinity 
chromatography followed by sephadex 200  size exclusion chromatography.
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Infection neutralization and enhancement. DENV neutralization was measured using a 
flow based assay. The day before the infection, 5,000 Vero cells were plated in 96-well 
flat-bottom micro-plates. Different dilutions of mAb were mixed with DENV (all used at 
an MOI of 0.04) in a final volume of 60j.il for lh at 37 °C and then added to Vero cells 
monolayers. After three days die cells were fixed with 1% formaldehyde, permeabilized 
in PBS 1% FCS 0.5% saponin, and stained with mouse mAb 4G2 (71) directed against 
the fusion loop of all DENV E proteins (23). The cells were incubated with a 1:200 
dilution of goat anti-mouse IgG conjugated to R-phycoerythiin (SouthemBiotech) and 
analyzed by flow cytometry. ADE was measured by a flow assay using K562 cells, a 
human eiytliroleukemia line that expresses FcyRHA and is resistant to DENV infection in 
the absence of enhancing antibodies. Monoclonal antibodies and DENV (at an MOI of
0.04) were mixed in a final volume of 60ul for 1 hour at 37 °C and added to K562 cells 
(5000 cells/well). After three days at 37°C, cells were fixed, permeabilized, and stained 
with mouse mAb 4G2 as above and the number of infected cells was determined by flow 
cytometry7 as above. EC50 values were determined by nonlinear regression analysis using 
a variable slope (GrapliPad Prism 5).
Determination of neutralization synergy. The increase in neutralization achieved by 
combinations of neutralizing mAbs was assessed using a variable antibody ratio approach 
(39). One antibody was serially diluted and then a fixed amoimt of a second neutralizing 
antibody at a weakly neutralizing concentration was added (to standardize the amount of 
that antibody bound to the virus). Attenuated DENV (at an MOI of 0.04) was mixed with
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antibodies and added to Vero cells after an incubation period of lh at 37 °C. Three days 
after infection, cells were analyzed by flow cytometry. The change in neutralization 
potency was assessed by comparing the EC90 obtained with a single antibody titration 
performed during the same assay.
Effect of LALA antibodies on ADE. Potent enhancing antibodies (0.lug/ml) or serum 
from primary dengue-infected donors were mixed with an equal volume of LALA 
cocktail (DV82.11 =2gg/ml; DV87.1=DV22.3= 0.2ug/ml). Attenuated DENV 1-4 virus 
strains (at MOI of 0.04) and the antibody were mixed, added to K562 cells, and incubated 
for three days. Cells were stained with mouse 4G2 and analyzed by flow cytometry as 
describe above.
Infection of AG129 mice. 129/Sv mice lacking the interferon a/p and y receptors 
(AG129) (72) were bred in the UC Berkeley Animal Facility. All experimental 
procedures were pre-approved by the UC Berkeley Animal Care and Use Committee 
(ACUC) and were performed according to the guidelines of the UC Berkeley ACUC. 
Mice were injected i.p. with mAb, PBS, or anti-DENV sera in a total volume of 200 pi, 
then infected 18-24 hours later with either 105 or 106 pfrr of DENV strain D2S10 diluted 
in lOOpl volume by intravenous (i.v.) injection into the tail vein. In some experiments, 
50pg of mAb were transferred to mice i.v. 24 horns post-infection to assess the 
therapeutic efficacy of the mAb.
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Quantitation of virus in tissues and serum. Viral load was determined in the indicated 
tissues as previously described (73), and expressed as pfu/g of solid tissues. Viral copy 
number was quantified by qRT-PCR in serum and liver samples. Viral RNA was 
extracted from 60pl of serum using the QIA-Amp RNA recovery7 kit (Qiagen). Liver 
samples were removed and saved in RNA-Later (Arnbion) at 4°C prior to processing. 
Total RNA was extracted using the RNEasy kit (Qiagen) according to the manufacturer’s 
instructions. Quantitation of viral RNA was performed using Taqinan reagents (One Step 
RT-PCR Kit, Applied Biosystems, Foster City, CA) and an ABI PRISM 7700 sequence 
detection system as previously described (74). Standardization of cellular RNA levels 
from liver samples was performed using a Taqmau rodent glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) control kit (Applied Biosystems) and compared to a standard 
curve based on known amounts of total mouse RNA provided by the manufacturer (73); 
Serum viremia levels were expressed as pfii equivalents/ mL as described previously 
(73), and liver viral load as pfu equivalens/gg total mouse RNA.
Statistical analysis. All data were analyzed with Prism software (GrapliPad Software). 
Kaplan-Meier survival curves were used to display mortality data, and log rank analyses 
were used to determine statistical significance between experimental groups.
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Figure 1. Staining of infected and permeabilized Vero cells identify antibodies to 
dengue virus. Vero cells were infected by DENVl, 2, 3, and 4 vaccine strains, fixed, 
permeabilized. and stained with EBV-transformed B cell culture supernatants, followed 
by fluorescently-labelled anti-human IgG polyclonal antibodies. Representative dot plots 
show staining by mAbs isolated from Donor 76 reactive against DENV3 alone (DV79.3), 
DENV 1 and DENV3 (DV63.1) or cross-reactive against the four DENV serotypes. 
Numbers in quadrants indicate the percentage of positive cells. The data shown are from 
one of two independent experiments performed in with similar results
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Figure 2. Characterization of antigen specificity by Western blot. mAbs that were not 
reactive by ELISA were subjected to Western blot analysis. Concentrated supernatants of 
uninfected control (—) or DENV3-infected Vero cells (+) were separated imder non­
reducing conditions. E protein was identified by DV55.1, specific for E protein in ELISA 
(A). NS1 protein was identified by a rabbit anti-NSl serum (B). prM and capsid migrate 
with apparent molecular weights of 20 and 16 kD, respectively. The data shown are from 
one of at least two independent experiments with similar results.
.prM
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Figure 3. Efficiency of neutralization and enhancement by E-DIII and E-DI/II- 
specific mAbs. A) For viral neutralization, serial dilutions of mAbs were incubated with 
DENV 1-4 before addition to Vero cells. Shown is the percentage of infected cells after 3 
days as a function of increasing mAb concentration (empty circles). Nonlinear regression 
analysis was used to calculate the EC so, indicated in the panel. B) For infection 
enhancement, serial mAb dilutions were incubated with DENV 1-4 before addition to 
K562 cells. Shown is the percentage of infected K562 cells (filled circles). The range of 
niAb concentrations where infection enhancement was observed is indicated in gray. 
Numbers in the gray areas represent logarithm power. The data shown are from one 
representative experiment out of three independent experiments performed.
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Figure 4. Three mAbs neutralize all four DENV serotypes by binding two distinct 
epitopes on each virus. Three mAbs (all IgGl) were selected for their specificity and 
neutralizing activity: DV87.1 binds E-DHI of DENV 1, 2 and 3; DV22.3 binds DENV^, 
and DV82.11 cross-reacts with E-DI/II of all DENV serotypes. A) Neutralization (empty 
circles) and enhancement (filled circles) of infection by recombinant wild-type mAbs. B) 
Neutralization (empty circles) and enhancement (filled circles) of infection by engineered 
LALA variant mAbs. Nonlinear regression analysis was used to calculate the EQo. 
indicated in the panel. Data are mean of duplicates. One representative experiment out of 
three performed.
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Figure 5. LALA cocktail reverses the effect of enhancing antibodies. LALA cocktail 
(DV82.11= 2ug/ml, DV87.1=DV22.3= 0.2iig/ml) was used in combination with mAbs 
directed against prM or DL'Et E protein or serum from primary DENV-infected donors at 
potent enhancing concentration (0.lug/nil) on K562 cells. The data show?n are from one 
experiment representative of two performed.
Appendices
100
«. 80-
‘>
31/2 60-
c
8
0-
40-
20-
—  i-------
4 6
Days post-infection
-* ■  1 ug DV87.1 
0  5 pg DV87.1 
G  1 |ig  DV87.1 LALA 
-0 -  5 jig DV87.1 LALA 
PBS 
-A  5 Mg 4G2
-m -  1 Mg DV82.11 
5 p g  DV82.11 
1 ugDV82.11 LALA 
0  5 ug DV82.11 LALA 
■©• PBS 
-A  5 ug 4G2
2 4 6 8
Days post-infection
2 . 4 6
Days postrinfection
0  DV87.1 
G  DV87.1 LALA 
DV82.11 
DV82.11 LALA 
JF- DV22.3 LALA 
PBS
Figure 6. LALA variants do not enhance DENV in vivo. A) Upper panel. 1 or 5 ug of
DV82.il, DV82.11 LALA variant, mAb 4G2 or PBS were transferred i.p. in 200pl 
volume into AG129 mice (n=3/group). The mice were subsequently infected 18 to 24 k 
later with 106 pfu DENV2 D2S10. Mortality was monitored for ten days. Lower panel. 
1 or 5 pg of DV87.1, DV87.1 LALA variant, mAb 4G2 or PBS were transferred i.p. in 
200pl volume into AG 129 mice (ri -3/group). The mice were infected 18-24 h iater with 
106 pfu DENV2 strain D2S10, and mortality was monitored daily for ten days. B) AG129 
mice (n=3/group) were administered 35 pi anti-DENVi 98J seriun i.p. and were infected 
24 hours later with 105 DENV2 D2S10 i.v.. Twenty-four hours after infection, the mice 
were treated with 50 pg of either DV87.1, DV87.1 LALA, DV82.11, DV82.11 LALA, 
DV22.3 LALA or PBS i.p, and mortality was assessed daily for ten days.
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B c ell Positive DENV-
Infecting Days immortaliz. Primary culture/total specific
Douor serotype P-i- efficiency screenms (%) B cells
Don 76 Primary"DENV3 241 14%
Staining of 
infected 
C6/36 cells
434/960
(45%) 16%
Don 7 Primary"DENV4 200 9.1%
ELISA 
E4 protein
81/2844
(2 .8%) 1.5%
Don 12 Secondary'DENVl 510 13.8% '
Staining of 
infected 
C6/36 cells
245/1632
(15.6%) 5.4%
Don 92 SecondaryDENV2 212 9%
ELISA 
DENV 1-4 
lysates
344/2208
(15.6%) 8.6%
Table 1. DENV immune donors and repertoire analysis. PBMC were obtained from 
donors after a primary7 or secondary DENV infection and frozen until the day of use. The 
infecting serotype and the days post infection are reported. IgG+ memory B cells were 
immortalized, and cultures secreting DENV-specific mAbs were identified using primary 
screening methods. The efficiency of immortalization of IgG+ B cells was estimated and 
the fraction of positive culture are indicated. The frequency of DENV specific B cells are 
reported.
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mAbs Donor Isotype. Specificity
ELISA 
E protein
Yeasts
DV2
Neutralization
(ECKUg/ml)
Range o f enhancement 
(loglO ug /m l)
DV
1
DV DV DV 
2 3 4
DUI
DV
3
DU
DU DUI
DV
1
DV
y
DV
3
DV
4
DV
1
DV
2
DV
3
DV
4
DV 1.1 Don 92 Yl, 7. E, D l'DII + + +  + . - + - 0.209 0.066 0.262 0.183 -2 . 1 - 2 ,1 - 2 ,1 -2 ,1
DV 4.4 Don 92 y l. 7. E, DI-DU . + + +  + - + - 0.248 0.214 0.167. 0.760 -2 ,1 -2 ,1 -1 ,1 - 2 ,1
DV 5.1 Don 92 vLlC E, DI/DU + + + * - + - 0.156 0.103 0.092 0.069 -2 ,1 -2 ,1 -2 ,1 -3 ,1
DV6.1 Don 92 yl, 7. E. DI-DU + + +. + - + - 0.382 0.296 0.351 0.170 -1 , 1 -2 ,1 -1 , 1 - 2 .1
DV 7.5 Don 92 '1. K E. DI-DU + + T ' + - + - 0.084 0.075 0.130 0.031 -■> 1
DV' 8.1 Don 92 y l, 7, E, DLDU + ~  + '■ + - + - 0.103 0.022 0.031 0.024 -3 _ 2 -2 ,1 - 3 ,1 - 3 ,0
DV 13.4 Don 92 y l, 7. E, D ID U + ' + ‘ . +  * - + ' ~ 0.063 0.023 0'016 0.045 -2 ,1 - 3 ,0 - 3 ,0 - 3 ,0
DV' 14.5 Don 92 Yl. >- E. D ID U + + + + - + - 0.053 0.049 0.060 0.040 - 2 ,0 - 2 ,0 - 2 ,0 - 3 ,0
DV 15.7 Don 92 yl. 7. E, D I/D n + + + • + - - 0.123 0.055 0.173 0.070 -2 ,1 -3 ,1 -2 .1 -3 ,1
DV 16.5 Don 92 yl.ic E, D ID U + + + T - + - 0.248 0.089 0.219 0.101 -2 ,1 -2 ,1 -2 ,1 -2 ,1
DV 17.6 Don 92 y l, 7. E. DLDU + '+ . +  + - + - 0.218 0.103 0.256 0.087 -2 ,1 -2 ,1 -2 , 1 - 2 ,  2
DV 18.4 Don 92 y l, k E. D ID U + + .+ T ' - +  - - 0.670 0.241 0.799 0.699 -2 ,1 -2 , 1 -2 .1 -2 .1
DV 19.3 Don 92 y l.K E, DLDU + + + + - + - 0.631 0.189 0.368 0.114 -2 , 1 -2 ,1 -2 ,1 -2 ,1
DV' 20.1 Don 92 y l. k E, DLDU + + +  + - + - 0.244 0.128 0.777 0.226 -2 ,1 - 2 ,1 -1 ,1 -2 ,1
DV21.1 Don 92 . y l, * E. D ID U + + + *  ' - - 0.161 0.055 0.069 0.101 - 2 ,1 -2 ,1 -3 .1 - 3 ,1
DV 2S.S Don 92 y l .x E. DI/DU + ~  4  + - ' + - 0.106 0.04S .0.233 0.092 - 2 ,0 - 2 ,0 - 2 .0 - 2 .1
DV 38.1 Don 92 y l, 7, E. DLDU + 4  +  ‘ + - +  . ■ ~  . 0.111 0.036 0.239 0.106 -2 ,1 -3 ,1 -2 ,1 - 3 ,1
DV 78.6 . Don 76 y l, k E. DLDU + + + + - n.d. ~ 0.591 0.251 0.809 0.367 -2 ,1 -2 ,1 - 2 .1 - 2 .1
DV82.11 Don 76 y l, 7, E, DLDU + + + , * - u.d. - 0.043 0.024 0.090 0.117 - 2 .1 - 2 ,1 -2 .1 -2 .1
DV' 90.3 Don 76 y l. 7. E. DI-DU + - n.d. - 0.342 0.454 - -2 ,1 - -1 . 1 -
DV 74.4 Don 76 y l, A E. DI/DU - -  -r - - n.d. - - - 0.020 - -  ' - -2 ,0 -
DV 79.3 D on 76 y l, k E, DI/DU - -  + - - n.d. - - 0.023 - - - - 2 .0 -
DV 76.5 Don 76 Yl.K E. DLDU _  *  - - n.d. - - - - - - 1 ,2 - 2 ,1 -2 ,1 -2 ,1
DV 55.1 Don 76 y l, 7. E .D U I + + '+  - + n.d. + 0.013 0.577 0.014 - - 3 ;o -1 , 1 - 3 ,1 —
DV 87.1 Don 12 yl, k e , d u i + T + - +  ■ n.d. + 0.004 0.004 0.008 - - 3 ,1 -2 ,1 - 2 ,0 -
DV63.1 Don 76 Yl.K E.D IU + -  + - + n.d. - - 0.006 - 0.006 - -4,-1 - - 3 .0 -
DV 22.3 Don 7 y l, 7. E - -  -  +  ' - n.d. - - - 0.006 - - - -2 .1
DV' 66.1 Don 76 y l, k ’ E - -  -  - - n.d. - - - 1.950 - - -2 ,1 -
DV' 61.2 Don 76 Yl,K E - -  -  ~ - n.d. - - - - - 0 , 2 -2 ,1 -2 ,1 -2 ,1
DV 57.4 Don 76 y l, K E - -  -  ~ - n.d. - - 0.200 0.167 0.193 - - 3 ,0 - 3 ,0 - 2 ,0
DV 77.5 Don 76 y l, K E - -■  -  ~ - n.d. - - - - - - 1 ,2 - 2 ,0 -2 .1 -2 .1
Table 2. Characterization of E-reactive human mAbs. The table reports the 
donor from which the mAbs were isolated and the mAb isotype and light chain 
usage as determined by specific ELISA. The target specificity of the mAbs 
was determined by ELISA performed with recombinant E proteins (from 
DENV1-4 serotypes). Four mAbs did not recognize E proteins by ELISA but 
bound E protein in Western blot. Viral neutralization was performed using 
Vero cells and attenuated DENV1-4 viruses. Shown are ECso values. 
Enhancement of infectivity was performed using K562 cells and attenuated 
DENV1-4 viruses. Shown is the range of mAb concentrations where infection 
enhancement was observed (see example in Fig. 3). The data shown are 
representative of two independent experiments.
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WNV
1114138 E Din DI/II W101R G106E W233F
DV 5.1 
DV 6.1 
DV 14.5 
DV 15.7 
DV 16.5 
DV 18.4 
DV 19.3
Table 3. Cross-reactive E mAbs bind DI/II and map to fusion loop. Some cross­
reactive E specific mAbs stained yeast expressing DI/II of WNV. Mutations in conserved 
residues (W101R, G106E) abolished the ability of three mAbs to bind to E protein. 
DV6.1 showed decreased binding with E containing the W233F mutation.
mAbs Donor Isotype Specificity
Neutralization 
(EC50 tig/ml)
Range o f enhancement 
(log 10 iig /in l)
DV
1
DV DV 
2 3
DV
4
DV DV 
1 2
DV DV 
3 4
DV 64.3 Don 76 y l ,  K prM 0.327 0.402 0.067 0.128 - 4 , 1  - 4 ,1 -4 ,1 -3 , 1
DV 69.6 Don 76 y i ,  a prM 0.912 1.559 0.129 0.070 -4 , 1 -3 , 1 - 4 , 1  -4,2.
DV 27.2 Don 92 y l ,  k prM 0.391 0.345 0.110 0.076 -3 , 1 -3 , 1 - 3 , 1  -3 , 1
DV 75.9 Don 76 y l ,  k •prM - - - -2 , 0  - 1 ,2 -3 , 0 -2 , 0
DV 62.5 Don 76 y l ,  a prM - -  . - - -2 , 1 -2 ,1 -2 , 1 -2 , 1
DV 52.1 Don 76 y l ,  k prM - - - - - 3 , 1  -
DV 86.2 Don 76 y l ,  a capsid
DV 34.4 Don 92 y l ,  k n.d. - 0.010 - 0.431 -  - 3 , 0 -  -1 , 2
Table 4. Characterization of non-E-reactive mAbs. Out of fifty mAbs isolated, seven 
mAbs 92 bound prM protein and one bound the C protein as determined by Western blot 
assay (See Fig. 2). The specificity of mAb DV34.4 was not assigned. The mAb isotype 
and light chain usage were determined as described in Table 2. Viral neutralization and 
enhancement assays were performed on Vero and K562 cells, respectively, using 
attenuated DENV 1-4 viruses. Shown are EC.50 values of neutralization and range of mAb 
concentrations of infection enhancement. The data shown are representative of two 
independent experiments.
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mAbs Donor Isotype
ELISA
NS1 NS3
DV 70.1 Don 76 y l ,  k +
DV 54.7 Don 76 y l ,  k +
DV 60.3 Don 76 Y l .K +
DV 56.12 Don 76 y i . X +
DV 59.3 Don 76 V4,X +
DV 53.4 Don 76 y i , x +
DV 51.6 Don 76 yl ,?. +
DV 65.5 Don 76 y i : k
DV 67.9 Don 76 y l A +
DV 71.1 Don 76 y l, X . .+ -
DV 68.2 Don 76 y3, X -  +
Table 5. Reactivity of human mAbs against DENV non-structural proteins. Out of
fifty mAbs isolated, 11 bound NS proteins: The mAb isotype and light chain usage were 
determined by ELISA. Antigenic specificity was determined by ELISA using 
recombinant NS1. NS3, NS4B and NS5 proteins.
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Appendix 2. Models constructed from clinical parameters at 
enrolment
Results from Bayesian model averaging using clinical parameters at enrolment 
(Figure 7-1) indicate that additional covariates that are included in models with 
reasonable plausibility are sex, vomit, tenderness, and liver enlargment. The best 
model is model 1 including age and present of bleeding sign.
Age 
Sex -  
BMI -  
Vomit -  
Join_pain -  
Flush -  
Rash -  
Abdominal_pain -  
Watery_stools -  
Bleeding 
lominal_tenderness -  
Liver_enlargment 
Lethargy
■ P T T i m n n
m . .
i  i ii
l / l
J  - ■  M l W D K f
--------- 1---------1------- 1------1----- 1----- I I I I. I I I I I I I I I I I 1 I IIIIMIIIIIIIIIIIIflllllllllllllllllllll'T'TTl I
Model# 1 2 3 4 5 6 7 9 11 14 18 22 27 34 42 53
Cum. post, probability 0.08 0.16 0,29 0.39 0.49 0.58 0.66 0.74 0.83 0.9 0.97
Figure 7-1: Prognostic models constructed from clinical covariates by 
Bayesian model averaging (BMA).
Black and gray rectangles, respectively, correspond to covariates included in the model 
with a positive or negative association with outcome while blank spaces mean covariates 
that aren’t included in the model. Cum.post.probability represents as cumulate posterior 
probability. The posterior probability here means the probability o f the model that is 
assigned after the relevant covariate is taken into account.
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Appendix 3. Models constructed from haematological parameters 
at enrolment
Results from Bayesian model averaging are displayed in Figure 7-2. 
According to this figure, the selected model (model 1) has a posterior probability of
0.15 but other models which exclude hematocrit (model 2, posterior probability 0.13), 
or exclude hematocrit and add lymphocyte count (model 3, posterior probability 0.09) 
would also be plausible given the data. The best model is model 1 including 
haematocrit, platelet, white cell count, and ALT>40 U/L.
Age 
. Sex 
Haematocrit 
Platelet 
log2(WBC)
Lympho 
Neutro 
AST>40 
ALT>40
Model
Cum. post, probability 0 15 0.28 0.37 0.48 0.59 0.67 0.75 0.82 0.9 0.96
Figure 7-2: Prognostic models constructed from haematological 
parameters by Bayesian model averaging (BMA).
Black and gray rectangles, respectively, correspond to covariates included in the model 
with a positive or negative association with outcome while blank spaces mean covariates 
that aren’t included in the model. Cum.post.probability represents as cumulate posterior 
probability. The posterior probability here means the probability o f the model that is 
assigned after the relevant covariate is taken into account.
Appendices
Appendix 4. Models constructed from clinical and haematological 
parameters at enrolment
Results from Bayesian model averaging using clinical and haematological 
parameters at enrolment altogether (Figure 7-3) show model 1 has the highest 
posterior probability and is the simplest model.
Age 
Sex 
BMI 
Vomit 
JoinjDain 
Flush 
Rash
AbdominaijDain 
Watery_stools 
Bleeding 
lominaljenderness 
Liver_eniargment 
Lethargy 
Haematocrit 
Platelet 
log2(WBC)
Lympho 
Neutro 
AST>40 
ALT>40
Model# 1 2 3 4 5 7 9 11 14 17 .21 26 32 39 47 57 69 83
Cum. post, probability 0.06 0.18 0.26 0.35 0.44 0.52 0.6 0.67 0.75 0.82 0.9 0.96
Figure 7-3: Prognostic models constructed from clinical haematological 
parameters by Bayesian model averaging (BMA).
Black and gray rectangles, respectively, correspond to covariates included in the model 
with a positive or negative association with outcome while blank spaces mean covariates 
that aren’t included in the model. Cum.post.probability represents as cumulate posterior 
probability. The posterior probability here means the probability o f the model that is 
assigned after the relevant covariate is taken into account.
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Appendices
Appendix 5. Clasification tree generated using the clinical signs 
and symptoms at enrolment for predicting DHF
Bleeding <> 0.5
®  Age <> 14.5
DF/OFIs 
316 obs
©  ©
DF/OFIs DHF
152 obs 29 obs
Figure 7-4: Clinical classification tree for predicting DHF at early illness. 
Table 7-1: Perfomance of the clinical classification tree
Sesitivity 18/109 (0.17)
Specificity 377/388 (0.97)
PPV 18/29 (0.62)
NPV 377/468 (0.81)
Accuracy 395/497 (0.79)
Appendices
Appendix 6. Clasification tree generated using the haematological 
profile at enrolment for predicting DHF
Platelet >< 115.5
i i
WBC >< 4.75 Haematocrit <> 42.5
®  WBC ><2.95 l(ALT >40) <> 0.5 0
I I I I
221<obs Neutroo 66.95 Age <>12.5 @  Age <>11 2^ s
I------------------ 1 I----------------1---------------------------I---------- 1
©  Platelet ><162.5 ©  Neutro >< 56.95 ®  ©
DF/OFIs I DF/OFIs I  Z. DF/OFIs DHF
84 obs 3 Platelet <> 151 5 32obs 7 ©  14obs 12obs
DF/OFIs . ^  DF/OFIs DHF
24 obs ^ 14 obs 7 obs
DF/OFIs DHF 
15 obs 8 obs
Figure 7-5: Classification tree for predicting DHF based on 
haematological profile at enrolment.
Table 7-2: Perfomance of the haematological classification tree
Sesitivity 45/109 (0.41)
Specificity 378/388 (0.97)
PPV 45/55 (0.82)
NPV 378/442 (0.86)
Accuracy 423/497 (0.85)
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Appendices
Appendix 7. Case report form of the early clinical and laboratory 
features study
Study Code FG
C l i n n i c a l ,  v i r a l ,  g e n e t i c  a n d  i m m u n o l o g i c a l  r i s k  f a c t o r s  f o r  DSS
Screening page
Inclusion criteria (please check box):
1. Dengue is a possible diagnosis D
2. Patient is aged between 2-18 years □
3. They have a history of symptoms o f <72hrs □
4. Their parents give fully informed assent □
Enrolling doctor’s signature:
Date:
- 179-
Appendices
Demographic Information at Enrolment
Name of patient: Name of patient’s mother (father) ■  • ■
Address (within 2 weeks before admission to hospital): • '____________________■
Name of school________________    . Boarding-school [ ] Day-boarding school [ ] Other [__]
Date of enrolment [ I  V I_ ]/[ I_ J  dd/mm/yy Time of enrolment [ I 1/ I  ]hrs/min
Date of Fever onset [ I 1/ I ]/[ I \  dd/mm/yy Approx. Time of fever onset [ _ ! _ ! /  I 1 hrs/min
Date of birth \ I 1/f. I 1/f__I 1 dd/mm/yy Sex [ 1 Male
(if date o f birth is unknown) Age: [__I 1 (YY)
Weight on enrolment [ I 1 1 .  [__] kg Height [__I I_J cm
[__] Female
.Recent Medical History (chief “complaints” which led to presentation) -
Fever [__] Vomiting \ 1 Diarrhoea [__] Muscle pain [__]
Severe abdominal pain \ 1 Bleeding f 1 Other f
Joint pain [__] Retroorbital pain [__]
1
Referral and previous management (DK=”don’t know”)
Is the patient referred from another INPATIENT health care facility? 
Is the patient referred from an OUTPATIENT health care facility?
I f ‘yes’, did the patient receive intravenous fluid in the last 24 hours?
f lno  I lyes
[__] no [__] yes
[ lno [ ]yes \ 1 DK
Has the patient taken aspirin during the week before enrolment? [ lno  r lyes f 1 DK
Pregnancy present? r 1 no f. 1 yes I 1 DK
Past Medical History (DK=”don’t know”)
Diabetes (__] no f 1 yes [__] DK
Other f lno  f 1 yes - i f ‘yes’, please specify: f
Asthma [__]no [__] yes [__] DK
1
*
Status at Discharge (to be filled in at discharge!)
Date of discharge/death: [ I_J/[ I_ ]/[ 1 ] dd/mm/yy
Outcome: [ ] Full recovery without complication. If NO insert a code here [__]
(1 -  Incomplete recovery; 2 -  Left against medical advice; 3 -  Transferred ; 4 -  Death 
5 -  Other (specify):   _ _ )
C lin ic ian ’s final diagnosis:
This is a case of dengue only [__]no [__]yes (If‘no’, please continue)
This is a case of dengue plus other diagnosis or complication 1: [__1 no [ 1 yes
I f ‘yes’ please specify diagnosis/complication 1: f _____________ .______________ 1
This is NOT a case of dengue, but other main diagnosis: [___________  ]
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